Translational Studies of Equine Infectious Anemia Virus RNA and Analysis of the Viral Regulatory Proteins. by Schiltz, Rodney Louis
Louisiana State University
LSU Digital Commons
LSU Historical Dissertations and Theses Graduate School
1994
Translational Studies of Equine Infectious Anemia
Virus RNA and Analysis of the Viral Regulatory
Proteins.
Rodney Louis Schiltz
Louisiana State University and Agricultural & Mechanical College
Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_disstheses
This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in
LSU Historical Dissertations and Theses by an authorized administrator of LSU Digital Commons. For more information, please contact
gradetd@lsu.edu.
Recommended Citation
Schiltz, Rodney Louis, "Translational Studies of Equine Infectious Anemia Virus RNA and Analysis of the Viral Regulatory Proteins."
(1994). LSU Historical Dissertations and Theses. 5825.
https://digitalcommons.lsu.edu/gradschool_disstheses/5825
INFORMATION TO USERS
This manuscript has been reproduced from the microfilm master. UMI 
films the text directly from the original or copy submitted. Thus, some 
thesis and dissertation copies are in typewriter face, while others may 
be from any type of computer printer.
The quality of this reproduction is dependent upon the quality of the 
copy submitted. Broken or indistinct print, colored or poor quality 
illustrations and photographs, print bleedthrough, substandard margins, 
and improper alignment can adversely affect reproduction.
In the unlikely event that the author did not send UMI a complete 
manuscript and there are missing pages, these will be noted. Also, if 
unauthorized copyright material had to be removed, a note will indicate 
the deletion.
Oversize materials (e.g., maps, drawings, charts) are reproduced by 
sectioning the original, beginning at the upper left-hand corner and 
continuing from left to right in equal sections with small overlaps. Each 
original is also photographed in one exposure and is included in 
reduced form at the back of the book.
Photographs included in the original manuscript have been reproduced 
xerographically in this copy. Higher quality 6" x 9" black and white 
photographic prints are available for any photographs or illustrations 
appearing in this copy for an additional charge. Contact UMI directly 
to order.
University Microfilms International 
A Bell & Howell Information Company 
300 North Zeeb Road. Ann Arbor, Ml 48106-1346 USA 
313/761-4700 800/521-0600

Order N u m b er 9508598
Translational studies o f  equine infectious anem ia virus R N A  and  
analysis o f  th e viral regulatory proteins
Schiltz, Rodney Louis, Ph.D.
The Louisiana State University and Agricultural and Mechanical Col., 1994
U M I
300 N. ZeebRd.
Ann Aibor, MI 48106

TRANSLATIONAL STUDIES OF 
EQUINE INFECTIOUS ANEMIA VIRUS RNA 
AND ANALYSIS OF THE VIRAL REGULATORY PROTEINS
A Dissertation
Submitted to the Graduate Faculty of the 
Louisiana State University and 
Agricultural and Mechanical College 
in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy
m .
The Department of Biochemistry
by
Rodney Louis Schiltz 
B.S., Louisiana State University, 1984 
August 1994
ACKNOWLEDGMENTS
I wish to express my sincere appreciation to all of those who have 
assisted m e and provided materials used in these studies. I w ould like to 
particularly acknowledge Xiu-Zhu Chen, a research associate who worked in 
our laboratory from the Fall of 1990 until the Fall of 1992 when the majority of 
this work was performed. Ms. Chen was a valuable and trusted assistant and 
co-worker. She helped to prepare materials, including subclones, and 
performed many transcription and translation experiments. Her competence 
and dedication was a tremendous help in the accomplishment of this work. I 
also wish to express my sincere gratitude to my mentor and major professor Dr. 
Ding Shih. His constant encouragement and guidance made this work a reality.
I would like to thank the members of my graduate committee, Dr. Sue 
Bartlett, Dr. Simon Chang, Dr. Gus Kousoulas, Dr. Pat DiMario and Dr. Fred 
Enright for their guidance and helpful discussions. I thank Dr. Ron Montelaro 
for encouraging my major professor to become involved in equine infectious 
anemia virus gene regulation. Our collaboration with him and many members 
of his research group has directly benefited this research. The following 
members of Dr. Montelaro's research group have made contributions to this 
work. Dr. Keith Rushlow provided a number of subclones and vectors and 
taught me most of what I know about cloning. Dr. Siyamak Rasty and Dr. 
Susan Payne provided cDNAs used in this work. Dr. Judy Ball and Dr. Mark 
Miller assisted in the synthesis of peptides and the analysis of antisera raised 
against these peptides.
I wish to thank Dr. Chuck Issel and his associates Jackie McManus and 
Sue Haigus for providing equine cells and cultured virus. I would also like to 
thank Linda Shaffer, a technician in our lab who assisted with maintaining cells 
and virus. I express appreciation to Dr. A. Baghian for providing COS-7 cells
and for spending a good deal of time helping me to perform immuno­
fluorescence assays. I thank Dr. S. V. Z. Rao for assisting in the microsequence 
analysis of the EIAV SI and S2 proteins. I thank Dr. Eric Achberger for 
allowing me to use his video densitometer and tutoring me on its proper use.
I wish to thank my family for their moral support throughout the years.
I thank m y mother, Mrs. Bonnie Tosso, and my father, Mr. Rodney M. Schiltz.
I owe special thanks to my wife, Helen, for her patience and encouragement. I 
, thank my son, Stephen, for the joy he has given me and providing motivation 
for the completion of these studies. I wish to extend special thanks to my 
mother-in-law, He Chunji, for coming from China to live with us and caring for 
my son during the preparation of this dissertation. I sincerely appreciate her 
sacrifice of leaving her home and family to come to a strange land with a 
language she does not understand to help me during this time.
Finally, I wish to thank Dr. Ezzat Younathan for allowing me to take a 
leave of absence from my job in his laboratory, at a time when he most needed 
me, so that the completion of my doctoral training could become a reality. I 
also wish to thank Dr. Gary Winston for encouraging me to take a leave of 
absence so that I could complete the requirements for the doctoral degree, and 
for initiating discussions between myself, Dr. Shih and Dr. Younathan in order 
to work out the details of this leave of absence.
TABLE OF CONTENTS
ACKNOWLEDGMENTS.....................................................................................  ii





Retroviral Gene Expression...............................................  7
Equine Infectious Anemia Virus..................................... 48
Research Objectives.............................................................  72
2 IN VITRO TRANSLATION OF EIAV MULTICISTRONIC
RNAS
Introduction..........................................................................  73
Materials and Methods.......................................................  76
Results....................................................................................  82
Discussion...............................................................................116
3 IN VIVO EXPRESSION OF THE EIAV ORF PROTEINS
Introduction...........................................................................125
Materials and Methods....................................................... 128
Results and Discussion........................................................133







1. Genome and virion structure of a typical retrovirus.................................. 5
2. The structure of HIV-1 proviral D N A ..........................................................  8
3. The HIV-1 LTR...................................................................................................11
4. The structure of HIV-1 TAR RN A .................................................................. 17
5. The structure of the HIV-1 Rev response elem ent....................................... 23
6. The 4.0-kb size class of HIV-1 RNAs.............................................................. 37
7. The 1.8-kb size class of HIV-1 RNAs.............................................................. 39
8. Schematic representation of EIAV disease course....................................... 50
9. Schematic representation of the EIAV proviral genome.............................52
10. A comparison of the HIV-1 and EIAV TAR RNAs...................................... 60
11. Schematic representation of the EIAV open reading frames and
transcripts........................................................................................................70
12. Schematic representation of the EIAV 3.5-kb R N A ..................................... 75
13. Schematic diagram of the pSP720 in vitro transcription vector and
nucleotide sequence of the corresponding in vitro transcrip t................84
14. Translation of the pSP720 and pSP585 RNAs in wheat germ extracts
and identification of the protein products by im m unoprecipitation... 87
15. Predicted amino acid sequences of the tat and S2 ORFs and location
of the synthetic peptides used for antisera preparation..........................88
16. Microsequence analysis of the [3H]-glycine labeled S2 protein.................90
17. Microsequence analysis of the [3H]-glycine labeled SI protein
and SDS-PAGE of purified SI and S2 p ro te ins........................................92
18. Microsequence analysis of the [3H]-arginine labeled SI p ro te in ..............95
19. Quantitation of the SI, S2, and Agp90 proteins produced from
the pSP720 RNA in wheat germ extracts................................................... 97
20. Effect of m 7GpppG cap analog on the pSP720 RNA translation...............99
21. Effect of potassium ion concentration on the translation of
pSP720 RNA in wheat germ extracts........................................................ 103
v
22. Effect of magnesium ion concentration on pSP720 RNA
translation in wheat germ extracts.............................................................107
23. Co-translation of pSP720 RNA with BMV RNA 4 in wheat
germ extracts................................................................................................. 110
24. Translation of EIAV Tat is not initiated at AUC-388 in vitro .....................114
25. In vitro translation and immunoprecipitation of the S3 p ro te in ...............117
26. CAT assays of uninfected and EIAV-infected cells .................................... 135
27. Time course of EIAV Tat trans-activation in cytopathically-
infected FDD cells......................................................................................... 139
28. RNAs corresponding to Tat cDNA expression plasmids and
CAT assays..................................................................................................... 141
29. Immunoprecipitation of in vitro translated ORF S2 protein
with EIAV-infected horse IgG......................................................................146
30. Expression of EIAV Tat from a consensus methionine codon..................150
31. Northern blot analysis of pSV3.5kb RNAs in transfected COS-7 cells ....154
32. Western blot analysis of the S3 protein in EIAV-infected equine cells ....156
33. Time course of S3 expression in EIAV-infected FDD cells........................159
34. Comparison of the S3 protein expressed in EIAV-infected FDD cells
and COS-7 cells transfected with a S3 cDNA expression plasm id.......161
35. Expression of the S3 protein in transfected COS-7 cells.............................163
ABSTRACT
The 3.5-kb RNA of equine infectious anemia virus (EIAV) is shown here 
to encode the SI, S2 and envelope proteins in vitro. SI is expressed from this 
RNA despite the lack of an AUG codon. Deletion mutants of a cDNA derived 
from the 3.5-kb RNA were used to determine that sequences within the first 14 
codons of ORF SI are required for SI expression in vitro and trans-activation in 
vivo. Amino-terminal sequence analysis of the in vitro synthesized SI protein is 
consistent with initiation at a CUG codon.
The translation properties of the 3.5-kb RNA have been examined in 
wheat germ extracts. The cap-dependence of the three cistrons was examined 
by addition of m 7GpppG cap analog to the wheat germ extract translation 
mixtures. The results indicated a near proportionate reduction in the 
expression of each of the cistrons suggesting that their translation is dependent 
on cap binding followed by ribosome scanning. The relative efficiencies of 
expression of the three cistrons were examined in translation reactions where 
the concentrations of magnesium (Mg++) and potassium (K+) ions were varied. 
Increasing the level of Mg++ appeared to favor translation of the SI protein, 
whereas increasing the K+ concentration resulted in significantly reduced 
translation of SI with concomitant enhanced translation from the downstream 
cistrons.
The in vitro synthesized S2 protein was immunoprecipitated with sera 
obtained from EIAV-infected horses demonstrating that this protein is 
expressed in vivo. A 20-kd protein produced in vitro and in vivo from a Rev (S3) 
cDNA was immunoprecipitated with a monoclonal antibody directed against 
an epitope of the gp90 envelope protein. This finding indicates that env gene 
sequences provide a translational initiation codon for Rev protein expression. 
The Rev protein could be detected in EIAV-infected cells within 20 hours after





Retroviruses have been intensely studied for decades due to their 
ability to transduce cellular proto-oncogenes and cause neoplastic cell 
grow th or cancer. More recently, interest in retroviral vectors for the 
budding field of gene therapy has provided additional insight into the 
replication and expression mechanisms of these viruses. In the last decade 
the investigation of retroviruses has taken on a new sense of urgency with 
the identification of hum an immunodeficiency virus (HIV) as the causative 
agent of acquired im mune deficiency syndrome (AIDS). The vast am ount of 
information gathered regarding HIV-1 in a relatively short period of time is 
unprecedented in science. Yet, like cancer, not enough information has 
been gathered to effectively treat this disease. The virus studied in this 
dissertation, equine infectious anemia virus (EIAV), is related to HIV-1 and 
consequently shares some common features. In this review some 
characteristics common to all retroviruses will first be described , then the 
HIV literature relevant to the studies performed herein will be presented, 
followed by a review of the relevant EIAV literature.
Retrovirus Taxonomy
The retroviruses are so named because they reverse the normal flow 
of genetic information by making double-stranded DNA from their genomic 
RNA. The retrovirus family contains three subfamilies: the oncovirinae, 
lentivirinae, and spumavirinae. The sub-family oncovirinae contains a 
large num ber of endogenous and exogenous avian and mammalian RNA 
tum or viruses (oncoviruses). The genomes of the vast majority of these 
viruses include only the three essential retroviral genes (gag, pol and env)
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that encode the virion structural proteins and the viral enzymes. Notable 
exceptions to this are the replication competent cellular oncogene- 
containing viruses , such as Rous sarcoma virus (RSV). In addition, the 
hum an T cell leukemia viruses (HTLV-I, -II) and bovine leukemia virus 
(BLV) encode at least two essential trans-acting proteins functionally 
homologous to the HIV-1 Tat and Rev proteins (see The HIV-1 Tat Protein 
and The HIV-1 Rev Protein).
The retroviruses of the sub-family lentivirinae, the lentiviruses, 
result in slow persistent degenerative diseases in their respective host 
organisms, hence the prefix lenti- derived from the Latin word meaning 
slow. Members of this family include the prim ate immunodeficiency 
viruses (SIV, HIV-1, and HIV-2), feline immunodeficiency virus, the 
recently reported canine immunodeficiency virus (Perk et ah, 1992) and a 
num ber of ungulate viruses (equine infectious anemia virus, bovine 
immunodeficiency-like virus, visna-maedi virus, and caprine arthritis- 
enteritis virus). All members of this family encode functional equivalents 
of the HIV-1 Tat transcriptional trans-activator and Rev regulator of 
expression of virion proteins. Additional proteins that contribute to the 
specific pathogenicities of these viruses are also common.
The subfamily spum avirinae contains a num ber of viruses found in a 
w ide variety of mammals, including hum ans, that cause no known disease 
(Weiss, 1988). These viruses are named for their ability to induce 
m ultinucleated syncytia w ith num erous vacuoles producing a foamy 
cytopathic effect in culture, hence the prefix spuma- derived from the Latin 
word meaning foam. Like the lentiviruses, the prototypic spumavirus, 
hum an foamy virus (HFV), encodes a transcriptional frans-activator as well 
as three other proteins with undeterm ined functions.
With the increasing availability of nucleotide sequence data for 
retroviruses, it has been suggested that this traditional division of 
retroviruses based on pathogenicity should be replaced by a taxonomic 
scheme based on genetic similarities (Cullen, 1991). In such a scheme, the 
retroviruses would be divided into two basic groups, the simple and the 
complex retroviruses. The simple retroviruses would include the majority 
of the oncoviruses, but w ould exclude the HTLVs and BLV. The simple 
retrovirus genomes contain only the obligatory gag, pol and env genes and 
perhaps an oncogene. These viruses exhibit a simple splicing pattern in 
which the gag and pol genes are expressed from unspliced genomic RNA, 
and the env gene and oncogene, if present, are expressed from a single 
spliced RNA. The complex retroviruses would include the rem ainder of 
the retroviruses, including the lentiviruses, the spumaviruses, the 
oncoviruses HTLV-I, -II and BLV. These viruses express a num ber of 
regulatory and auxiliary proteins from a variable num ber of alternatively 
spliced transcripts. In addition, these viruses exhibit a temporal regulation 
of gene expression im parted by the action of the Rev-like protein, where 
regulatory proteins are expressed early in infection from small multiply- 
spliced transcripts and the virion proteins are expressed late infection from 
the unspliced and singly-spliced RNAs.
Retrovirus Virion Structure
Retroviruses are enveloped positive strand RNA viruses. The RNA 
is said to be of positive sense, since it is capable of being directly translated to 
produce virion proteins. The genomic RNA resembles normal cellular 
RNAs, in that it is capped at its 5'-end with the standard cellular cap 
structure, 5'm7GpppG5', and polyadenylated at its 3'-end. The retroviral 
genome is diploid, in that each virion particle contains two copies of the
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genomic RNA that are non-covalently linked near their 5'-termini (Fig. 1A). 
The RNA exists in a ribonucleoprotein complex with a large num ber of 
copies of a basic nucleocapsid (NC) protein, and is also associated with 
several copies (5-10) of the reverse transcriptase (RT) enzyme (Fig. IB). A 
specific cellular tRNA molecule is base paired to the RNA near its 5' end. 
This tRNA functions as the primer for the reverse transcription reaction. 
The ribonucleoprotein complex is encapsidated into a core that is made up 
of predom inantly the major capsid (CA) protein. The core is surrounded by 
a matrix (MA) protein. The matrix protein is believed to form a monolayer 
directly beneath the phospholipid envelope. Retroviruses acquire this 
envelope from the cellular plasma membrane as they bud from the surface 
of an infected cell. The envelope bears two glycoproteins, the 
transm em brane protein (TM) and the surface protein (SU). The SU protein 
is highly glycosylated and the TM protein is only sparsely glycosylated.
These two proteins exist in the virion in a one-to-one ratio with the 
transm em brane protein anchoring the surface protein to the virion.
The Retroviral Life Cycle
Upon infection, virion particles attach through their surface 
glycoproteins to cellular receptors of the target cells. After binding to the 
receptor a hydrophobic portion of the transmembrane protein is believed to 
m ediate fusion of the viral envelope with the cell plasma membrane 
releasing the viral core into the cytoplasm. Once the capsid is released into 
the cytoplasm, the process of reverse transcription of the viral genomic 
RNA into double-stranded DNA by the virion associated reverse 
transcriptase occurs. The intracellular capsid appears to be much less tightly 
associated than the virion capsid thereby allowing small molecules required 








Figure 1. Genome and virion structure of a typical retrovirus. (Adapted 
from Coffin, 1991).
freely enter this structure. A consequence of the reverse transcription 
reaction is that the resulting DNA is flanked by direct repeats comprised of 
sequences derived from both the 5'- and 3'- ends of the genomic RNA.
These repeats m ay be from 200-800 bp in length and are known as the long 
terminal repeats (LTRs). Once the synthesis of the double-stranded DNA 
copy of the genomic RNA, known as a provirus, is completed the capsid 
structure is translocated to the cell nucleus by an as yet undeterm ined 
mechanism. At this point the proviral DNA, while still associated with the 
capsid structure, becomes random ly integrated into the host cell 
chromosome through a reaction catalyzed by the virion-associated integrase 
protein.
Once integrated, the proviral DNA is transcribed by RNA polymerase 
II of the host cell. The prim ary RNA transcript may be packaged as genomic 
RNA into progeny virions, directly transported to the cytoplasm for 
translation or spliced to provide mRNAs encoding the env protein or in the 
case of m ore complex retroviruses a num ber of other protein products. The 
prim ary transcript is translated to produce the products of the gag and pol 
genes. The gag products are the internal viral structural proteins (CA, MA, 
and NC) and the pol products are the virion-associated enzymes (RT, IN, 
PR). Both the Gag and Pol proteins are translated as polyproteins that m ust 
be post-translationally cleaved. The Gag and Pol precursors are directed to 
the inner surface of the cellular plasma membrane at regions where a high 
density of the enu-encoded glycoproteins stud the outer surface of the 
membrane. Most retroviruses do not form defined intracellular viral 
particles, rather the first detectable virions are seen as egressing buds from 
the infected cell plasma membrane. It appears that the core is not
completely formed at the time of egress, as freshly budded particles are not 
electron dense bu t become so soon after their release from the cell.
Retroviral Gene Expression 
In this section, general principles of retroviruses gene expression will 
be described with emphasis on lentiviral gene expression. The expression 
strategies of the complex retrovirus HIV-1 will be used as a model to 
describe the regulation of gene expression in lentiviruses, however some 
strategies utilized by all retroviruses are also discussed. Although the 
complex retroviruses are unique in their use of virally-encoded trans-acting 
factors to regulate gene expression, all retroviruses m ust encode multiple 
proteins from the gag and pol genes by translation of the full length 
genomic RNA. Also, all retroviruses m ust use some type of strategy to 
regulate the levels of spliced (env) and unspliced (gag/pol) RNA. Although 
the complex retroviruses contain additional genes, the overall genome 
structure and LTR structure is similar in all retroviruses.
The Structure of the HIV-1 Proviral Genome
The HIV-1 proviral genome is 9.7-kb in length and contains long 
terminal repeats of approximately 650-bp each (Fig. 2). There is some 
sequence variability between individual HIV-1 isolates, particularly in the 
LTRs and the env gene. For convenience the genomic organization of one 
of the earliest published sequences, HIV-1/SF-2 (Sanchez-Pescador et al., 
1985; GenBank accession K02007), is described here. The LTRs of HIV-1/SF2 
are 634 bp long and are described in detail below. The 5'-LTR functions as a 
complex prom oter to induce the transcription of the full-length viral RNA 
which serves as the genomic RNA for progeny virions and as an mRNA for 
translation. The 5-LTR is followed by a short leader region of 154-bp (nt 
635-789) that is defined as the sequence between the U5 region of the 5-LTR
8





v p r L l v p u
-tat — 
-  r e v




Figure 2. The structure of HIV-1 proviral DNA. (Adapted from Rosen and 
Pavlakis, 1990).
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and the gag gene ATG initiation codon. The overlapping gag and pol genes 
follow the leader region and account for just over 44% of the entire HIV-I 
genome (nt 790-5102). The pol/env intergenic region is 1128-bp in length (nt 
5103-6231) and is the site for m ost of the small genes characteristic of 
lentiviruses. This entire region is utilized by the virus to encode the vif, 
vpr, and vpu genes and the first coding exons of the tat and rev genes. The 
proteins produced from these genes and their roles in viral replication are 
discussed later. The tat and rev genes are the only HIV-1 genes that are 
interrupted by an intron. The first coding exon of tat (trans-activator of 
transcription) encodes 72 amino acids of the 86 amino acid protein. The 
splice donor signal that is utilized to connect the two tat exons is followed 
immediately by an in-frame termination codon. This allows the synthesis 
of a functional 72 amino acid Tat protein (Tati) from partially spliced RNAs 
(see The mRNAs Produced by HIV-1). The first coding exon (25 codons) of 
the rev (regulator of virion expression) gene overlaps with the last 75-bp of 
the first coding exon of the tat gene in an alternative reading frame. The 
first coding exons of tat and rev are 3'-coterminal and their second coding 
exons are 5'-coterminal, since they utilize the same splice donor (nt 6053) 
and acceptor (nt 8382) sites to join their two coding exons. The second 
coding exon of rev (nt 8383-8657) encodes the majority of this protein (91 
codons), whereas the second coding exon of tat encodes only 14 amino acids 
that appear to be dispensable for Tat function. The intron that separates the 
two coding exons of tat and rev contains the rev responsive element (RRE). 
Unspliced and partially-spliced RNAs that contain the RRE are retained in 
the nucleus in the absence of the Rev protein. Therefore, fully-spliced 
RNAs that contain the two exon form of tat (Tat-2) and rev do not require 
the action of Rev for their expression (see The HIV-1 Rev Protein). The
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ATG initiation codon (nt 6070) of the vpu (viral protein U) gene (nt 6070- 
6314) lies 17-bp downstream of the ta tl /r e v l  splice donor site. The final 28 
codons of vpu overlap w ith the 5'-end of the 856 codon env gene (nt 6232- 
8799). The final currently identified gene of HIV-1 is the nef (negative 
effector) gene (nt 8801-9433), which immediately follows the env gene (nt 
6232-8799) and extends into the 3'-LTR (nt 9102-9736). The nef gene  ATG 
codon is separated from the env gene termination codon by a single base 
pair, and the nef gene overlaps the majority of the U3 region of the 3'-LTR. 
The HIV-1 LTR
The U3 region (nt 1-452) of the 634-bp HIV-1 LTR constitutes the 
majority of the LTR and contains the viral promoter and most of the cis- 
acting elements involved in transcriptional m odulation by cellular factors 
(Fig. 3). As mentioned above, the border between the U3 region and the R 
region (nt 453-550) defines the transcriptional start site (+1). Immediately 
upstream  of the start site lies the TATA box (-28—>-24), the binding site for 
the TATA binding protein (TBP), a component of the RNA polymerase II 
transcription factor TFIID. Mutations in the TATA box appear to have 
surprisingly little effect on basal transcription levels (Berkhout and Jeang, 
1992; Olsen and Rosen, 1992), but dramatically reduce Tat-mediated trans- 
activation (see The HIV-1 Tat Protein). Initial analysis of deletion mutants 
of the U3 region determ ined that sequences upstream  of position -167, 
relative to the transcription start site (+1), contain an apparent negative 
regulatory element, since deletion of these sequences resulted in a 2 to 3-fold 
increase in basal transcription levels (Rosen et al., 1985). LTR sequences 
from -167—>-28 were identified as an enhancer element, since they are 
capable of activating transcription irrespective of distance and orientation 
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Figure 3. The HIV-1 LTR. (Adapted from Antoni et al., 1994).
1985). This enhancer was subsequently determined to be bipartite in nature, 
consisting of two adjacent binding sites (-105—>-80) for the B-cell 
transcription factor, NF-kB (Nabel and Baltimore, 1987), and three 
contiguous binding sites (-78->-47) for the mammalian transcription factor 
Spl (Jones et al., 1986). Of the three Spl binding sites only the central site, 
Spl II, contains the core consensus hexanucleotide Spl binding sequence 
GGGCGG. The flanking sites, however, do exhibit a perfect match at 8 of 10 
residues to the extended decanucleotide consensus Spl binding sequence 
T/GGGGCGGRRY. All three sites bind purified Spl in vitro w ith the most 
distal site, Spl III, having the highest binding affinity and the proximal site, 
Spl I, having the lowest (Jones et al., 1986). Interestingly, in reconstituted in 
vitro transcription reactions, the high affinity binding site, Spl III, could be 
deleted with only a marginal reduction in basal transcription activity. 
Unfortunately, in vivo investigations of basal transcription levels have 
proven difficult due to the extremely low level of transcription from the 
HIV-1 LTR in the absence of the viral trans-activator, Tat. Somewhat 
conflicting results have been reported on the importance of the individual 
Spl sites to Tat-mediated trans-activation. It is generally agreed, however, 
that at least one functional Spl site is required for Tat-mediated trans­
activation  in non-lymphoid cells (Harrich et a l, 1989; Southgate and Green, 
1991) and that NF-kB can at least partially fulfill the requirem ent for an Spl 
site in cells producing high levels of this factor, such as B-cells and activated 
T-cells (Parrott et al., 1991). Since the NF-kB factor is an inducible factor that 
is responsive to a number of stimuli that activate T-cells, it is likely to be 
involved in activation of transcription of latent integrated HIV-1 proviral 
DNA (Antoni et al., 1994).
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A large num ber of factors have been identified to bind to the broadly 
defined negative regulatory element (NRE) within the U3 region of the 
HIV-1 LTR (-454-4-167). In several cases more than one factor has been 
shown to bind at a single site. The physiological relevance of any of these 
factors, however, has yet to be elucidated. A site termed URE (upstream 
regulatory element) or TCF-1 (T-cell factor 1 binding site) (-150—>-121) binds 
the T cell specific factor T C F la (Waterman and Jones, 1990). Deletion of this 
element results in enhanced transcription from the HIV-1 LTR in T-cells 
(Nakanishi et al., 1991). The fact that this element is duplicated in some 
viral isolates obtained from infected patients (Koken et al., 1992) is 
suggestive of an in vivo role for this element, although none has yet been 
found. This element does not fall within the originally defined NRE, but 
could contribute to down-regulation of the HIV-1 LTR.
A consensus binding site (-173—>-159) for the transcription factor USF- 
1, originally defined as an activator of the adenovirus major late promoter 
(Carthew et al., 1985), lies upstream  of the TCF-1 site. At least five different 
proteins have been shown to bind to this region including the following: 
the originally defined 44-kd USF-1 protein (Lu et al., 1990); sp50, a 50-kd T 
cell-specific protein, (Smith and Greene, 1989); HIV-TF1, a 39-kd 
phosphorylated protein (Maekawa et al., 1991); and two other proteins of 70 
and 110-kd (Giacca et al., 1992). Although the precise role of these proteins, 
if any, in HIV infection remains to be determined, it is interesting to note 
that the T-cell-specific protein, sp50, is known to negatively regulate the 
interleukin 2 (IL-2) receptor a  promoter (Smith and Greene, 1989).
A binding site (-254—>-216) for a factor involved in activation of the 
IL-2 promoter, NFAT-1 (nuclear factor of activated T cells), lies upstream  of 
the USF-1 binding site. The NFAT-1 can bind to this site within the LTR in
1 4
vitro, bu t deletions of this site in infectious proviral clones indicate that this 
sequence represses HIV gene expression (Lu et al., 1990). It is unclear how a 
factor known to activate expression in one promoter (IL-2) may repress 
transcription in another (HIV LTR). A second protein, ILF-1, has been 
identified that binds the NFAT-1 sequence in both the IL-2 promoter and the 
HTV-1 LTR and represses transcription from both promoters (Li et al., 1991).
It is conceivable that the HIV-1 LTR may preferentially bind the repressive 
factor (ILF-1) due to either the prim ary sequence of the binding site or the 
environm ent provided by other proteins bound near this region.
The sequences located from -350 to -300 in U3 contain binding sites for 
the transcription factor A pl (Franza, 1988), steroid/thyroid  hormone 
receptors such as COUP-TF (chicken ovalbumin upstream  promoter 
transcription factor) (Cooney et al., 1991), the c-myb cellular proto-oncogene 
gene product (Dasgupta et al., 1990), and two novel factors, NRT-1 and NRT- 
2 (Yamamoto et al., 1991). The novel NRT binding sites repressed 
transcription when placed into a heterologous promoter, but deletion of the 
region containing these sites in an infectious proviral clone of HIV-1 did not 
significantly augm ent transcription, casting doubt as to the involvement of 
this region in negative regulation of HIV transcription.
The R region of the LTR contains the trans-activation responsive 
(TAR) sequence element. Although proteins have been shown to bind to 
TAR DNA, they did not affect Tat-mediated trans-activation. Rather Tat 
binds to TAR RNA on nascent transcripts to activate transcription initiation 
a n d /o r  elongation (see The HIV-1 Tat Protein). One of the proteins that 
binds to TAR DNA is the leader binding protein 1 (LBP-1) (Jones et al., 1988).
This protein binds the LTR at three sites that span the U 3/R  border region 
and includes sequences near the TATA box. The LBP-1 binding sites near
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the transcription start site are high affinity sites believed to be im portant for 
detectable levels of basal transcription (Boris-Lawrie et al., 1992; Jones et al.,
1988). The LBP-1 binding site that lies near the TATA box is a low affinity 
binding site and appears to exert a repressive effect on transcription by 
blocking access of the basal transcription factor TFIID to the TATA box (Kato 
et al., 1991). The R region of the LTR also contains the AAUAAA consensus 
polyadenylation signal near its 3' end. Due to its location in the redundant 
region of the viral RNA, the polyadenylation signal is present near both the 
5' and 3'-termini yet only the 3' signal results in polyadenylation. Deletion 
studies in a number of retroviruses, including HIV, have shown that 
sequences within U3 and therefore only present upstream  of the 3' poly­
adenylation signal in the genomic RNA, are required for efficient 
polyadenylation of viral RNA (Dougherty and Temin, 1987; DeZazzo et al.,
1991).
The U5 region of the LTR has been less extensively studied in HIV 
and other retroviruses, since it does not appear to perform any obvious 
regulatory function in gene expression. The only im portant sequence in U5 
thus far identified is the 3' terminal CA dinucleotide that is required for 
integration.
The HIV-1 Tat Protein
The protein products encoded by the tat and rev genes of HIV-1 are 
required for viral replication in vitro (Dayton et al., 1986; Fisher et al., 1986a;
Sadaie et al., 1988; Terwilliger et al., 1988). Both are small highly basic RNA- 
binding proteins translated from any of a num ber of small multiply-spliced 
RNAs. The Tat (frfl»s-activator of transcription) protein trans-activates 
transcription from the viral LTR by as much as 1000-fold (Arya et ah, 1985;
Sodroski et ah, 1985a). The Tat protein contains three distinct functional
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domains: (1) an amino-terminal cysteine rich domain that has been shown 
to be involved in metal binding and dim erization in vitro (Frankel et al.,
1988); (2) a carboxyl-terminal basic region known to be required for nuclear 
and nucleolar localization of the protein; (3) a central conserved core 
dom ain believed to be the transcriptional activation domain.
Unlike nearly all know n viral and cellular trans-acting factors, the ex­
acting sequence (TAR, trans-activation responsive element) required for Tat 
function is located immediately downstream  of the transcription start site in 
the LTR (Rosen et al., 1985). This observation led to the speculation that Tat 
may exert its function at the level of the viral RNA rather than at the DNA 
level. The TAR RNA is capable of forming an imperfect, yet highly stable, 
hairpin loop structure containing a 3-nt pyrim idine bulge near the 5'-end of 
the loop and is located at the 5'-end (nt +1- +59) of all HIV-1 mRNAs (Fig. 4). 
Indirect evidence for TAR function at the RNA level was provided by 
mutagenesis studies that demonstrated that the prim ary sequence of the 
nucleotides (nt) involved in the predicted stem structure could be 
significantly altered w ithout affecting fraws-activation as long as base pairing 
was maintained (Hauber and Cullen, 1988). In contrast, any changes in the 
predicted loop sequence or 3-nt pyrimidine bulge severely affected trans- 
activation (Feng and Holland, 1988; Berkhout and Jeang, 1989; Roy et al.,
1990a, b). Direct binding of Tat to TAR RNA has been dem onstrated in vitro 
using E. coli expressed Tat and in vitro transcribed TAR RNA (Dingwall et 
al., 1989). Subsequent binding experiments employing synthetic peptides 
corresponding to portions of Tat showed that the arginine-rich basic motif 
near the carboxyl terminus of Tat is required for Tat binding to TAR (Weeks 
et al., 1990; Calnan et al., 1991). Mutagenesis studies of the TAR stem loop 
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Figure 4. The structure of HIV-1 TAR RNA (Adapted from Cullen, 1992).
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al., 1990b). Interestingly, m utations in the loop, previously shown to be 
critical for Tat trans-activation in vivo, had no effect on Tat binding in vitro.
This indicated that there may be other factors required for Tat-mediated 
fnms-activation in vivo. A t least three independent research groups have 
reported cellular TAR and Tat binding proteins (Marciniak et al., 1990a;
Sheline et al., 1991; Wu et al., 1991), however the significance of these 
proteins in Tat-mediated trans-activation  and their roles in normal cellular 
gene expression remain to be elucidated. The reported development of a 
HeLa cell in vitro transcription system that supports Tat trans-activation  
(Marciniak et al., 1990b) should greatly facilitate future studies.
Tat-mediated trans-activation was initially suggested to be both 
transcriptional and post-transcriptional (Cullen, 1986; Rosen et al., 1986), 
however it is now generally accepted that the major effect of Tat is at the 
transcriptional level. A num ber of researchers have reported increased 
levels of HIV-1-specific RNAs in the presence of Tat ( Peterlin et al., 1986;
Muesing et al., 1987). Furthermore, these increases are known to be the 
result of enhanced synthesis rather than increased RNA stability (Hauber et 
al., 1987). Early studies on the mechanism of Tat trans-activation 
dem onstrated that Tat does not affect the overall level of transcriptional 
initiation at the HIV-1 LTR, bu t rather stabilizes the elongation complex to 
prevent prem ature termination (Kao et al., 1987). That is, in the absence of 
the Tat protein, transcription complexes that initiate at the HIV-1 LTR 
dissociate after synthesis of the TAR structure (nt +59). Thus, the TAR 
sequence was proposed to act as a transcriptional terminator and Tat as an 
antiterm inator, through a mechanism similar to that found for the 
bacteriophage lambda N  protein. A prediction of the anti-termination 
model w ould be that deletion of the TAR structure or m utations that
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disrupt base-pairing of the TAR stem should result in constitutive high 
level expression from the HIV-1 LTR. Such m utations do not result in this 
predicted effect, and the subsequent finding that Tat frans-activation was 
dependent on the positioning of TAR at the 5'-terminus of the viral RNA 
dem onstrated that this model was insufficient to fully explain the 
transcriptional activation by Tat (Selby et al., 1989).
Subsequent experim ents perform ed both in vivo and in vitro have 
dem onstrated that HIV-1 LTR-directed transcription terminates at m ultiple 
and perhaps random  sites downstream  of the TAR structure (Laspia et al.,
1989; Marciniak et al., 1990b). It was suggested that the accumulation of 
TAR RNA in vivo is the result of the action of 3'-exonuclease activity on 
these various prem aturely term inated transcripts w ith the TAR secondary 
structure rendering this structure resistant to the action of these nucleases 
(Selby et al., 1989). An alternative to the anti-termination model was 
proposed in which Tat acts as an RNA sequence-specific processivity factor 
(Cullen, 1990). In this model, Tat is proposed to bind the TAR stem-loop of 
the nascent RNA and recruit elongation factors to the transcription 
complex, thereby allowing transcription to continue unim peded. In the 
absence of Tat, the necessary factors are not recruited and the destabilized 
elongation complex dissociates from the DNA tem plate at random  locations 
downstream  of the TAR structure (Karn and Graeble, 1992).
A num ber of lines of evidence indicate that Tat plays a role in 
activation of transcriptional initiation. Some interesting insights into the 
role of Tat in transcriptional initiation have been obtained using the herpes 
simplex virus (HSV) VP16 trans-activation protein. VP16 is a member of a 
large group of eucaryotic trans-acting proteins that enhance transcriptional 
initiation through their acidic activation domain. W hen the acidic
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activation domain of VP16 was fused to the RNA binding domain of the 
HIV-1 Rev protein, another viral trans-acting RNA binding protein, it was 
able to trans-activate an HIV-1 LTR in which the TAR sequence was 
replaced by a portion of the Rev-responsive element (RRE) RNA (Tiley et 
al., 1992a). The level of this VP16-mediated trans-activation was comparable 
to the level observed with Tat on the wild type HIV-l LTR and 
dem onstrated position dependence of the c/s-acting RNA element. From 
these data it may be inferred that Tat and VP16 activate transcription 
through a common mechanism even though Tat does not contain the 
classical acidic activation domain.
Further evidence of Tat's involvement in initiation was obtained 
from the analysis of HIV-1 LTR m utations of the TATA element (Berkhout 
and Jeang, 1992; Olsen and Rosen, 1992). A minimal prom oter for basal 
transcription from the LTR has been defined as consisting of sequences from 
-43 to +80 (Berkhout and Jeang, 1992). This minimal prom oter is not trans­
activated by Tat despite the presence of the TAR structure. However, the 
addition of a single cellular transcription factor binding site upstream  of the 
TATA box, such as SP1 or NF-kB, renders this promoter inducible by Tat 
indicating the potential requirem ent of an interaction between Tat and 
another upstream  prom oter binding factor for frans-activation (Berkhout 
and Jeang, 1992). Replacement of the HIV-1 TATA element and 
surrounding sequences (-20 to -35) with TATA elements from other fully 
functional promoters resulted in the loss of Tat-mediated trans-activation  
w ithout significantly affecting basal transcription levels or promoter 
induction by upstream  DNA binding factors. However, minimal alterations 
of the TATA element resulted in a 3- to 10-fold reduction in Tat-mediated 
traas-activation (Olsen and Rosen, 1992). Recently, Tat has been shown to
specifically bind the TATA binding transcription factor TFIID (Kashanchi et 
ah, 1994). This binding is mediated by the central core region believed to 
include the Tat activation dom ain and m utations at a single amino acid 
residue within this domain fail to bind TFIID. It has been suggested that 
there are two distinct classes of transcription complexes assembled on the 
prom oter region of the HIV-1 LTR or that there are two promoters that 
share the same start site (Cullen, 1993). One class or promoter has a very 
low level of basal transcriptional activity and is highly processive, the other 
has a high level of basal activity and is non-processive. The predom inant 
role of the non-processive prom oter may be to provide transcripts 
containing TAR that can be bound by Tat protein. The binding of TAR by 
Tat w ould result in transcriptional activation of the processive promoter, 
but not the non-processive promoter. The high level of transcription from 
the processive promoter w ould passively down-regulate the non-processive 
prom oter by a competitive mechanism. In this proposed mechanism, Tat 
activates transcription at the level of initiation in much the same manner as 
the DNA-binding activators, but would give the appearance of being a 
transcription elongation processivity factor, since more complete transcripts 
are produced.
The HIV-1 Rev Protein
The HIV-1 Rev (regulator of virion expression) protein is a 116 amino 
acid nuclear phosphoprotein that is required for the expression of the viral 
structural genes from the unspliced and singly-spliced RNAs and therefore 
is required for viral replication. Early in the HIV-1 infection cycle only 
m ultiply spliced RNAs encoding the Tat, Rev, and Nef (see The mRNAs 
produced by HIV-1) proteins are found in the cytoplasm of an infected cell 
(Kim et ah, 1989b). In studies where the nuclear and cytoplasmic RNA have
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been examined, it was determined that large amounts of unspliced and 
partially spliced RNA exists in the nucleus (Felber et ah, 1989; Malim et ah, 
1989a). The accumulation of the Rev protein beyond an undeterm ined 
critical level results in the export from the nucleus of the unspliced gag/pol 
RNA and the singly-spliced vif, vpr, ta tl and vpu/env  RNAs. These RNAs 
encode the virion structural proteins (Gag, gpl60), the virion associated 
enzymatic activities (RT, IN, PR), and auxiliary proteins that are involved in 
virion morphogenesis (Vpu), infectivity (Vif), and cytopathicity (Vpr). 
Expression of Rev results in the transport of the under-spliced RNA from 
the nucleus to the cytoplasm with the concomitant reduction in the levels 
of the small multiply-spliced RNAs (Malim et ah, 1988; Malim et ah, 1989a). 
Since the Rev protein reduces the levels of the multiply-spliced HIV-1 
mRNAs in the cytoplasm, it negatively regulates its own synthesis. 
Therefore, the HIV-1 Rev protein is involved in temporal regulation of 
gene expression allowing the expression of small multiply-spliced RNAs 
encoding the viral regulatory proteins early in the infection cycle and 
perm itting the expression of the virion associated proteins from unspliced 
and singly-spliced RNAs late in the infection cycle.
Rev exerts its effect on HIV-1 gene expression by directly binding to a 
specific region of viral RNA, the Rev response element (RRE). The cis- 
acting Rev element consists of a 234-nt region of the env gene that lies 
immediately upstream  of the second coding exons of tat and rev (Fig. 5).
This portion of env is found only in the unspliced and singly-spliced 
transcripts of HIV-1 and not in the multiply-spliced RNA. The RRE forms a 
defined secondary structure and the primary high affinity Rev binding site 
within this structure has been determined to lie in a 13-nt region (Tiley et 
ah, 1992b). The Rev protein appears to contain two distinct functional
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Figure 5. The structure of the HIV-1 Rev response element.
domains, an amino-terminal highly basic nuclear localization and RNA 
binding motif and a carboxyl-terminal "activation domain". W ithin a 
stretch of 13 amino acid residues of the basic region are nine arginine 
residues. The importance of this region in nuclear localization and RNA 
binding has been dem onstrated through extensive mutagenesis (Malim et 
al., 1989b; Perkins et al., 1989; Berger et a l, 1991). Sequences flanking the 
amino-terminal basic dom ain are known to be involved in 
m ultim erization of the Rev protein, and this m ultim erization is required 
for Rev activity in vivo (Malim and Cullen, 1991). The identification of the 
carboxyl-terminal domain as an activation domain is based on the 
observation that m utations in this region exhibit a trans-dom inant 
phenotype, that is unlike m utations in the RNA-binding and 
m ultim erization dom ains m utations of the carboxyl-terminal dom ain 
cannot be complemented by the addition of wild-type Rev protein supplied 
in -trans. The belief is that these m utant proteins efficiently bind the RRE 
sequence in vivo, bu t are unable to efficiently interact w ith some 
component of the splicing or the transport machinery and therefore behave 
as competitive inhibitors to wild-type Rev. It appears that an arrangement 
of leucine residues, distinct from the leucine zipper motif found in a 
num ber of transcription factors, is critical for m ediating the interaction with 
some cellular protein(s). Clearly, the identification and functional 
characterization of a cellular Rev-interacting protein(s) will shed significant 
light onto the mechanism of Rev function.
The precise mechanism of action of the Rev protein, like that of the 
Tat protein, is poorly understood. It is clear that there is a requirem ent for 
sub-optimal splice sites. All retroviruses use sub-optimal splicing signals to 
regulate the levels of spliced and unspliced viral mRNAs. Introduction of
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consensus splicing signals into a simple retrovirus results in a dramatic shift 
tow ard spliced RNA and little Gag and Pol proteins being produced (Katz et 
al., 1988). The sub-optimal splice sites of simple retroviruses affords the 
virus a passive mechanism to regulate the levels of spliced and unspliced 
RNAs (Katz and Skalka, 1990). In the case of the complex retroviruses, 
w here a relatively large num ber of alternatively spliced RNAs may be 
generated, the Rev protein directs an active effort to m aintain a balance 
between fully spliced and partially spliced or unspliced RNAs. The 
requirem ent for sub-optimal splice sites was demonstrated using a P-globin 
expression clone containing the HIV-1 RRE (Chang and Sharp, 1989). 
Introduction of the RRE into the wild-type p-globin gene did not alter the 
splicing pattern of the cytoplasmic mRNA either in the presence or the 
absence of the Rev protein. Mutagenesis of both splice sites, so that splicing 
could not occur, resulted in transport of unspliced RNA to the cytoplasm in 
a Rev-independent manner. However, m utation of a single splice site, 
resulted in the retention of the unspliced RNA in the nucleus in the 
absence of Rev and export of unspliced RNA to the cytoplasm in the 
presence of Rev. These findings led to the proposal that the binding of 
splicing factors to the sub-optimal splice sites of HIV-1 results in the 
retention of the unspliced RNA in the nucleus. The interaction of Rev 
w ith the RRE may serve to release the unspliced RNA from slow-acting 
splicing factors bound to sub-optimal splicing signals, thereby allowing the 
RNA to be exported to the cytoplasm.
The above experiments appear to indicate a requirem ent for the 
presence of sub-optimal splice sites to im part Rev-dependence on mRNA, 
however there are other factors that contribute to Rev function. A num ber 
of researchers have identified RNA sequences in the gag (Maldarelli et al.,
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1991; Schwartz et a l, 1992b,c), pol (Cochrane et a l, 1991) and env (Rosen et 
a l,  1988) genes that prom ote the instability of the RNAs containing them, 
that is, RNAs of the full-length and 4-kb class. When these sequences are 
placed into heterologous constructs containing reporter genes, they result in 
Rev/RRE-dependent expression of the chimeric mRNAs. For example, a 
260-bp inhibitory sequence located within the 3'-end of the pol gene when 
placed in the 3'-untranslated region (UTR) of a bacterial chloramphenicol 
acetyl transferase (CAT) reporter construct, resulted in an approximately 40- 
fold reduction in CAT activity. Co-expression of Rev did not restore the 
CAT activity unless the RRE was also placed into the CAT reporter construct 
(Cochrane et a l, 1990).
A 218-nt inhibitory region within the 5'-end of the gag gene was 
shown to result in a 4-fold reduction in half-life of RNAs containing this 
sequence (Schwartz et a l, 1992b). Co-expression of Rev resulted in 
stabilization of mRNAs carrying the inhibitory sequence. This gag 
inhibitory sequence, like that found in pol described above has a relatively 
high AU content of slightly greater than 60%, a common feature of cellular 
mRNAs w ith short half-lives (Shaw and Kamen, 1986; Jones and Cole, 1987; 
Wilson and Treisman, 1988). In an effort to examine the significance of the 
AU content of the gag inhibitory sequence, site-specific m utations were 
introduced at the second and third positions of gag codons to increase the 
GC content of this region while maintaining the gag amino acid coding 
sequence. Only after the introduction of 28 point m utations over a 270-nt 
region of gag was Rev-independent gag expression achieved (Schwartz et a l, 
1992c). Neither this gag inhibitory sequence described here, nor the pol 
sequence described above contain splice sites, so the Rev-dependence of 
these messages cannot be explained by the binding of splicing factors. It is
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believed that cellular proteins may bind to the inhibitory sequences and 
result in nuclear retention and degradation. Thus, the binding of Rev to the 
RRE m ay provide a general mechanism of releasing HIV RNA from such 
proteins as splicing factors and the putative inhibitory sequence binding 
proteins, thereby allowing its efficient expression in the cytoplasm.
The HIV Rev protein has also been implicated in the efficient 
translation of HIV mRNAs by increasing the efficiency of polysome loading. 
Two independent lines of evidence have shown that the RRE-containing 
RNAs fail to assemble into polysomes in the absence of Rev. In the above 
studies that determ ined the inhibitory element in gag, it was noted that 
while the level of gag RNA in the cytoplasm in response to Rev was 
increased about 10-fold, the levels of the p24 gag-encoded protein increased 
nearly 1000-fold. Thus, the increase in cytoplasmic mRNA expression was 
insufficient to account for the net increase in Gag proteins produced 
(DAgostino et al., 1992). In a separate study, it was determ ined that the large 
discrepancy between the levels of cytoplasmic and nuclear RRE-containing 
RNAs noted in non-lymphoid cells were not detected in cells of lym phoid 
origin, the in vivo host cell population for HIV. In these cells the 
cytoplasmic levels of the unspliced and singly-spliced viral RNAs were not 
significantly altered by the expression of Rev, yet the proteins encoded by 
these RNAs were not expressed in the absence of Rev (Arrigo and Chen, 
1991). Both of these research groups used sucrose density centrifugation and 
RT-PCR to show that the RRE-containing RNAs were found in complexes 
of 40S to 80S that co-sedimented with RNAs bound to ribosomal subunits or 
a single ribosome (monosome). In the presence of Rev, these RNAs were 
efficiently loaded onto polysomes. One possible explanation for these 
findings is that in the absence of Rev, RRE-containing RNAs may be
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transported from the nucleus while bound to protein factors, such as the 
putative inhibitory sequence binding protein(s) or splicing factors. The 
specificity for the export of these protein-bound RNAs may be different 
between cell lines, such that they may be more efficiently transported in 
lymphoid cells. In the case of the gag inhibitory sequence-containing RNAs 
that lack splicing signals, binding of the putative inhibitory sequence 
binding protein in the absence of bound splicing factors may be insufficient 
for full nuclear retention of these RNAs. The proteins bound to these 
RNAs may serve as an im pedim ent to translation and prevent assembly of 
the RNAs into polysomes. In the presence of Rev, these proteins may be 
rem oved from the RRE-containing RNAs prior to transport and thereby 
rendering them available for efficient polysome loading. Clearly, the 
complex regulation im parted by the Rev protein will be the topic of 
extensive investigation in the years to come.
The Auxiliary Proteins of HIV-1
In addition to Tat and Rev, HIV-1 contains at least 4 auxiliary proteins 
that, although not required for HIV-1 expression, appear to play im portant 
roles in infectivity, morphogenesis, and pathology of this virus. The 
auxiliary proteins of HIV-1 include the products of the vif, vpu, vpr, and nef 
genes. The Nef protein, like Tat and Rev, is an early gene product, 
synthesized from multiply-spliced RNAs that lack the RRE. This protein 
was initially identified as a negative effector of HIV gene expression, since 
infectious proviral clones with m utations in this gene exhibited enhanced 
replication rates in cultured T cells (Fisher et al., 1986b; Luciw et al., 1987). 
Further studies employing the HIV LTR linked to a reporter gene, showed 
that LTR sequences within the negative response element (NRE, -156—>-356) 
were required for Nef-dependent down regulation of HIV expression
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(Ahmad and Venkatesan, 1988). However, other researchers have been 
unable to duplicate these N ef-dependent repressive effects on HIV 
replication (Kim et al., 1989a) or HTV-LTR driven transcription (Hammes et 
al., 1989). In fact, in one case the Nef protein has been shown to significantly 
augm ent replication of some viral strains in cultured cells (Terwilliger et al., 
1991). Therefore, the role of Nef in the HIV life cycle remains controversial. 
Among HIV strains passaged extensively in culture, the nef gene often 
acquires prem ature termination codons indicative of lack of selective 
pressure for the maintenance of this gene in culture. However, the 
conservation of this gene in all prim ate immunodeficiency viruses is highly 
suggestive of an im portant in vivo role for the Nef protein.
The nef gene encodes a 27-kd phosphoprotein that is localized to the 
inner surface of the cellular plasma membrane through an N-terminal 
myristic acid post-translational modification (Allan et al., 1985; Franchini et 
al., 1986). Nef has been reported to bear homology to GTP-binding proteins, 
most notably p21 Ras, that are often involved in signal transduction 
pathways. Nef has been reported to bind GTP, to have GTPase activity, and 
to be capable of autophosphorylation (Guy et al., 1987), although other 
researchers have been unable to confirm this finding (Kaminchik et al.,
1990; Nebreda et al., 1991). The Nef protein has been shown to reduce the 
cell surface expression of the CD4 receptor in T cells (Guy et a l, 1987; Garcia 
and Miller, 1991). Recently, this reduction in CD4 has been attributed to 
Nef-induced endocytosis of CD4 followed by lysosomal degradation of the 
internalized receptor molecules (Aiken et a l, 1994). Since CD4 is involved 
in the regulation of T-cell activation through the T cell receptor (TCR) 
complex, it has been proposed that Nef results in de-regulation of T-cell 
activation and enhanced cellular transcription through the NF-kB enhancer
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(Aiken et al., 1994). This proposal gains support from the finding that 
transgenic mice expressing N ef exhibit increased TCR signalling 
(Skowronski et al., 1993). A significant role for Nef in the development of 
AIDS has been dem onstrated in rhesus macaques infected w ith ne/-defective 
simian immunodeficiency virus (SIV). Animals infected with nef deletion 
m utants of SIV failed to develop SAIDS (simian AIDS), and animals 
infected w ith SIV strains containing point m utations in Nef rapidly selected 
for revertants that restored nef function (Kestler et al., 1991). Clearly, further 
in vivo studies will be required to precisely identify the role of the Nef 
protein in HIV infection.
The roles of the Vpr, Vpu and Vif proteins in HIV-1 infection are not 
well understood. These proteins, along with the Nef protein, have been 
termed non-essential or accessory proteins, because the genes encoding 
them are often m utated in cultured virus isolates and such m utations do 
not abrogate viral replication in cultured cells. However, the conservation 
of these genes in natural isolates of HIV-1 indicates that they play an 
im portant role in the pathogenesis of HIV-1 infection. It has recently 
become apparent that the vpu, vpr and nef genes are required for efficient 
viral production in  prim ary macrophage cultures, but not in prim ary T 
lymphocytes (Balliet et al., 1994; Balotta et al., 1993), while the v if gene is 
required for production of infectious virions in both prim ary cell types 
(Akari et al., 1992; Gabuzda et al., 1992). Therefore, each of these genes is 
likely to be im portant in vivo, since HIV-1 infection of macrophages is 
believed to be im portant for viral persistence, latency, and transmission of 
the virus to the central nervous system (reviewed by Gendelman et al.,
1989).
The HIV-1 viral protein R (Vpr) is a 15-kd nuclear arginine-rich 
protein and is found in virions at molar ratios equivalent to the Gag 
proteins (Cohen et al., 1990a; Lu et al., 1993; Paxton et al., 1993). The 
carboxyl-terminal Gag protein, p6, is required for efficient incorporation of 
Vpr into virions (Paxton et al., 1993). The role of the p6 Gag protein in HIV- 
1 virion structure is unknown, and this additional Gag protein is only 
found in the prim ate lentiviruses and equine infectious anemia virus (p9). 
Co-transfection experiments with Vpr expression plasmids and reporter 
plasm ids showed that Vpr is capable of modestly activating transcription 
from the HIV-1 LTR (2-3-fold), as well as a num ber of other heterologous 
promoters (Cohen et al., 1990b). However, these results have yet to be 
confirmed by others, and the mechanism of Vpr transcriptional activation 
has not been investigated. It has been suggested that virion associated Vpr 
may activate HIV-1 gene expression immediately following proviral 
integration allowing the Tat protein to be produced which induces high 
level transcriptional trans-activation (Cohen et al., 1990a).
The HIV-1 viral protein U (Vpu) is a 16-kd integral membrane 
phosphoprotein (Strebel et al., 1989). The amino-terminal half of the 
protein contains 27 hydrophobic amino acids believed to be involved in 
m em brane anchoring, while the carboxyl-terminal portion of the protein is 
believed to form two am phipathic alpha helices of opposite net charge that 
have been proposed to be involved in the formation of homo-oligomers 
(Henklein et al., 1993). Vpu is unique to HIV-1, unlike the other accessory 
proteins that each have homologs in the other prim ate lentiviruses. Vpu 
appears to perform two distinct functions in HIV-1 infected cells. Early 
studies using cloned virus isolates with m utations introduced into vpu  
resulted in an increased intracellular accumulation of virion proteins
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associated with increased cytopathicity and syncytia formation and a delay in 
the appearance of free virus particles in cell culture supernatants (Klimkait 
et al., 1990; Terwilliger et al., 1989). Examination of infected cells in culture 
by electron microscopy showed that many virions were bound to the outer 
surface of the plasma membrane or sequestered within intracellular 
vacuoles (Klimkait et al., 1990). On the basis of these studies, it was 
concluded that Vpu is im portant for the release of m ature virions from 
infected cells.
It was later found that co-expression of the HIV-1 envelope 
glycoprotein, gpl60, with the CD4 receptor in HeLa cells resulted in impaired 
gpl60 production, and that the apparent block could be relieved by co­
expression of Vpu (Willey et al., 1992a). CD4 and gpl60 are integral 
membrane proteins, and as such are synthesized on ER-bound ribosomes.
The interaction of the two precursor molecules within the ER prevents the 
proper processing and transport of both by a mechanism termed interference 
(Buonocore and Rose, 1990; Crise et al., 1990). Co-expression of Vpu results 
in rapid degradation of CD4 that is complexed to gpl60 in the ER thereby 
allowing efficient expression of gpl60 and contributing to the down- 
regulation of CD4 observed in HIV-1 infected T-cells (Willey et al., 1992b).
Amino acid residues in the carboxyl-terminal cytoplasmic dom ain of CD4 
are necessary and sufficient to induce Vpu-mediated CD4 degradation 
(Lenburg and Landau, 1993; Vincent et al., 1993; Willey et al., 1994). The 
role of Vpu in the efficient transport of CD4 is readily reconciled with the 
fact that Vpu and gpl60 are synthesized from bicistronic RNA and thus are 
coordinately regulated at the translational level (see Translation of HIV-1 
mRNAs). Vpu appears at present to be a true bi-functional protein as its 
role in virus release occurs at the cellular plasma membrane and its role in
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CD4 degradation occurs within the ER. Artificial retention of Vpu within 
the ER prevents its function in viral release. Furthermore, the 
phosphorylation of Vpu is required for CD4 degradation within the ER, but 
has little effect on the viral release properties of this protein (Schubert and 
Strebel, 1994).
The HIV-1 viral infectivity factor (Vif) is a 23-kd protein that exists in 
both a soluble cytoplasmic form and a membrane-associated form 
(Goncalves et al., 1994). Vif increases the infectivity of virions produced in 
prim ary T-cells by as much as 1000-fold and has been implicated in cell to 
cell transmission of virus (Fisher et al., 1987; Strebel et al., 1987). The Vif 
protein is produced from a Rev-dependent RNA (see The mRNAs produced 
by HIV-1) late in the infection cycle (Garrett et al., 1991; Schwartz et al.,
1991). Some interesting insight into the role of Vif in HIV-1 infection has 
arisen from the observation that some CD4+ T-cell lines, unlike prim ary T- 
cells, produce highly infectious virions when infected with v if m utants 
(Gabuzda et al., 1992). For example, vif' HIV-1 infection of the CEM T cell 
line (nonpermissive cell line), like prim ary T cells, produced virions that 
were not infectious in any other cell line examined. However, virions 
produced from the infection of the Jurkat T cell line, or from transfection of 
CD4“ COS-1 monkey kidney cells (permissive cell lines), could infect 
multiple T cell lines, including CEM (Gabuzda et al., 1992). In an attem pt to 
reconcile the observation that some T-cell lines require the expression of Vif 
to produce infectious virions while others do not, it was proposed that the 
permissive cell lines may contain a cellular Vif-like compensating activity.
These experiments, combined with the fact that Vif is expressed late in 
infection, have shown that Vif exerts its effect on virions during their
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assembly. That is, the effect of Vif on virion infectivity is imposed on the 
virion in the producer cell not the cell being infected.
M utant viruses that lack v if produce virions that are indistinguish­
able from wild type vif+ viruses in terms of their content of virion proteins, 
genomic RNA, and even their ability to bind and enter CD4+ T-cells (Blanc 
et al., 1993; Ma et al., 1990). However, it is clear that viruses produced from 
v if m utants in nonpermissive cell lines display delayed kinetics w ith respect 
to the onset of viral DNA synthesis (Sova and Volsky, 1993; von Schwedler 
et al., 1993). It was recently discovered that retroviral virions contain partial 
reverse transcription products, indicating that viral DNA synthesis occurs to 
some extent prior to or during formation of the m ature virus particle (Lori 
et al., 1992; Trono, 1992). Examination of the levels of viral DNA in virions 
produced from wild type and vif' HIV-1 isolates detected no differences, 
indicating that Vif is not required to render virions competent for DNA 
synthesis (von Schwedler et a l, 1993). Thus, it is currently believed that Vif 
alters virions at the time of their formation in a manner that makes them 
m ore competent for DNA synthesis after being internalized in an infected 
cell (von Schwedler et al., 1993). It should be noted that Vif bears some 
sequence homology to cysteine proteases and treatment of HIV-l-infected 
cells w ith inhibitors of cysteine proteases results in production of virions 
w ith reduced infectivity (Guy et al., 1991). Although the viral cytoplasmic 
dom ain of the HIV-1 transmembrane protein, gp41, has been reported to be 
a target of Vif proteolytic activity (Guy et al., 1991), this finding has been 
disputed by several research groups (Gabuzda et al., 1992; Ma et al., 1994; 
von Schwedler et al., 1993). It is clear, however, that both cysteine residues 
of Vif are required for its function (Guy et al., 1991; Ma et al., 1994).
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The mRNAs Produced by HIV-1
During HIV-1 infection three major size classes of transcripts are 
produced, and their relative abundance in the cytoplasm of an infected cell 
is tem porally regulated (Kim et al., 1989b). Early in the infection only small 
transcripts of approximately 1.8-kb in length are produced. This size class 
consists of a heterogeneous group of transcripts that encodes the products of 
the tat, rev, and nef genes. Once a critical level of the Rev protein has 
accumulated in the nucleus of an infected cell, the RRE-containing 9.2-kb 
unspliced genomic RNA and a num ber of RNAs of approximately 4-kb 
accumulate in the cytoplasm. The genomic RNA may be either directed to 
the inner surface of the plasma membrane for packaging into progeny 
virions or m ay be translated to produce the Gag capsid precursor and the 
pol-encoded viral enzymatic activities. The 4-kb class of mRNAs, like the
1.8-kb class RNAs, is a heterogeneous class but are primarily responsible for 
the synthesis of the enz>-encoded gpl60 glycoprotein. However, some RNAs 
in this size class also encode the auxiliary proteins Vpu, Vif, and Vpr.
The various HIV-1 RNAs are produced by alternative splicing events 
involving at least 5 splice donors (SD) and 11 splice acceptors (SA). The 
presence of 8 competing splice acceptors between the 3'-end of pol and the 
5 -end  of env  leads to much of the heterogeneity in HIV-1 mRNAs. All 
HIV spliced RNAs contain a 289-nt leader exon (exon 1) due to the presence 
of a unique splice donor at nucleotide (nt) 289 of the genomic RNA (In this 
section the n t designations will be relative to the transcription start site, +1).
The singly-spliced RNAs of the 4-kb size class are generated by splicing of the 
leader exon splice donor to one of the various acceptors in the pol/env 
intergenic region (Fig. 6). In simplified terms, there are essentially five 
classes of singly-spliced RNAs, in which the leader is spliced to a splice
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acceptor (SA) that lies upstream  of the vif (SA2), vpr (SA3), ta tl (SA4), vpu  
(SA5) or nef (SA7) dstrons. All bu t the nef RNA, are of the 4.0-kb size class 
of HTV RNAs and are structurally multicistronic. Noticeably missing from 
the above list of cistrons that are immediately preceded by an upstream  
splice acceptor, is the env cistron. To date no splice acceptor has been 
identified to lie within the 161-nt sequence between the initiation codon of 
vpu and that of env. Thus, HIV-1 env m ust be expressed as the second 
cistron in bicistronic RNAs that contain vpu as the first cistron. In an 
exhaustive study Purcell and M artin (1993) have examined the relative 
levels of each of the spliced transcripts produced by HIV-1 infection of 
peripheral blood mononuclear cells (PBMCs) using a semi-quantitative PCR 
method. A lthough approximately 80% of the vpu/env  RNAs result from 
the splicing of exon 1 to the acceptor immediately upstream  of vpu (Env 1), 
another 12% also contain the first exon of rev due to splicing of exon 1 to 
one of three closely-spaced acceptors lying directly upstream  of the rev 
initiation codon (Env 2-4) (Purcell and Martin, 1993). The 4.0-kb RNAs 
encode the vpu/env, tat-1, vpr, and vif RNAs at a molar ratio of 92:5:2:1, 
therefore the vpu/env  RNAs represent the vast majority of this class of 
RNAs.
In addition to the singly-spliced RNAs, the 4.0-kb class of transcripts 
also contains some multiply-spliced RNAs. These RNAs arise from the 
inclusion of two small non-coding exons (exon 2 and exon 3) into a number 
of the singly-spliced RNAs described above. Exon 2 consists of 49-nt w ithin 
the pol cistron and exon 3 consists of 73-nt w ithin the vif cistron. Exon 2 is 
bordered by the splice acceptor (SA2) used to produce the vif RNA described 
above (Vif 2) and the second splice donor (SD2) in the full length RNA. 
Since this splice donor lies upstream  of the v if AUG codon, this exon does
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Figure 6. The 4.0-kb size class of HIV-1 RNAs.
38
not provide any translational initiation signals w hen spliced to downstream  
exons. The Vif protein is the only HIV-1 protein produced from a spliced 
RNA that can only be expressed from a single RNA (Vif 2). The Vpr protein 
can be produced from two different transcripts. The singly-spliced transcript 
described above (Vpr 3) accounts for 98% of the vpr RNA and a second 
transcript containing exon 2 spliced to exon 3E (Vpr 4) accounts for only 2% 
of the vpr RNA of the 4.0-kb size class. As will be discussed below, vpr can 
also be expressed from RNAs of the 1.8-kb size class. The Tat-1 (72 amino 
acid) protein can be produced from 4 different RNAs: the singly-spliced Tat 
5 transcript described above (85%); a doubly-spliced RNA containing exon 2, 
Tat 6 (9%); a doubly-spliced RNA containing exon 3, Tat 7 (6%); or a triply- 
spliced RNA containing both exons 2 and 3, Tat 8 (<1%). Since the vpu/env  
singly-spliced RNAs are produced from 4 different splice acceptors and each 
of these four transcripts may contain exon 2, exon 3, or both, there are 16 
different vpu/env RNAs produced. However, as m entioned above, the 
singly-spliced RNAs account for 92% of the total vpu/env RNAs. The only 
m ultiply-spliced vpu/env  RNAs found at appreciable levels are the Env 5 
(3%) and the Env 8 (5%) RNAs. These RNAs contain non-coding exons 2 
and 3, respectively, spliced to the major env splice acceptor (SA 5).
The 1.8-kb RNAs encode the Tat-2 (86 amino acid), Rev, Nef, and Vpr 
proteins. These RNAs are identical to those of the 4-kb class described above 
except for the absence of the intron located between the two coding exons of 
Tat and Rev (SD4 to SA7, Fig. 7). This intron contains the Rev-responsive 
element (RRE) and a large portion of the env cistron, thus this intron will 
be referred to as the env /RRE intron here. Although a multiply-spliced 
RNA encoding Vif (1.2a.7, where exon 2a represents an extended version of 
exon 2 that contains sequences from SA2 to SD4) has been predicted
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Figure 7. The 1.8-kb size class of HIV-1 RNAs.
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(Schwartz et ah, 1990b), none has yet been found (Purcell and Martin, 1993). 
There are two 1.8-kb RNAs that encode Vpr and four that encode Tat-2 that 
are similar to the 4-kb Vpr and Tat-1 RNAs, respectively, except that they 
lack the cmzj/RRE intron. As is the case for the 4-kb RNAs, the 
predom inant 1.8-kb RNAs lack the additional non-coding exons (exons 2 
and 3). The predom inant 1.8-kb vpr RNA (Vpr 1) accounts for 72% of the
1.8-kb vpr RNA, while the major 1.8-kb Tat-2 RNA (Tat 1) accounts for 48% 
of the total Tat-2 RNA.
The 16 vpu/env  4.0-kb RNAs give rise to two groups of 1.8-kb RNAs. 
The 12 vpu/env  RNAs that utilize splice acceptors 4a, 4b, and 4c give rise to
1.8-kb Rev RNAs (Rev 1-12), since these acceptors lie upstream  of the Rev 
AUG initiation codon. The other four vpu/env  RNAs that utilize SA5 lack 
the Rev initiation codon and give rise to multiply-spliced RNAs that encode 
Nef (Nef 2-5). The three 1.8-kb Rev RNAs that lack non-coding exons (Rev 
1-3) account for 80% of the Rev RNAs. As mentioned above, there is a 
singly-spliced form of Nef RNA that lacks non-coding exons (Nef 1), 
however this RNA only accounts for 5% of the total Nef RNA. The 
predom inant Nef RNA (Nef 2, 49%) contains a single non-coding exon 
(exon 5). It is currently not clear if these non-coding exons affect the 
expression of the Nef protein, but it seems likely that the presence of the 
non-coding exon may reflect the inability of the cellular splicing machinery 
to completely overlook the extensive array of splice acceptors in the pol/env 
inter genic region. All of the other spliced RNAs described herein utilize at 
least one of the splice acceptors in this region.
One novel 1.8-kb HIV RNA worthy of mention results from the 
inclusion of a small exon (exon 6), located in the env cistron (SA6, nt- 
6611/SD5, nt-6724), into the Tat-2 RNA (Tat 1) between the two coding exons
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of Tat-2 (exons 4 and 7) (Schwartz et ah, 1990a). The insertion of this intron 
results in a frameshift of the Tat open reading frame to produce a chimeric 
28-kd protein, Tev or Tnv, that contains the first 72 amino acids of Tat, 38 
codons of gp90, and the carboxyl-terminal 91 amino acids of Rev. This 
protein has been identified in HIV-infected cells and has the functions of 
both Tat and Rev (Benko et ah, 1990; Salfeld et ah, 1990). These RNAs and 
their corresponding proteins have only been detected when cells are infected 
w ith one particular infectious proviral HIV clone of HIV-1 (HXB2). These 
RNAs could not be detected in the semi-quantitative PCR studies described 
above, and are therefore generally believed to be cryptic splice sites that are 
not broadly relevant to the majority of strains of HIV-1. Additional splice 
acceptors immediately upstream  of SA7, SA7a and SA7b, have also been 
previously reported (Schwartz et ah, 1990a). The use of these splice sites 
w ould result in deleterious mutations of the essential tat and rev genes, and 
were not detected in the semi-quantitative study. Thus, these sites are also 
presum ed to be cryptic splice sites that are not generally relevant to HIV-1 
replication and pathogenesis.
Translation of HIV-1 mRNAs
Retroviruses, in general, utilize a num ber of strategies to express a 
relatively large num ber of protein products from a single prim ary transcript. 
As dem onstrated above, a major strategy employed by HIV-1 is alternative 
splicing. However, all retroviruses m ust synthesize the gag-encoded virion 
core proteins and pol-encoded enzymatic activities from a single mRNA, 
the full-length genomic RNA. In most retroviruses, the gag gene encodes 
four proteins, and the pol gene encodes the three viral enzymes. All of 
these proteins are synthesized from the monocistronic genomic RNA as a 
single polyprotein that undergoes post-translational cleavage. The majority
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of ribosomes that initiate at the gag AUG codon terminate translation at the 
gag termination codon to produce the Gag precursor polyprotein. However, 
the gag termination codon m ay be suppressed with low frequency to allow 
for the synthesis of the Gag-Pol precursor polyprotein. This mechanism of 
expression of the pol-encoded enzymes appears to fulfill two roles in viral 
replication. First, it allows for much lower molar ratios of the catalytically 
active virion enzymes relative to the gag-encoded structural proteins.
Second, synthesis of a Gag-Pol fusion protein allows for the viral-encoded 
enzymes to be targeted with the Gag precursor to the inner surface of the 
cellular plasma membrane, so that they may be packaged into m ature 
virions.
Two distinctive translational mechanisms have been identified that 
allow for synthesis of Gag-Pol polyproteins in retroviruses, read-through 
suppression and ribosomal frameshifting. In read-through suppression, a 
rare suppressor tRNA inserts an amino acid into the nascent Gag 
polypeptide in response to the gag termination codon. This mechanism is 
utilized only by the mammalian oncoviruses (type C retroviruses), and has 
only been extensively investigated in Maloney m urine leukemia virus 
(MoMLV) (reviewed by Hatfield et al., 1992). The majority of retroviruses, 
including HIV-1, use ribosomal frameshifting to express Gag-Pol fusion 
proteins. Although ribosomal frameshifting can result in a shift to the -1 or 
+1 reading frame, only -1 frameshifting has thus far been observed in 
retroviruses. The frameshifting event requires the presence of defined cis- 
acting sequences in the viral RNA surrounding the frameshift site.
Sequences immediately upstream  of the frameshift site are characterized by 
a string of identical nucleotides that are necessary but not sufficient to trigger 
the frameshift. In HIV-1 RNA, there is a string of six uridine residues
followed by an adenine residue. It is the adenine residue in this sequence 
that is read twice, once as the final nucleotide in a gag codon (UUA) and 
then again after ribosome slippage as the first nucleotide in the first codon 
(AGG) of the pol reading frame (Jacks et al., 1988). Additional sequences 
downstream  of the frameshifting site are also required. Although there is 
no clear sequence conservation among retroviruses in this region, there is 
significant structural conservation. In all retroviruses examined to date, 
there is the potential to form a stable stem loop structure immediately 
downstream  of the frameshifting site and in some cases an RNA 
pseudoknot may be formed (Chamorro et al., 1992). The unusually high 
stability of such structures may result in ribosomal pausing at the frameshift 
site, thereby facilitating the slippage. Some retroviruses, such as hum an T 
cell leukemia virus type 1 (HTLV-1), undergo two ribosomal frameshifting 
events. In these cases, the virally-encoded protease is encoded in an 
alternative reading frame between and overlapping both the gag and pol 
cistrons. Thus, one ribosomal frameshift occurs to produce a G ag/Protease 
precursor protein and another occurs to produce the G ag/Protease/Pol 
polyprotein. Once synthesized, the Gag and G ag/Pol precursors are post- 
translationally cleaved by the virally-encoded protease to produce the 
m ature viral proteins.
Most retroviruses produce one singly-spliced mRNA that encodes the 
envelope polyprotein consisting of the surface glycoprotein (SU) and the 
transm em brane glycoprotein (TM). These mRNAs are translated on 
endoplasmic reticulum (ER) bound ribosomes due to the presence of an ER 
signal peptide at the amino terminus of the SU protein. This signal peptide 
is cleaved co-translationally by a cellular signal peptidase. The precursor 
protein is cleaved post-translationally by an as yet undeterm ined cellular
protease to form the m ature SU and TM proteins, that remain associated 
through disulfide bonds. In the case of HIV-1, there are multiple envelope 
length RNAs produced, as described above. Many of these contain the 
coding regions of other HTV genes and are therefore structurally 
multicistronic. In fact, there have been no RNAs detected in HIV-1 infected 
cells that contain env as the first cistron. The simplest env RNA described 
above, Env 1 (Fig. 6), also contains the overlapping vpu gene. This RNA is 
functionally bicistronic in transfected cells, producing both the Vpu and 
gpl60 (Env) protein (Schwartz et al., 1990b). Although the vpu cistron is the 
first cistron of this mRNA, there is very little Vpu protein produced as 
compared w ith Env. Examination of the sequence of all known HIV-1 
isolates dem onstrated that the vpu AUG initiation codon lies in a relatively 
weak context for translational initiation. The consensus sequence context 
for translational initiation is CC A/G CC AUG G, where, other than the AUG 
itself, the most im portant residues for efficient initiation are the purine in 
the -3 position, with adenine being preferred to guanine, and the guanine in 
the +4 position (Kozak, 1986). In all of the HIV-1 strains examined, the vpu 
AUG contains a pyrimidine, most often a cytidine, in the +4 position. 
M utagenesis studies have shown that the conservation of a pyrim idine in 
the +4 position of the vpu cistron is critical for efficient env expression 
(Schwartz et al., 1992a). On the basis of these observations, it was concluded 
that env is expressed from the vpu/env  RNA (Env 1) by leaky ribosome 
scanning through the inefficiently recognized vpu AUG. As will be shown 
below, this is a common mechanism used by HIV-1 to express multicistronic 
mRNAs. Since there are no env RNAs that do not also encode vpu, the 
synthesis of the two proteins encoded by these genes is coordinately 
regulated. This would appear to be beneficial to efficient virion production,
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since, as discussed above, the Vpu protein is believed to aide in the selective 
degradation of CD4 that is complexed with gpl60 in the endoplasmic 
reticulum  (Willey et al., 1992b).
In addition to the major env transcript (Env 1), there are three other 
vpu/env  transcripts (Env 2-4) that also contain the first exon of the rev 
gene. A lthough the protein coding potential of these mRNAs has not been 
examined in detail yet, it appears likely that they will also be found to 
produce the Vpu and gpl60 proteins. As will be presented below, the rev 
AUG codon, like that of vpu, lies in a sub-optimal sequence context 
allowing for leaky ribosome scanning. The next largest group of the 4.0-kb 
RNAs (5%) are those including the first coding exon of tat, such as Tat 5 (Fig.
6). A lthough the tat gene consists of two coding exons, the first exon of tat 
encodes 72 of the 86 total amino acids of the Tat protein. It is known that 
the first 72 amino acids of Tat are sufficient to provide full trans-activation 
of the HIV-1 LTR (Sodroski et al., 1985b), thus the first exon contains the 
essential Tat residues. The splice donor site (SD 4, nt 6274), that joins the 
two coding exons of tat, is followed immediately by an in-frame UAA 
termination codon, allowing for the synthesis of a fully functional 72 amino 
acid one exon Tat protein (Tati) from the Tat 5 RNA. Although this RNA 
also contains the vpu and env cistrons, it is functionally monocistronic in 
vivo due to the presence of a relatively strong translation initiation codon 
for the Tati protein, AA GAA AUG G, where those nucleotides matching 
the consensus sequence are underlined (Schwartz et al., 1990b; Schwartz et 
al., 1992a). The coding potential of the vif and vpr 4.0-kb RNAs has not been 
investigated, however it may be anticipated that the vpr RNAs will be 
functionally multicistronic due to a weak AUG context (GA UAG AUG G).
The v if gene AUG codon does not appear to have a highly conserved
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sequence context. In some isolates it lies in a highly favorable context for 
translation (GG AUU AUG G) while in others it does not (AA CAG AUG G). 
Therefore, depending upon the strain examined, the vif RNAs may be 
anticipated to be mono- or multi-cistronic.
The RNAs of the 1.8-kb class that encode the Tat-2, Rev, and Nef 
proteins are also structurally multicistronic as m entioned above. The RNAs 
that encode Tat-2 (Tat 1, Fig. 7) were shown to be monocistronic in vivo 
producing only the Tat-2 protein and very little Rev or Nef protein 
(Schwartz, et al., 1990a). By analogy to the Tat-1 RNAs described above, the 
inhibition of expression of the dow nstream  reading frames has been 
attributed to the relatively strong context of the tat AUG initiation codon 
(Schwartz, et al., 1992a). The rev/nef RNAs (i.e. Rev 1-12), on the other 
hand, are functionally bicistronic expressing high levels of Nef protein 
(Schwartz, et al. 1990a). The mechanism of expression of Nef from these 
RNAs has been attributed to the relatively weak translation initiation 
context of the rev AUG (UC CCU AUG G). In particular, the presence of a 
highly conserved cytidine residue in the -3 position is believed to result in 
low level initiation of rev. The conservation of this sequence context across 
a broad range of HIV-1 isolates is suggestive of the presence of selective 
pressure to maintain this sequence. The significance of such selection is not 
as obvious as that for the inefficient expression of the Vpu protein described 
above. In that case, there are no env RNAs that do not contain vpu as the 
first cistron, so that env expression is entirely dependent on leaky ribosome 
scanning through the vpu AUG. However, the multicistronic rev RNAs 
only make up only a fraction of the 4.0-kb RNAs (13%) and the 1.8-kb RNAs 
(34%). The ORFs that lie dow nstream  of rev in these RNAs, namely vpu, 
env and nef, can be efficiently expressed from alternative RNAs that lack
the rev initiation codon. As mentioned above, the Env 1 vpu I env  RNA 
makes up  80% of the total 4.0-kb class of RNAs and the various 
monocistronic nef RNAs make up 52% of the 1.8-kb class (Purcell and 
M artin, 1993). The inefficient expression of rev may rather reflect a need to 
m aintain controlled levels of Rev to prevent large am ounts of virus 
production followed by cell lysis. The Rev protein is expressed exclusively 
from the 1.8-kb class of RNAs early in infection. Once a critical level of Rev 
has accumulated, the unspliced and partially spliced RNAs appear in the 
cytoplasm and the virion associated proteins are produced. As the level of 
Rev falls below this critical level, the export of the under-spliced RNAs 
from the nucleus is prevented until the critical level of Rev is once again 
attained. This allows the virus an opportunity to control the level of virion 
production and affords the ability of the virus to enter latency when levels 
of Rev are low. Constitutive expression of high levels of Rev might 
therefore prevent viral latency and result a highly cytopathic viral infection.
The presence of the non-coding exons 2 and 3 (Fig. 6, 7) in a num ber 
of low abundance HIV-1 mRNAs does not appear to alter the translational 
efficiency of any of the HIV proteins in vivo. Thus, the significance of the 
these non-coding exons remains to be determined. It seems likely that they 
m ust play some significant role in HIV-1 infection, since there are no other 
HIV-1 RNAs that utilize splice donors 2 and 3. These donors are only 
utilized to produce the two small non-coding exons. Their conservation in 
all known HIV-1 isolates is highly suggestive of some role in viral gene 
expression.
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Equine Infectious Anemia Virus 
Historical Perspective of Equine Infectious Anemia Virus
The disease equine infectious anemia (EIA) was first described in 
France in 1843 (Lignee, 1843) and shown to be transm itted by a filterable 
agent, i.e. viral, in 1904 (Vallee and Carre, 1904). There was little significant 
investigation of EIA until the virus was propagated in prim ary mixed 
leukocyte cultures in the late 1960's (Kobayashi and Kono, 1967). This led to 
the production of a mostly ineffective live-attenuated vaccine (Kono et al., 
1970), however the failure of the vaccine to provide broad protective 
im m unity led to the discovery of antigenic variation in EIAV (Kono et al., 
1973). The molecular basis of this variation was later determ ined to involve 
alteration of the gp90 surface glycoprotein at the genetic level (Montelaro et 
al., 1984; Salinovich et a l, 1986). With the lack of an effective EIAV vaccine 
the emphasis was shifted from prevention of viral disease to diagnosis and 
control. In 1972 Leroy Coggins introduced the agar gel immunodiffusion 
(AGID) test for detection of EIAV antibody in infected horses (Coggins et al., 
1972). This test, commonly referred to as the Coggins' Test, is still currently 
used as the standard for EIA diagnosis. In 1973 EIAV was first cultivated in 
established cell lines allowing for the production of large quantities of 
highly purified virus (Malmquist et al., 1973). These cultured virus stocks 
were used to demonstrate the reverse transcriptase activity of EIAV, thereby 
allowing its characterization as a retrovirus. With the discovery of the 
hum an lentiviruses HIV-1 and HIV-2, there has been intensive study of 
EIAV on the genetic level. The sequence of the entire proviral DNA 
genome of EIAV was first reported in 1987 (Kawakami et al., 1987). The 
sequence dem onstrated that EIAV contained three short open reading 
frames, S I, S2 and S3, in addition to the gag, pol and env genes common to
all replication competent retroviruses. The predicted protein products of 
the SI and S3 ORFs were shown to bear striking sequence homology to the 
Tat and Rev proteins of HIV-1. These are obligatory RNA-binding proteins 
that regulate the level of viral transcription (Tat) and the relative levels of 
spliced viral RNAs (Rev).
Equine Infectious Anemia, the Disease
Initial infection of horses w ith EIAV results in the onset of acute 
disease w ithin 7-10 days post-infection characterized by fever, anemia, 
thrombocytopenia, and viremia. Although some horses (<5%) may 
succumb to this prim ary infection, the vast majority (>95%) recover from 
this initial infection and progress to the chronic stage of disease. The 
chronic stage of EIAV is unique amongst the lentiviruses, and is 
characterized by recurring episodes of fever, anemia, and viremia. These 
episodes typically last for 3-5 days and the length of time between episodes 
varies from several weeks to months (Fig. 8). Each febrile episode is 
associated with the appearance of distinct antigenic variants of the gp90 
surface glycoprotein. The variants are apparently able to escape immune 
detection and result in a bout of viremia. The chronic stage normally lasts 
for about one year at which time the majority of horses become inapparent 
carriers of the virus and appear clinically normal. These horses remain 
infected for life and may undergo subsequent febrile episodes if sufficiently 
stressed.
The Proviral Genome of EIAV
The DNA proviral genome of EIAV is 8.4-kb long and is flanked by 
relatively small LTRs of approximately 300 to 320-bp dependent on the 
individual isolate. The overall structure of the LTRs and the c/s-acting 











Figure 8. Schematic representation of EIAV disease course. The rectal 
tem perature of a hypothetical EIAV-infected horse is plotted as a function of 
time. The base line represents normal tem perature and the spikes indicate 
febrile episodes. As indicated, various forms of stress m ay cause an 
inapparent carrier to re-enter the chronic stage of the disease.
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overall genome structure of EIAV is relatively less complex than that of 
HIV-1, in that it contains only three genes in addition to the obligatory gag, 
pol and env. In EIAV these genes have traditionally been called open 
reading frames (ORFs) S I, S2 and S3 based on the order of their appearance 
in the genome from 5' to 3'. The SI and S2 genes lie w ithin the p o l/en v  
intergenic region, while S3 overlaps the transm em brane (TM) glycoprotein 
coding region of the env gene in an alternative reading frame (Fig. 9).
The only complete proviral sequence of EIAV currently available 
through the GenBank database (locus: EIAVCG; Accession: M16575) will be 
used as a representative isolate for the purpose of this abbreviated 
description of the genome structure. This isolate is 8407-bp in length and 
contains LTRs of 321-bp each. A 143 leader region (nt 322-464) lies between 
the 5-LTR and the gag ATG initiation codon. This leader region contains a 
single splice donor signal (nt 459) that lies immediately upstream  of the gag 
ATG codon (nt 465) and allows RNA splicing of the leader sequence to all 
EIAV RNAs. The gag gene (nt 465-1925) encodes a precursor protein 
(Pr55^fl̂ ) that consists of the amino terminal p i 5 matrix protein (MA), the 
p24 capsid protein (CA), the p l l  nucleocapsid protein (NC) and the carboxyl 
terminal p9 protein of unknow n function. The gag (nt 465-1925) and pol (nt 
1727-5122) genes overlap by 241-bp, and pol has been proposed to be 
expressed from the genomic RNA through ribosomal frameshifting at the 
sequence AAAAAAC (nt 1721-1727). The pol gene (nt 1727-5122) encodes 
the viral enzyme activities in the sequence of protease/reverse 
transcriptase/R N ase H /endonuclease similar to other lentiviruses.
The pol gene termination codon is followed immediately by an open 
reading frame (nt 5123-5275) with the potential of encoding 50 amino acids, 
however this open reading frame lacks a methionine initiation codon.
5 2
Figure 9. Schematic representation of the EIAV proviral genome.
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This open reading frame (ORF), originally termed ORF SI (Rushlow et a l, 
1986) is now known to be the second coding exon of EIAV Tat. The RNAs 
encoding the Tat protein and their expression will be discussed further 
below.
A mere 7-bp downstream of the ORF SI termination codon lies a 
second small open reading frame (nt 5283-5483), ORF S2, that has the 
potential to encode 66 amino acids. The second codon in this ORF 
corresponds to a methionine residue that may be responsible for initiation 
of its synthesis. The predicted protein product of this ORF bears no sequence 
homology to other lentiviral auxiliary proteins, and no function has yet to 
be assigned to the ORF S2 protein. The majority of ORF S2 overlaps with 
the 5'-end of the env gene (nt 5312-7891) in an alternative reading frame. 
Only 23-bp separate the first ATG of ORF S2 and the ATG initiation codon of 
env. This arrangem ent of ORF S2 and env in EIAV is similar to that of vpu  
and env in HIV-1. The env gene of EIAV encodes a precursor protein of 
135-kd (gpl35) that contains the surface glycoprotein, gp90, at its amino 
terminal end and the transmembrane protein, gp45, at its carboxyl terminal 
end. Overlapping the gp45 coding region of the env gene in an alternative 
reading frame, lies a third small open reading frame, ORF S3 (nt 7234-7641). 
This gene has the capacity to encode a protein of 135 amino acids, but like 
ORF S I, contains no methionine codons. This gene is believed to encode 
the EIAV Rev protein, and an initiation codon is provided to this gene by 
splicing (see The EIAV S3/Rev Protein). The env gene and the 3-LTR are 
separated by 17-bp that include the poly purine tract which is im portant for 
reverse transcription of the genomic RNA.
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The EIAV LTR
The EIAV LTR contains a U3 region that varies in length between 
isolates from about 190 to 210-bp. The R region of the LTR consists of 76-bp 
and the U5 region of 36-bp. The R region contains the EIAV Tat trans- 
activation response (TAR) element that has been localized to nt +4 to +22 
relative to the transcription start site. Thus, like the TAR sequence of HIV- 
1, the EIAV TAR is found in all viral mRNAs and forms a stable stem-loop 
structure required for trans-activation. The Tat/TA R interaction of EIAV 
will be presented in greater detail below. The U3 region of all the variant 
EIAV LTRs thus far examined contains a TATA box located approximately 
25-bp upstream  of the transcription start. Deletion analysis of the LTR 
determ ined that sequences from -31 to -46 are required for both basal and Tat 
frans-activated transcription from the EIAV LTR (Carvalho and Derse, 
1993a). This region has been demonstrated to bind the macrophage-specific 
transcription factor PU.l (Carvalho and Derse, 1993a). Equine infectious 
anem ia virus, unlike the prim ate immunodeficiency viruses, only 
replicates appreciably in m ature tissue macrophages in vivo and not in 
peripheral blood monocytes or lymphocytes (Sellon et al., 1992). The PU.l 
factor is named for its ability to bind a purine rich sequence (GAGGAA) and 
is a member of the ets oncogene superfamily of DNA binding proteins 
(Klemsz et al., 1990). Members of this family are activated by phorbol esters 
and thus are subject to activation by stimuli that activate protein kinase C. 
W ithin 5-10 nt upstream  of the PU.l binding site lies an AP-1 site (-45 to -60). 
AP-1 binds homodimers of the constituitively-expressed Jun family of 
proteins or the Jun proteins may form heterodimers w ith the inducible Fos 
family of proteins. The EIAV AP-1 site (TGACGCG) differs from the 
consensus site (TGACTCA) at 2 of the 7 nucleotides that define the
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consensus. Interestingly, oligonucleotides containing the consensus AP-1 
sequence do not compete very effectively for factor binding to the EIAV AP- 
1 sequence (Carvalho and Derse, 1993b). This suggests that a particular 
Fos/Jun family dim er binds the EIAV AP-1 more strongly than to the 
consensus AP-1 sequence. The identification of this putative Fos/Jun 
protein remains to be determined.
A hypervariable region of 10 to 30-bp lies immediately upstream  of 
the AP-1 site. This region varies in length and sequence between various 
isolates of EIAV. In the isolates characterized to date, the hypervariable 
region always contains at least one duplicated factor binding site. The 
simplest may be a single duplicated PEA2 site (see below), while the more 
complex hypervariable regions have been shown to contain additional sites 
for AP-1, PU.l and PEA2 (Carvalho et al., 1993). The most frequent 
duplications in the hypervariable region contain one or two additional PU.l 
binding domains (Payne et al., 1994). The hypervariable region is flanked on 
the 5' side by a PEA2 binding site in all isolates examined to date (Carvalho 
et al., 1993; Payne et a l, 1994). The PEA2 factor binding site was first 
identified as one of three cis-acting elements in the polyom a virus enhancer 
A (PEA) (Piette and Yaniv, 1987). The binding sequence for PEA2 in the 
EIAV LTR is AACCGCA. Although the specific factors that bind this 
sequence have not yet been identified, oligonucleotides containing this 
sequence specifically bind nuclear factors in extracts derived from a variety 
of cell types. Functional studies, involving the EIAV LTR linked to the 
bacterial CAT gene, indicate that mutagenesis of the PEA2 site results in 
reduced promoter activity of the LTR that varies in m agnitude dependent 
on the cell line employed (Carvalho and Derse, 1993b). These data indicate 
that this site is likely to play a role in EIAV gene expression.
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Early functional studies using LTR deletion m utants dem onstrated 
that sequences lying between -110 and -76 contain a negative regulatory 
element (Dorn and Derse, 1988). These early studies were done in a feline 
fibroblast cell line (FEA). Subsequent analysis of similar deletion m utants in 
hum an carcinoma HeLa cells and canine osteosarcoma D17 cells, indicated 
that sequences within this region exert a positive effect on EIAV regulation 
(Carvalho and Derse, 1993b). Computer assisted sequence analysis 
determined that this region contains a binding site for the m ethylated DNA 
binding protein (MDBP/EP/EF-C) (Ben-Levy et al., 1989), first isolated on the 
basis of its preferential binding to sequences containing m ethylated CpG di­
nucleotides (Huang et al., 1984). MDBP is a ubiquitous mammaliam protein 
that binds to a wide range of related nucleotide sequences (Supakar et al., 
1988). Partially purified MDPB has been shown to bind to the enhancer 
elements of EIAV, mouse polyoma virus, and hepatitis B virus in a 
m ethylation-independent manner (Zhang et al., 1990). Nuclear extracts 
from a num ber of sources, including hum an monocytes and B cells, form 
specific complexes with oligonucleotides that contain the EIAV MDBP site 
(Carvalho and Derse, 1993b). Thus it appears that cellular proteins interact 
w ith MDBP site of EIAV and, depending on the cell type examined, exert a 
positive or a negative effect on gene expression.
Although no factors have as yet been shown to b ind  to the EIAV LTR 
at sequences upstream of the MDBP site, there is a directly repeated sequence 
(TGT/  AGGGG1T1TAT) at the 5'-end of the LTR that may be of potential 
factor binding site (Derse et al., 1987). However, deletion of these sequences 
from the LTR appear to have little effect on EIAV gene expression in feline 
fibroblasts (Dorn and Derse, 1988). Much of the difficulty in analyzing EIAV 
gene expression lies in the lack of availability of stable cell lines of equine
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monocytes. It is possible that these 5' repeats may have an effect on gene 
expression in vivo or in cultured horse macrophages. Studies in these cell 
types m ust be done to determine the significance of each of the factor 
binding sites described above in EIAV gene expression in the infected horse. 
Identification of the EIAV ta t  Gene
Early studies indicated that reporter plasmids under the control of the 
EIAV LTR were specifically trans-activated 250 to 900-fold in feline (FEA) 
and canine (Cf2Th) fibroblast cell lines infected with a cell culture adapted 
strain of EIAV (Derse et al., 1987). These studies indicated that EIAV 
produces a factor, functionally analogous to the HIV-1 Tat protein, that can 
activate the LTR in trans. To examine if the SI, S2 or S3 gene products are 
responsible for this activation, restriction fragments from proviral clones 
containing each of these genes were subcloned into eucaryotic expression 
plasmids and co-transfected into canine D17 cells w ith LTR-CAT reporter 
constructs. Expression from a restriction fragm ent containing the SI and S2 
genes (pSl,2) was found to trans-activate the EIAV LTR approximately 10- 
fold, while a fragment containing only SI (pSl) did not activate the LTR 
(Dorn and Derse, 1988). These data appeared to indicate that the S2 gene 
product may be involved in EIAV trans-activation, although the levels of 
trans-activation were 25 to 90-fold lower than observed in EIAV infected 
cells. A second research group employed the same strategy of expressing 
proviral restriction fragments to assess their trans-activation  potential and 
also found that restriction fragments that contained both SI and S2 were 
competent for trans-activation. However, these researchers were able to 
prevent expression of the trans-activator by inserting a stop codon into the 
SI gene or by using anti-sense nucleotides directed against regions of SI 
(Noiman et al., 1990a). Furthermore, restriction fragments that lacked the
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majority of the S2 coding frame retained trans-activation activity. Similar 
experiments confirming these results were published nearly simultaneously 
by the research group that initially identified ORF S2 as the gene that 
encodes EIAV Tat (Dorn et al., 1990). This group claimed that their initial 
characterization of S2 as encoding the trans-activator was erroneous due to a 
previously undetected m utation in their pSl construct. Based upon these 
findings and the observation of limited sequence homology between the SI 
protein and the prim ate immunodeficiency virus Tat proteins, it was 
concluded that the SI gene, not S2, encodes the EIAV Tat protein. The 
major problem with these experiments was the use of proviral restriction 
fragments to express the various ORF proteins. As mentioned above, the SI 
and S3 genes contain no methionine initiation codon, indicating that these 
ORFs may require additional 5' exons to provide translational initiation 
signals. As will be discussed below, the SI protein is initiated from a non- 
AUG codon located within the leader region that is spliced to ORF S I . The 
ORF SI restriction fragments described here contain two contiguous UUG 
codons that may inefficiently initiate translation. The high fraas-activation 
activity of this protein coupled with detection using an enzymatic assay, 
may allow for detection of relatively low amounts of protein produced from 
these codons.
The independent isolation of frans-activating cDNAs from EIAV- 
infected cells that contained S I, but lacked S2 led to the definitive 
characterization of ORF SI as the gene that encodes EIAV Tat (Noiman et 
al., 1990a; Stephens et al., 1990). These Tat cDNAs, however did not clearly 
define the translational start site for the Tat protein. A splicing event that 
resulted in the joining of the EIAV leader to SI did extend ORF SI in the 5' 
direction into the leader sequence. However, none of the additional codons
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provided by leader sequences was a methionine codon. Thus, it was 
proposed that the EIAV Tat protein m ust be initiated from a non-AUG 
codon. The initiation codon of SI has been proposed to be either a CUG or 
an AUC codon (Noiman et al., 1991; Stephens et al., 1990). Evidence in 
support of each will be presented briefly below (see EIAV Transcripts and 
Translation), and further support for the usage of the CUG codon to initiate 
EIAV Tat synthesis is presented in the work described here.
The EIAV frans-Activation Response Region
The earliest experiments perform ed to determine the location of the 
EIAV trans-activation response region (TAR) showed that sequences 
dow nstream  of the transcriptional start site were required, since deletion of 
the R and U5 regions of the LTR abrogated fraws-activation (Sherman et al.,
1988). The construction of additional deletion m utants enabled the 
assignm ent of EIAV TAR to sequences w ithin R lying between 4 and 22-nt 
downstream  of the transcription start site (Dorn and Derse, 1988). This 
region was predicted to form a small hairpin-loop structure and mutational 
analysis appeared to confirm that its formation was required for trans- 
activation (Carvalho and Derse, 1991). Mutations that prevented base- 
pairing in the stem resulted in loss of Tat-mediated fra«s-activation.
Com pensatory m utations that allowed base-pairing of the stem, but altered 
the prim ary sequence, resulted in the restoration of trans-activation. The 
EIAV TAR element consists of a 10-bp stem and a short 4-nt loop (Fig. 10).
The loop is closed by two U-G base pairs that have been proposed to provide 
a recognition signal for EIAV Tat binding, since the EIAV TAR element 
lacks the uridine bulge know n to be im portant for HIV-1 Tat binding to the 
HIV-1 TAR. NMR and ribonuclease sensitivity assays of the 25-nt EIAV 
TAR have confirmed that TAR assumes this structure in solution (Hoffman
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Figure 10. A comparison of the HIV-1 and EIAV TAR RNAs. For ease of 
comparison, only the minimal sequences required for HIV-1 Tat trans- 
activation are shown here. (Adapted from Derse et a l, 1993).
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et ah, 1993). Although direct binding of EIAV Tat to EIAV TAR has yet to be 
dem onstrated, mutations that alter the loop-proximal U  G bp to an A-U bp 
result in a 68% reduction in trans-activation (Carvalho and Derse, 1991). 
Unlike HTV-1 TAR (Feng and Holland, 1988), the sequence of the loop 
nucleotides appears to be of lesser importance in EIAV. Single nucleotide 
changes within the loop have been shown to modestly decrease or increase 
trans-activation, however deletion of one of these bases to create a 3-nt loop 
reduces trans-activation by 24-fold (Carvalho and Derse, 1991).
Of the lentiviruses, only the prim ate immunodeficiency viruses 
(HIV-1, -2 and SIV), the bovine immunodeficiency-like virus (BIV) and 
EIAV contain trans-activation responsive regions that are localized within 
the 5'-end of their respective transcripts. All of the other lentiviruses and 
other complex retroviruses appear to only require sequences w ithin the U3 
regions of their LTRs for trans-activation. Thus, these latter viruses contain 
more traditional DNA-binding transcriptional trans-activators. Thus, with 
respect to their Tat proteins and TAR RNAs, EIAV and BIV are more closely 
related to the prim ate immunodeficiency viruses than they are to the other 
ungulate lentiviruses, visna-maedi virus and caprine arthritis enteritis 
virus.
The EIAV Tat Protein
The Tat protein of HIV-1 can be divided into five domains from 
amino- to carboxy- terminal: (1) an amino-terminal domain; (2) a cysteine- 
rich domain; (3) a conserved core activation domain; (4) a highly basic 
domain; and (5) a carboxyl terminal domain. The Tat protein of EIAV 
contains each of these domains except for the cysteine-rich dom ain that has 
been implicated in dimerization of HIV-1 Tat (Frankel et al., 1988). The 
EIAV Tat ORF identified from cloned cDNAs has a coding potential of 83
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amino acids (Dorn et al., 1990). Although the precise non-AUG initiation 
codon utilized by Tat remains somewhat controversial, deletion analyses 
have clearly demonstrated that it m ust lie upstream  of Gly 16 (Dorn et al., 
1990; Schiltz et al., 1992). In this section the amino acid designations are 
relative to the Tat open reading frame as defined by the sequence lying 
between two termination codons. That is, Gly 16 is the 16th codon from the 
termination codon that defines the 5'- border of the Tat ORF. It is generally 
accepted that EIAV Tat m ost likely initiates at Leu 9 (CUG) (Carroll and 
Derse, 1993; Schiltz et al., 1992). This w ould produce a Tat protein of 75 
amino acids, where 29 amino acids are provided by exon 1 and 46 amino 
acids by exon 2. There is no homology to other lentiviral Tat proteins 
within the 29 amino acids of EIAV Tat encoded by exon 1. The homologous 
region begins 6 amino acids into exon 2 with the highly conserved Tat core 
sequence of YHCQ. Deletion analysis has shown that all of exon 1 and the 
first 4 codons of exon 2 can be deleted and replaced with a methionine codon 
w ithout significant loss of . trans-activation (Dorn et al., 1990). However, 
deletion of sequences upstream  of and including Tyr 35 in the core sequence 
resulted in a 64% reduction trans-activation. Further deletions that also 
include His 36 resulted in a near complete loss of trans-activation (Dorn et 
al., 1990). Thus, EIAV Tat sequences upstream  of Tyr 35 are non-essential 
for EIAV Tat activity, and serve only to provide a translational initiation 
codon.
Additional functional characterization of EIAV Tat has come from 
studies using chimeric HIV-1 Tat/EIAV Tat proteins and chimeric LTR 
reporter plasmids (Carroll et al., 1991). The wild-type HIV-1 Tat protein is 
incapable of activating the EIAV LTR and the EIAV Tat cannot activate the 
HIV-1 LTR (Carroll et al., 1991; Dorn et al., 1990). However, chimeric Tat
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proteins that contain the amino-terminal, cysteine-rich and core domains of 
HTV-1 Tat and the basic and carboxy-terminal regions of EIAV Tat were able 
to trans-activate the EIAV LTR to w ithin 80% of wild-type levels (Carroll et 
al., 1991). Replacement of either EIAV Tat domain with the corresponding 
HTV-1 Tat domain, did not result in trans-activation of the EIAV LTR. 
Furtherm ore, the removal of the three carboxy-terminal amino acids from 
the wild-type EIAV Tat (YLL) resulted in an 80% reduction in activity.
These results indicated that the EIAV TAR recognition domain is composed 
of amino acid residues from both the basic and carboxy-terminal domains. 
The HIV-1 core region believed to be the activation domain can functionally 
substitute for the EIAV core region indicating that these two proteins are 
likely to interact with similar cellular factors.
Little work has been perform ed to examine the mechanism of EIAV 
Tat trans-activation. Early studies appeared to indicate both a transcriptional 
and post-transcriptional com ponent to EIAV trans-activation (Sherman et 
al., 1988). These findings were based upon the observation that increases in 
protein production from EIAV-specific RNAs were greater than the 
increases in RNA levels in the presence EIAV Tat. However, it was argued 
that increases in steady-state RNA levels, either due to increased 
transcription or stabilization of transcripts, can account for EIAV Tat- 
m ediated trans-activation (Dorn and Derse, 1988). Similar disagreements 
were encountered during early studies of HIV-1 Tat trans-activation. It 
appears likely that the Tat proteins of the prim ate immunodeficiency 
viruses and EIAV will be found to mediate trans-activation through similar 
mechanisms, but additional experiments are required to confirm this 
possibility.
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The EIAV S3/Rev Protein
Limited amino acid sequence homology of the EIAV ORF S3 encoded 
protein to the HIV-1 and HIV-2 Rev proteins led to the preliminary 
characterization of the ORF S3 protein as EIAV Rev (Stephens et ah, 1990). 
Indirect evidence for Rev function of the S3 protein was derived from single 
cell clones of canine fibroblasts persistently infected with EIAV. Some of 
these clones produced little or no infectious virus and produced 
predom inantly small EIAV-specific mRNAs of about 1.5-kb in length. 
Isolation of EIAV-specific cDNA clones from these cells dem onstrated that 
the S3 coding frame contained mutations that w ould prevent synthesis of a 
normal S3 protein (Stephens et ah, 1990). The inability of cells infected with 
these virus isolates to express normal amounts of unspliced (gag/pol) and 
partially-spliced (env) transcripts, and the presence of S3 m utations was 
taken as indirect evidence for a Rev-like activity of the S3 protein.
Analysis of cDNA clones containing S3 indicated that this ORF is 
directly spliced to a small exon derived from sequences near the 5'-end of 
the env gene (Rosin-Arbesfeld et ah, 1993; Stephens et ah, 1990). This region 
of env does not contain the gpl35 initiation codon nor ER signal peptide, 
but does contain an internal env methionine codon the could potentially 
initiated the synthesis of the S3 protein. Such an env/S3 fusion protein 
w ould contain 29 amino acids derived from the gp90 coding region of env 
and 136 amino acids from ORF S3. The ORF S3 protein has been shown to 
be expressed during productive EIAV infection, since sera from infected 
horses specifically recognizes an ORF S3 protein expressed in E. coli (Saman 
et ah, 1990). Antisera produced against the S3 protein expressed in E. coli 
(Saman et ah, 1990) or against S3-specific synthetic peptides (Rosin-Arbesfeld 
et ah, 1993) showed that an S3 protein of 18 to 20-kd is expressed in EIAV-
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infected cell cultures. The S3 protein has also been reported to be packaged 
into m ature virions (Rosin-Arbesfeld et al., 1993). This surprising finding is 
difficult to reconcile with the proposed role of the S3 protein as EIAV Rev. 
The Rev proteins of other lentiviruses are nuclear proteins that are not 
virion-associated.
The Rev proteins of the lentiviruses other than EIAV, unlike the Tat 
proteins, are all structurally similar and contain two distinct functional 
domains: an amino-terminal basic dom ain and a carboxy-terminal leucine- 
rich activation domain. The EIAV S3 protein, however, contains no readily 
identifiable activation domain. It has been docum ented that the activation 
domains of the Rev proteins of visna virus and HIV-1 are functionally 
interchangeable (Tiley et al., 1991). Interestingly, the distantly related 
complex retrovirus HTLV-1 encodes a Rev-like protein, Rex, that also 
contains a homologous activation dom ain that can functionally substitute 
for the corresponding dom ain of HIV-1 Rev (Hope et al., 1991). In an 
attem pt to identify a Rev-like activation dom ain in the EIAV S3 protein, 
chimeric proteins were produced that contained the amino-terminal visna 
Rev RNA-binding motif linked to various regions of the EIAV Rev S3 
protein and tested for their ability to allow expression of the visna envelope 
protein (Fridell et al., 1993). W hen the entire coding region of the S3 protein 
was linked to the visna Rev RNA-binding domain, the visna envelope 
protein was expressed at levels 30-50% of that when coexpressed with wild- 
type visna Rev. The minimal S3 sequence required to allow expression of 
visna envelope was determ ined to lie between amino acid residues 32 and 
55. Although this region does not contain a typical Rev leucine-rich 
domain, it does contain two leucine residues (Leu 36 and Leu 49) that have 
been shown to be critical for visna envelope expression by site-specific
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mutagenesis (Fridell et al., 1993). Interestingly, the wild type EIAV S3 was 
able to partially substitute for visna Rev in this assay indicating that EIAV 
S3 may be able to interact with the visna KRE. These results indicated that 
the EIAV S3 protein does indeed harbor Rev-like activity, and therefore will 
be henceforth referred to as EIAV Rev.
The definitive identification of the EIAV S3 protein as a Rev-like 
protein has recently been established using full-length proviral clones that 
contain deletions in ORF S3 (Martarano et al., 1994). Deletions in ORF S3 
resulted in a lack of Gag protein synthesis that could be restored by 
providing EIAV Rev in trans. Northern blot analysis of nuclear and 
cytoplasmic RNA showed that the S3 deletion m utants contained no 
detectable cytoplasmic RNA corresponding to the full-length 8.2-kb gaglpol 
RNA or the singly-spliced 3.5-kb env RNA, but contained near wild type 
levels of the small fully-spliced RNAs. Thus, the EIAV Rev protein 
appeared to increase the steady-state level of the intron-containing RNAs in 
the nucleus and promote their export to the cytoplasm (Martarano et al., 
1994). In contrast to the case of HIV-1 Rev, there were also markedly 
reduced levels of the intron-containing RNAs (8.2-kb and 3.5-kb) within the 
nucleus.
A closer examination of the population of the fully-spliced transcripts 
produced in the presence and absence of Rev using PCR, showed that there 
were two major transcripts produced and that their relative levels were 
Rev-dependent. In the absence of a functional Rev protein, the 
predom inant fully-spliced RNA contained four exons: (1) the leader/T atl 
exon; (2) the Tat2/ORF SI exon; (3) the Revl exon, derived from the 5'-end 
of env; and (4) the Rev2/ORF S3 exon. This RNA is a bicistronic RNA that 
produces both EIAV Tat and Rev (Carroll and Derse, 1993). In the presence
of functional Rev protein, an alternative transcript which lacks exon 3 
(Revl) predominates. Since this RNA is incapable of encoding Rev, the 
EIAV Rev protein regulates its own synthesis through alternative splicing 
(Martarano et al., 1994).
The EIAV Rev response element (RRE) has not yet been clearly 
defined. A large proviral DNA fragment that extends from the 3'-end of the 
pol gene to the 5'-end of ORF S3 (nt 4473-7247) was shown to im part Rev- 
dependence on a CAT-expression construct when placed downstream  of the 
CAT coding region. That is, low levels of CAT were expressed in the 
absence of Rev from this construct, but providing EIAV Rev in-trans 
resulted in high-level CAT expression (Rosin-Arbesfeld et al., 1993). These 
results indicated that the EIAV RRE lies within this rather large region. 
Attempts to determ ine the precise sequences involved in the formation of 
the EIAV RRE showed that two separate regions of the env gene are 
involved: (1) n t 5337-5552; and (2) nt 7241-7713. These two regions include 
the two coding exons for the EIAV Rev protein, exon 3/R ev l (nt 5437-5537) 
and exon 4/Rev2 (nt 7235-7641). These regions were defined by making 
deletion m utants in the env gene region of Rev-defective proviral clones 
and assaying for the ability of these clones to produce EIAV Gag proteins 
when co-transfected w ith Rev expression plasmids. Deletion of sequences 
within either one of these regions resulted in reduced Gag expression, while 
deletion of both yielded no Gag protein. Deletion of sequences between 
these two regions (5552-7241) resulted in high level Gag expression, 
indicating that these sequences are not involved in formation of the RRE 
(M artarano et al., 1994). Thus, EIAV appears to contain two distinct RREs 
that can act independently, bu t only yield efficient expression when present 
together on the same RNA. No obvious highly structured regions of RNA
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have been identified to be associated with these regions, and it has yet to be 
determ ined if there is a direct interaction between Rev and viral RNA.
EIAV RNAs and their Translation
Early research in EIAV gene expression was performed in canine and 
feline fibroblast cell lines that are permissive for infection with cell culture 
adapted strains of EIAV. N orthern blot analyses of EIAV-specific 
transcription patterns in these cells have yielded variable results. Some 
researchers have reported as many as five different transcripts in EIAV- 
infected canine cells: 8.2-kb, 5.0-kb, 4.0-kb, 2.0-kb and 1.8-kb RNAs (Noiman 
et al., 1990b).
In our laboratory, we have examined EIAV transcriptional patterns in 
two types of prim ary equine fibroblasts that differ in the type of EIAV 
infection they support. One of these, fetal equine kidney cells (FEK), results 
in a persistent infection w ith EIAV as do the canine and feline cells 
m entioned above. The other, fetal donkey dermal cells (FDD), results in a 
highly cytopathic infection w ith EIAV. Examination of the transcription 
patterns in these equine cells, showed only three EIAV transcripts: the 8.2- 
kb full-length RNA; a 3.5-kb RNA; and a possibly heterogeneous group of 
low molecular weight transcripts of approximately 1.5-kb (Rasty et al., 1990). 
Interestingly, the 3.5-kb transcript was produced at very high levels relative 
to the other transcripts in the cytopathic FDD infection. Characterization of 
cDNA clones corresponding to the 3.5-kb transcript showed that it was 
produced by a single splicing event that joined the viral leader sequence 
(SD1, n t 459) to a splice acceptor site (SA1, nt 5134) located within the 5'-end 
of ORF SI (Schiltz et al., 1992).
N orthern blot analysis of the EIAV transcripts in prim ary 
m acrophage cultures infected with a horse virulent strain of EIAV showed
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that the full-length (8.2-kb) RNA predominates and the low molecular 
weight transcripts were difficult to detect (Stephens et al., 1990). Recently, 
PCR has been used to examine the transcripts produced within tissue 
macrophages from an EIAV-infected horse (Beisel et a l, 1993). This study 
showed that there are 5 EIAV-specific transcripts produced in vivo: the 8.2- 
kb full-length RNA; a 3.5-kb singly-spliced RNA identical to that previously 
cloned from FDD cells; and three separate low molecular weight transcripts 
formed by alternative splicing of four exons. The low molecular weight 
transcripts of EIAV are produced by the alternative utilization of 3 splice 
donors and 3 splice acceptors (Fig. 11 A). The three low molecular weight 
transcripts differ in the num ber of exons that they contain. The simplest of 
these transcripts is a singly-spliced transcript where the EIAV leader region 
(SD1, n t 459) is spliced directly to exon 4 (rev-2) through a splice acceptor site 
(SA3) located at nt 7234 (tm, Fig. 11B). This RNA is not believed to produce 
functional EIAV Rev protein, since the ORF S3 sequences are not preceded 
by a translational initiation codon. The splicing event places the trans­
m embrane glycoprotein sequences in frame with the first coding exon of the 
EIAV tat gene. Thus, this RNA results in the synthesis of a truncated 
transmembrane protein of 27-kd that has been detected in infected cells, but 
its role in EIAV infection has not been determined (Beisel et al., 1993). A 
second low molecular weight RNA that contains three exons encodes the 
EIAV Tat protein. This RNA is produced by splicing of exon 1 (tat-1, Fig.
11B) to SA2 (nt-5134), followed by the utilization of a second splice donor 
signal (SD2, n t 5276), located immediately downstream of the Tat 
termination codon, which is spliced to exon 4 (tat, Fig. 11B). The third low 
molecular weight transcript contains four exons and encodes both the Tat 





































Figure 11. Schematic representation of the EIAV open reading frames and 
transcripts. A. EIAV proviral DNA. The relative positions of each of the 
EIAV open reading frames are shown. Although the rev-1 exon is in the 
same reading frame as env, it is depicted as a separate exon here for clarity. 
The positions of the three splice donor (SD) and acceptor (SA) sites are 
shown below the open reading frames. B. The transcripts of EIAV. The 
five transcripts of EIAV identified in infected horses are shown. The dotted 
lines indicate the introns that are removed by splicing. The open reading 
frames contained in each transcript are indicated to the left.
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the inclusion of exon 3 (rev-1, Fig. 11B), located within the 5'-end of the env 
gene (SA2, nt-5435; SD3, nt-5536), between exons 2 (tat-2) and 4 (rev-2) of the 
RNA described above. The inclusion of the rev-1 exon in this transcript 
results in the addition of 29 codons of the gp90 coding region of env being 
spliced in-frame to ORF S3. Included in these 29 codons of env is an AUG 
codon that lies in favorable sequence context (AGC AUG G) to initiate 
translation of the EIAV Rev protein.
The bicistronic nature of the multiply-spliced tat/rev RNA has 
recently been confirmed both in vitro and in transfected cells (Carroll and 
Derse, 1993). These researchers used site-specific mutagenesis to 
dem onstrate that translation of the second cistron (S3) was dependent upon 
the translation of the EIAV Tat protein (SI)  from a sub-optimal initiation 
codon. In order to investigate the mechanism of translation of this 
bicistronic RNA, these researchers had to first unam biguously identify the 
Tat initiation codon. This was accomplished by individually altering each of 
the three most likely initiation codons, CUG-364, CUG-373 and AUC-388, to 
a GUA valine codon. Mutagenesis of CUG-364 and AUC-388 had no effect 
on fraMs-activation, but alteration of CUG-373 resulted in the loss of trans- 
activation. The dependence of expression of the EIAV Rev protein (S3) on 
initiation of the Tat protein from a sub-optimal initiation codon was 
dem onstrated by mutagenizing CUG-373 to an AUG codon. This alteration 
resulted in dramatically reduced expression of the Rev protein in cells 
transfected with the m utant tat/rev cDNA. These results indicate that the 
EIAV Rev protein is expressed by leaky ribosome scanning through the Tat 
CUG initiation codon. Furthermore, inefficient recognition of the Tat CUG 
codon is required for the synthesis of all EIAV proteins other than Tat, since 
this CUG codon is located in the viral leader region upstream  of the first
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splice donor signal. That is, this CUG codon is present in all EIAV RNAs 
and is located upstream  of all the other cistrons in the respective RNAs.
Research Objectives 
The overall goal of the research presented in this dissertation was to 
characterize the properties of the protein products encoded by the small 
open reading frames, S3, S2 and S3, and analyze the translational 
characteristics of the RNAs that express these proteins. The specific goals 
that are addressed in this dissertation are as follows: (1) examination of the 
in vitro protein coding potential of the 3.5-kb RNA that contains the S3, S2 
and env coding regions; (2) examination of the translational initiation of 
the EIAV tat gene, which does not contain an AUG initiation codon; (3) 
dem onstration of Tat trans-activation in prim ary equine fibroblasts that are 
either persistently or cytopathically-infected w ith EIAV; (4) dem onstration 
of the significance of the putative S2 protein in EIAV infection by 
determ ining if sera obtained from EIAV-infected horses contain antibodies 
that recognize the in vitro synthesized S2 protein; and (5) to examination 
of the translational initiation signals for the S3 protein. Specifically, if, it can 
be expressed from an e«u-encoded AUG codon by analyzing the ability of a 
monoclonal antibody directed against an epitope of the gp90 envelope 
protein to detect the S3 protein produced in vitro and in vivo.
CHAPTER 2
IN  VITRO  TRANSLATION OF EIAV MULTICISTRONIC RNAS
Introduction
EIAV gene expression has been primarily studied in canine and feline 
fibroblast cultures which are permissive for persistent EIAV infections. 
Analyses of RNA transcription patterns in such cells yielded variable 
observations in the temporal appearance and abundance of EIAV-specific 
transcripts (Dorn et al., 1990; Noiman et a l, 1990b; Stephens et a l, 1990). The 
simplest and most consistent transcription patterns were observed in EIAV- 
infected primary horse macrophage cultures and equine fibroblasts [fetal 
equine kidney (FEK) and fetal donkey dermal (FDD) cells] in which transcripts 
corresponding to the 8.2-kb genomic RNA and the presumably singly-spliced 
3.5-kb envelope message were predominantly synthesized (Rasty et a l, 1990; 
Stephens et a l, 1990). Small multiply-spliced transcripts of 1-2 kb were present 
at very low abundance and were often difficult to detect.
Previous studies showed that infection of FDD cells with EIAV results in 
severe cytopathology and eventual cell death within 14-21 days post-infection, 
whereas infection of FEK cells results in persistent virus production in the 
absence of any apparent cytopathology (Orrego et a l, 1982). Interestingly, in 
cytopathically infected FDD cells, the proportion of the 3.5-kb mRNA to the full 
length 8.2-kb transcript was found to be substantially greater than in 
persistently infected FEK cells, which synthesized the two RNAs in 
approximately equal abundance at all stages of infection (Rasty et a l, 1990). 
Examination of the properties of the predominant 3.5-kb EIAV transcript of 
FDD cells might provide some insight into the mechanisms of cytopathicity 
observed in this cell type.
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Analysis of the nucleotide sequence of cDNA clones corresponding to 
the 3.5-kb RNA showed that this RNA is structurally tricistronic, since it 
contains the tat, ORF S2 and env genes (Schiltz et al., 1992). Although many of 
the RNAs of HIV-1 and other lentiviruses are structurally multicistronic, the 
presence of strong translational initiation signals for the first cistrons renders 
nearly all of these RNAs functionally monocistronic in vivo. (Schwartz et al., 
1990b; Schwartz et al., 1992a). The only known exceptions to this are the HIV-1 
bicistronic vpu/env and rev/nefm RN As, each of which efficiently expresses the 
downstream cistron by leaky scanning through the relatively weak sub-optimal 
AUG initiation codons of the respective upstream cistrons (Schwartz, et al., 
1992b). The first cistron of the EIAV 3.5-kb RNA (ta t/S2 /env  RNA) is the ORF 
SI cistron which encodes the EIAV Tat protein (referred to interchangeably as 
Tat or SI in this document) (Fig. 12). This cistron is devoid of an AUG initiation 
codon and has been proposed to be initiated at either a CUG or an AUC codon 
(Carroll and Derse, 1993; Dorn et al., 1990; Noiman et al., 1991). Recent results 
indicate that the EIAV S1/S3 (tat/rev) 1.5-kb mRNA is bicistronic in vitro and in 
vivo due to leaky ribosome scanning through the Tat non-AUG initiation codon 
(Carroll and Derse, 1993).
The ORF S2 cistron in the 3.5-kb RNA overlaps the env cistron in an 
alternative reading frame. The ORF S2 cistron contains three AUG codons; 
however, only two of these lie near the 5'-end of the gene and neither of these 
lie in a favorable sequence context for translational initiation. The first AUG 
codon of ORF S2 (AUG-1) is the second codon in the ORF and is located a mere 
11-nt downstream of the Tat UAA termination codon and 24-nt upstream of the 
env gene initiation codon which lies in a highly favorable sequence context for 
translational initiation (AAC AUG G) (Fig. 12). ORF S2 AUG-1 is also the first 
AUG that would be encountered by scanning ribosomes in the 3.5-kb RNA,
UAA GGUU UGA IJAU AUG GGAUUAUUUGGUAAAGG GGU AAC AUG £  
tat Stop S2  AUG-1 env Start
Figure 12. Schematic representation of the EIAV 3.5-kb RNA. The arrangement 
of the tat, S2 and env genes in the 3.5-kb transcript are shown above. L, the 133- 
n t leader region that extends from the cap site to the UGA termination codon 
that defines the 5'-end of the tat ORF. SS, the splice site that joins the two 
coding exons of the tat gene. The nucleotide sequence of the region 36-nt region 
that lies between the tat termination codon and the env initiation codon is 
shown below. The UAA termination codon of the tat gene and the UGA 
termination codon that defines the 5'-end of ORF S2 are shown in bold. The 
first AUG codon in ORF S2 and the env gene AUG initiation codon are also 
shown in bold. The im portant context nucleotides in the -3 and +4 positions of 
the AUG codons are underlined. Note the uridine residue in the -3 position of 
the ORF S2 AUG codon.
while the highly favorable env AUG would be the second. The near optimal 
sequence context of the env AUG would appear to preclude translation 
initiation of ORF S2 from the second AUG codon in ORF S2. (AUG-2). Thus, it 
is likely that an S2 protein expressed in vivo would have to be initiated at AUG- 
1. Therefore, the EIAV 3.5-kb RNA is a prime candidate to be a multicistronic 
RNA, since the non-AUG initiation codon of the Tat cistron and the sub- 
optimal AUG codon of the ORF S2 cistron would be anticipated to allow 
appreciable leaky ribosome scanning to the favorable env AUG initiation codon.
In addition to its tricistronic nature and the involvement of a non-AUG 
codon in translational initiation, another interesting property of the 3.5-kb RNA 
is that the termination codon for the SI cistron and the translational initiation 
signals of the S2 and env cistrons all lie closely together within an 
approximately 40-nt region (Fig. 12). Furthermore, this is the only RNA 
identified to date isolated from either EIAV-infected cultured equine cells 
(Rasty et al., 1990) or infected animals (Beisel et al., 1993) that has the capacity to 
encode the S2 or env protein. In addition, the presence of ORF SI in the 
tricistronic RNA may allow this trans-activator protein to be produced late in 
infection, when little or no multiply-spliced (S1/S3) transcripts are expected to 
be produced (Cullen, 1991). Clearly, this multi-functional RNA provides a 
number of unique features that warrant extensive investigation. In the studies 
described herein, the cDNA corresponding to the 3.5-kb RNA was used to 
analyze the translation characteristics of this unique mRNA in vitro.
M aterials and M ethods 
Plasm id Constructs for In Vitro  Transcription
The pSR-1 cDNA clone was obtained by Dr. Siyamak Rasty (Schiltz et al, 
1992) and was derived from the singly-spliced 3.5-kb EIAV RNA using an env- 
specific primer located immediately downstream of the Sma I restriction site (nt
5689-5695) and contains ORF SI, ORF S2, and env [All nucleotide sequence 
designations are based on the reported proviral DNA sequence (Kawakami et 
al., 1987), GenBank accession no. M16575]. The resulting cDNA was subcloned 
into pUC9. The pSP-1 cDNA was obtained from Dr. Susan Payne (Case 
Western Reserve University) and was derived from the 1.5-kb multiply-spliced 
ORF SI / ORF S3 EIAV mRNA. The resulting cDNA was subcloned into a 
Bluescript vector (Stratagene Cloning Systems). Plasmids for in vitro 
transcription were constructed by subcloning restriction fragments of the cDNA 
clones pSR-1 or pSP-1 into pSP65 (Promega Corporation).
The pSR-1 cDNA clone was digested with either Stu I (nt 254-259) or 
Sma I (nt 391-396) followed by digestion with Msc I (nt 5653-5657) to generate a 
720-bp (Stu I/M sc I) or 585-bp (Sma 1 /Msc I) restriction fragment. These blunt- 
ended DNAs were subcloned into Sma I digested pSP65 generating pSP720 and 
pSP585, respectively. pSR-1 was digested with BamH I (nt 386-391) to produce 
a 280-bp fragment that was subcloned into the BamH. I site of pSP65 to generate 
pSP280. A 623-bp Sma I (nt 254-259 & 5689-5695) restriction fragment was 
isolated from pSR-1 and ligated to the large fragment of pSP280 digested with 
Sma I to generate plasmid pSP634. pSP-1 was digested with either Stu I (nt 254- 
259 & 8162-8167) alone or Stu I and Pvu II (nt 5159-5164), and restriction
fragments containing ORF S3 were isolated and ligated to Sma I digested pSP65
/
generating pSPSl-S3 and pSPS3, respectively. All ligation mixtures were 
transformed into E. coli strain DH5a, and the resulting recombinant plasmids 
were screened for the orientation that properly aligned the EIAV ORFs with the 
SP6 promoter using appropriate restriction enzymes.
In Vitro Transcription and Translation
All plasmids for in vitro transcription, except pSP634, were linearized at 
the Hind  III site located in the vector polylinker region downstream of the
doned inserts. The pSP634 plasmid was linearized at the Msc I site in the env 
gene. The linearized DNAs were transcribed in vitro using one of several 
commercially available kits [Riboprobe® Transcription System (Promega 
Corporation); mCAP™ mRNA Capping Kit (Stratagene Cloning Systems); 
Ambion MEGAscript™ in vitro Transcription Kit (Ambion, Inc.)] using SP6 
RNA polymerase and m7GpppG cap analog to cap the transcripts according to 
the manufacturer's recommendations (4:1, m 7GpppG:rGTP). The transcripts 
were purified by gel filtration through pre-packed columns of G-50 sephadex 
(NICK Columns, Pharmacia LKB Biotechnology) prior to ethanol precipitation 
to ensure removal of trace amounts of m 7GpppG and rNTPs. This treatment 
also permitted accurate quantitation of the transcript concentration by 
measuring the optical density at 260 nm. The concentrations of the transcripts 
were confirmed by analysis on non-denaturing agarose gels against a standard 
viral RNA, brome mosaic virus (BMV) RNA 3. In vitro translation systems 
utilizing wheat germ extract (WGE) and micrococcal nuclease-treated rabbit 
reticulocyte lysate (RRL) were purchased from Promega Corp. A typical 50 pi 
WGE translation mixture contained the following: 25 pi of WGE; 80 pM amino 
acid mixture lacking the radiolabeled amino acid; 25 pCi [35S]-methionine or 15 
pCi of a [3H]-labeled amino acid (leucine, glycine or arginine); 60 mM 
potassium acetate; 40 units of placental ribonuclease inhibitor (RNAsin); and 
1.5 pg RNA substrate. The reaction volume was adjusted to 50 pi with 
deionized and glass distilled water. The K+ concentration of the WGE was 
optimized for the in vitro transcripts as suggested by the manufacturer and 
optimal amino acid incorporation was obtained when 60 mM K+ was added to 
the translation reaction. A typical 50 pi RRL translation contained the 
following: 35 pi of RRL; 20 pM amino acids lacking the labeled amino acid; 40 
pCi [^S]-methionine or 25 pCi [3H]-labeled amino acid; 40 units of RNAsin;
and 1.5 fig RNA substrate. The reaction volume was adjusted to 50 fil with 
deionized and glass distilled water. L-[4,5-3H]-Leucine (161 Ci/m m ol; 5 
m Ci/m l) and L-[2,3,4,5-3H]-Arginine (62 Ci/m m ol; 1 m C i/m l) were obtained 
from Amersham Corp.; L-[2-3H]-Glycine (49 Ci/mmol; 1 m Ci/m l) was 
obtained from Dupont NEN® Research Products. L-^S]-m ethionine (1200 
Ci/m m ol; 10 m Ci/m l) was obtained from either ICN Biomedicals, Inc or 
Dupont NEN® Research Products. RNA 4 of brome mosaic virus (BMV) was 
prepared as previously described (Shih and Kaesberg, 1973). The amount of 
[3H]-leucine incorporated into trichloroacetic acid insoluble proteins was 
determined in duplicate or triplicate samples using a modified standard filter 
paper assay method (Mans and Novelli, 1961).
Preparation of Antisera and Radioimmunoprecipitation Assays
Synthetic peptides corresponding to portions of the EIAV Tat, S2 and S3 
proteins were prepared using either a SAM-II automated peptide synthesizer 
(BioSearch), or by manual methods using the RaMPS system (Dupont).
Peptides were initially purified by gel filtration on Sephadex G-25 followed by 
reverse phase HPLC, and further characterized by plasma desorption mass 
spectrometry to confirm their purity and sequence. The purified peptides were 
linked to keyhole limpet hemacyanin (KLH) using glutaraldehyde following a 
standard protocol (Reichlin, 1980). The KLH-linked peptides were injected 
intramuscularly and subcutaneously into New Zealand white rabbits in 
Freund's complete adjuvant (FCA). The rabbits were boosted with the same 
antigen in Freund's incomplete adjuvant after three weeks to produce 
hyperimmune sera, which was harvested two weeks after boosting. The titer of 
the sera against the peptides was determined by an ELISA system optimized 
for use with synthetic peptide antigens (Ball, 1990). High titer sera were 
defined to give an OD49onm in excess of 0.5 at a dilution of 1:10,000. The IgG
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fraction was partially purified from the sera by ammonium sulfate precipitation 
and DEAE-Sephadex column chromatography as previously described (Chua et 
al., 1982). The radiolabeled in vitro translation products were radio- 
immunoprecipitated (RIP) with the appropriate antisera (typically 100 pg IgG) 
by the method of Anderson and Blobel (1983). Briefly, 50 |ul translation samples 
adjusted to 1% SDS were boiled for 4 minutes. Four volumes (200 pi) of 
dilution buffer (1.25% Triton X-100,190 mM NaCl, 60 mM Tris-HCl, pH  7.4,6 
mM EDTA, 10 un its/m l aprotinin protease inhibitor) at 4°C were added, 
followed by 100 pg of IgG. The samples were incubated for at least 12 hours on 
an Adams Nutator mixer at 4°C. Thirty pi of a 1:1 suspension of protein A- 
Sepharose CL-4B (Sigma Chemical Co.) were added and the incubation was 
continued for two hours at room temperature. The beads were washed four 
times (1 ml per wash) with 0.1% Triton X-100,0.02% SDS, 150 mM NaCl, 50 mM 
Tris-HCl, pH  7.5,6 mM EDTA, and 10 un its/m l aprotinin at room temperature. 
A final wash was performed in the same buffer lacking detergent. The beads 
were resuspended in 40 pi of SDS-gel electrophoresis buffer and boiled for 4 
minutes prior to applying to slab gels.
Sodium Dodecyl Sulfate Polyacrylamide Gel Analysis of In Vitro Translation 
Products
The translation products were fractionated on either a standard 15% 
discontinuous gel system or a 20% sodium dodecylsulfate (SDS)-polyacryl- 
amide gel system (Guilian et al., 1985) to facilitate resolution of the SI (8-kd) 
and S2 (7-kd) proteins. Typically, between 25k and 50k cpm of radiolabeled 
protein was loaded onto a given lane. After electrophoresis the gels were 
impregnated with an autoradiographic image enhancer (National Diagnostics) 
prior to drying and exposure to Kodak XAR or XRP X-ray film. Exposure was 
at -70°C for 16 to 24 hours.
Densitometric Quantitation of the In Vitro Translation Products
The X-ray flourographs were scanned on a BioRad Model 620 video 
densitometer and the optical density (OD) of each protein band was normalized 
on the basis of the number of leucine residues in each protein to obtain a molar 
OD for each protein. The molar OD for each individual protein was divided by 
the total molar OD of all three EIAV proteins in a given experiment to 
determine the molar fraction of each protein produced. Each of the three 
pSP720-derived proteins is presented as a percentage of the total EIAV protein 
produced in a particular translation experiment.
Automated Protein Sequencing
The EIAV Tat protein was synthesized in wheat germ extracts 
program m ed with pSP720 RNA in the presence of [3H] arginine, as described 
above. The pSP720 transcript encodes both Tat and S2, which are difficult to 
completely resolve on SDS gels. Due to the similarity in the gel mobilities of the 
Tat and S2 proteins, the Tat protein was immunoprecipitated from the 
translation mixture prior to gel electrophoresis. The S2 protein was synthesized 
in the presence of [3H] glycine from pSP585 RNA, which lacks sequences 
required for Tat expression. The Tat and S2 proteins were fractionated on 15% 
discontinuous gels which upon completion of electrophoresis were placed 
directly into Autoflour (National Diagnostics) image enhancer for 30 minutes. 
The dried gels were exposed to Kodak XAR film and placed at -70°C overnight. 
Using the autoradiograph as a template, the appropriate protein band was cut 
from the dried gel and rehydrated in a minimal volume of water. The gel slice 
was crushed, and the labeled proteins eluted in 2-3 ml of Tris saline buffer (50 
mM Tris-HCl, pH  7.5; 100 mM NaCl) at 37°C for 3 hours with constant mixing. 
The gel fragments were removed by centrifugation, and the supernatant was 
lyophilized and resuspended in 100 gl of 1 m g/m l bovine serum albumin (BSA)
to act as a carrier protein. The protein mixture was desalted by passing it 
through a G-10 Sephadex column. Radioactive fractions were pooled, 
lyophilized, and resuspended in 50-100 pi of doubly distilled deionized water. 
These samples were subjected to automated amino terminal sequence analysis 
on an Applied Biosystems 470A Protein Sequencer. Radioactivity from each 
cycle of the sequencer was determined by adding the cycle eluate to 3 ml of 
Liquisdnt scintillation cocktail (National Diagnostics) and counting in a 
Beckman LS 6000IC liquid scintillation counter.
Results
Expression of the ORF SI, ORF S2, and env Genes from the In Vitro 
Transcripts
Synthetic transcripts corresponding to the 3.5-kb RNA were produced in 
order to determine if this RNA is functionally tricistronic in vitro. Towards this 
end, a Stu 1/ Msc I restriction fragment of the cDNA was subcloned into the in 
vitro transcription vector pSP65 generating pSP720 (the numerical portion of the 
plasmid designation indicates the approximate number of base pairs of the full 
length 3.5-kb cDNA present in the construct). The Stu I site, located in the R 
(redundant) region of the LTR, lies 47-bp downstream of the EIAV transcription 
start site (nt 210); therefore the in vitro transcripts produced from pSP720 lack 
the first 47-nt of the 5'-UTR (untranslated region) which include the 5'-terminal 
trans-activation responsive stem-loop structure (+1-+25). The Msc I site lies 
within the gp90 coding region of the env gene, therefore a truncated gp90 
protein would be produced from these transcripts. Thus, the pSP720 in vitro 
transcription construct contains the extended ORF SI, the entire ORF S2, and a 
3'-truncated env gene. This env truncation results in the synthesis of a 15-kd 
protein (Agp90) that can be readily examined under the gel electrophoresis 
conditions required for Tat (8.5-kd) and S2 (7-kd) resolution. The pSP720-
derived in vitro transcripts contained 25-nt of vector-derived sequence at their 
5'-ends followed by the remaining portion of the R region (29-nt), the U5 region 
(36-nt), the leader region (24-nt), and the extended ORF SI (252-nt) (Fig. 13). A 
second transcription plasmid, pSP585, was constructed by subcloning of the 
Sma I/M sc  I restriction fragment into the Sma I site of pSP65. The Sma I site (nt- 
394) lies within the extended portion of ORF SI immediately downstream of the 
AUC codon proposed by Noiman et al. (1991) to initiate Tat synthesis.
Therefore, transcripts produced from this construct would be devoid of both 
proposed Tat initiation codons. In both the pSP720 and pSP585 constructs, ORF 
S2 (198-nt) begins a mere 7-nt downstream of the Tat UAA termination codon. 
This ORF contains 66 potential codons the second of these is a methionine 
codon. The env gene overlaps the majority of ORF S2 and begins 26-nt 
downstream of the Tat termination codon. The fourth codon in the env ORF is a 
potential AUG initiation codon. Truncation of the gp90 coding region of the 
env gene at the Msc I site results in only the first 117 codons of this ORF being 
present in the in vitro transcripts. Linearizing the template DNAs at the Hind  
III site within the pSP65 polylinker resulted in the extension of the Agp90 ORF 
by three codons (G, I, and L) (Fig. 13). Therefore, the in vitro transcripts 
employed contain a truncated env ORF of 120 codons with an apparent 
molecular mass of approximately 15-kd on SDS-polyacrylamide gels.
The pSP720 and pSP585 plasmid DNAs were employed as transcription 
templates to produce synthetic capped RNAs, which were translated in wheat 
germ extracts in the presence of [3H]-leucine. In vitro translation of pSP720 
RNA resulted in the synthesis of three major polypeptide products with relative 
molecular weights of 15-kd, 8.5-kd, and 7-kd (Fig. 14, lanes 1 and 8). These 
products correspond closely to the predicted sizes of Msc I truncated gp90 
envelope protein (Agp90), the EIAV Tat protein, and the putative S2 protein,
Figure 13. Schematic diagram of the pSP720 in vitro transcription vector and 
nucleotide sequence of the corresponding in vitro transcript. The upper portion 
of the figure depicts the open reading frames present in the pSP720 in vitro 
transcription vector and shows the restriction sites used to produce this 
construct. The stippled box represents the SP6 promoter and the solid black 
boxes represent the poly-cloning site of the pSP65 vector. The nucleotide 
sequence of the pSP720 transcript is shown below. The nucleotides derived 
from the pSP65 vector are shown in italics and the DNA restriction sites used to 
produce the pSP720 DNA are indicated. The Sma I and BamH I restriction sites 
involved in the construction of the pSP585 and pSP634 transcription plasmids 
are also indicated. The CUG and AUC codons that have been independently 
reported to initiate Tat synthesis are underlined along with their respective -3 
and +4 context nucleotides. The first AUG in ORF S2 and the env AUG are also 
underlined with their context nucleotides. The termination codons for the Tat, 
S2, and Agp90 proteins are underlined. The cloning results in the extension of 
the gp90 coding region into the pSP65 poly-cloning site. This results in the 
addition of three non-native gp90 amino acids (GIL)  being added to the 
carboxy-terminal end of the Agp90 protein. The amino acid sequence of the 
carboxy-terminal end of Agp90 is shown below the nucleotide sequence. The 
poly-cloning site also provides an in-frame UAG termination codon. The 
amino acid sequence of an epitope of gp90 recognized by monoclonal antibody 
86 (mab 86) is also shown below its nucleotide sequence. The numbers above 
the nucleotide sequence indicate the nucleotide number in the pSP720 RNA.
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respectively. The pSP585 RNA supported translation of only two of these 
products, the 15-kd and 7-kd polypeptides (Fig. 14, lane 5). The 15-kd product 
from both pSP585 and pSP720 RNA programmed translation reactions was 
specifically immunoprecipitated with a monoclonal antibody directed against 
an epitope of the gp90 envelope protein mapping to a region approximately 50 
amino acids from its amino terminus (Ball, 1990) (Fig. 14, lanes 2 and 6).
The 8.5-kd band specific for pSP720 RNA translation was immunoprecipitated 
by a rabbit polyclonal antisera produced against a synthetic peptide (Fig. 15) 
corresponding to a predicted immuno-reactive domain of the EIAV Tat protein 
(Fig. 14, lane 3). The 7-kd protein common to both pSP720 and pSP585 RNA 
translation reactions was immunoprecipitated by a combination of low titer 
rabbit polyclonal antisera produced against three different overlapping 
synthetic peptides (Fig. 15: S2a, S2b, S2c) that span the entire ORF S2 amino 
acid sequence (Fig. 14, lane 4). This combination of ORF S2 antisera did 
demonstrate some cross-reactivity with the EIAV Tat protein product (Fig. 14, 
lane 4 and lane 7). However, a high titer ORF S2 antiserum (S2d) obtained 
more recently demonstrated no cross-reactivity with EIAV Tat (Fig. 14, lane 9). 
This ORF S2 antiserum also specifically precipitates two minor products with 
mobilities of 5.5- and 4-kd, which are presumed to be S2-related peptides 
produced by either translational initiation at the internal AUG codons of S2 or 
degradation products of S2. Lanes 8 and 9 of figure 14 were intentionally over 
exposed to demonstrate the specificity of the antiserum. These data indicate 
that a single cDNA species corresponding to the 3.5-kb singly-spliced mRNA of 
EIAV is capable of directing the synthesis of EIAV Tat, the S2 protein, and the 
envelope protein in vitro. Furthermore, since no EIAV Tat protein is detected 
upon translation of pSP585 RNA, sequences located between the Stu I site in R
Figure 14. Translation of the pSP720 and pSP585 RNAs in wheat germ extracts 
and identification of the protein products by immunoprecipitation.
Fluorograph of an SDS-PAGE analysis of wheat germ extracts programmed 
with pSP720 (lanes 1 and 8) and pSP585 (lane 5) synthetic transcripts in the 
presence of [3H]-leucine. Radioimmunoprecipitation of labeled translation 
products with a monoclonal antibody directed against the gp90 envelope 
glycoprotein (lanes 2 and 6) and rabbit polyclonal antisera specific to the Tat 
(lane 3) or S2 (lanes 4,7, and 9) protein products. Molecular weight markers (M) 
are BRL [14C]-labeled low molecular weight standards.
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Figure 15. Predicted amino acid sequences of the tat and S2 ORFs and location 
of the synthetic peptides used for anti-sera preparation. The synthetic peptide 
corresponding to the carboxy-terminus of Tat is underlined. The four different 
synthetic peptides, S2a-d, corresponding to the putative S2 protein are marked 
with brackets.
and the Sma I site in tat, which include the predicted CUG and AUC initiation 
codons, are required for in vitro expression of the EIAV Tat protein. 
Amino-terminal Sequencing of the In Vitro Synthesized EIAV Tat and ORF 
S2 Polypeptides
In order to gain a better understanding of the expression of the ORF SI, 
ORF S2, and envelope proteins from the tricistronic 3.5-kb RNA, I 
determined the presumptive translational initiation sites of the in vitro 
synthesized SI and S2 proteins by amino-terminal sequencing of radiolabeled 
polypeptides. The radioactive amino acid of choice for sequencing of the S2 
protein was [3H] glycine, since the first methionine codon in ORF S2 is followed 
immediately by a glycine codon and three of the first seven codons correspond 
to glycine residues. The S2 protein was synthesized from pSP585 RNA and 
approximately 7 x 104 cpm of gel purified protein was subjected to amino 
terminal sequence analysis. The sequencer fraction corresponding to the first 
amino acid residue registered in excess of 7 x 103 cpm, while further peaks of 
radioactivity were observed for amino acid residues 4 and 6 (Fig. 16). The 
anticipated amino acid sequence of the S2 polypeptide initiating at the first 
methionine codon of this ORF i s M G L F G K G .  Assuming the amino 
peptidase activity of the wheat germ extract has cleaved the initiator 
methionine residue from this protein, the peaks of radioactivity occur precisely 
as expected, that is, in fractions 1,4, and 6. Additional peaks of radioactivity 
were noted in fractions 16,17, and 20, which are also predicted sites of glycine 
residues in the ORF S2 protein (Fig. 16). These data confirm that the in vitro 
synthesized polypeptide assigned to be encoded by ORF S2 on the basis of its 
ability to specifically react with ORF S2-specific peptide antisera, is indeed the 
S2 protein, and its synthesis in vitro is apparently initiated at the first 




G L F G K G V T W S A S H S M G G S Q G E S Q  
S2 Amino Acid Residue
Figure 16. Microsequence analysis of the [3H]-glycine labeled S2 protein. The 
[3H]-labeled S2 protein was gel-purified and subjected to automated protein 
sequence analysis. The fractions obtained from the sequencer were dispensed 
into 3 ml of Liquiscint scintillation solvent (National Diagnostics) and measured 
for the presence of radioactivity. The amount of radioactivity in counts per 
minute (CPM) is shown for each fraction. For convenience the predicted amino 
acid sequence of the S2 protein is plotted on the x-axis rather than the residue 
number.
The ORF SI protein, EIAV Tat, was of particular interest to sequence, 
since it is believed to be initiated at a non-AUG codon, but the precise codon 
utilized had not been determined. The most likely candidate was a CUG codon 
at n t 373 that lies in a favorable sequence for translational initiation, AAC CUG 
G, that is with an adenine nt in the -3 position and a guanine nt in the +4 
position (Kozak, 1986). Initial attempts to sequence the SI protein synthesized 
from pSP720 RNA and labeled with [3H] glycine were ham pered by difficulties 
in resolving SI and S2 completely on 15% preparative discontinuous SDS- 
polyacrylamide gels. As a result, sequence analysis of gel-purified SI gave 
some low level peaks of radioactivity in fractions 1,4 and 6, which were 
reminiscent of those seen for S2 sequencing (Fig. 6A). H ad SI been initiated at 
CUG 373,1 would have expected a peak of radioactivity corresponding to 
glycine num ber one of SI in fraction number seven or eight from the sequencer 
depending on the absence or presence of the initiator methionine on the mature 
protein. No peak was noted in this position despite the fact that in excess of 1 x 
105 cpm of radioactive product was loaded onto the sequencer (Fig. 17A). To 
confirm that SI was indeed purified from the gel, 2 x 104 cpm of gel-purified SI 
was run on a 15% analytical discontinuous gel with 2 x 104 cpm of gel-purified 
S2. The fluorograph of the gel clearly showed differential migration of the two 
bands suggesting that the major portion of the SI preparation was indeed SI 
and that S2 was only a minor contaminant of this preparation (Fig. 17B). The 
contaminating S2 protein also served as a control for the amino acid sequencer 
demonstrating that the instrument was functioning properly. These data 
suggested that the SI protein may be amino terminally blocked preventing 
analysis of its amino acid sequence.
The possibility that the amino terminus of the SI protein was acetylated 
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Figure 17. Microsequence analysis of the [3H]-glycine labeled SI and SDS- 
PAGE of purified SI and S2 proteins. A. Counts per minute (CPM) of tritium 
in each fraction of the automated sequencing of the gel purified SI protein 
plotted against the amino-terminal amino acid residues of the predicted SI 
protein initiated at CUG-373 and the S2 protein. B. SDS-PAGE analysis of the 
gel purified SI and S2 proteins. Two exposures of the same fluorograph are 
shown in mirror image. The left panel was exposed for 16 hrs, while the right 
panel was exposed for one week.
incubated with citrate synthase (CS) and oxalacetate (OAA) to deplete the 
extracts pool of acetyl-Coenzyme A (Palmiter, 1977), the acetyl donor for the 
acetyltransferase reaction. The SI protein synthesized under these conditions 
did appear to yield some low level peaks of radioactivity in fractions 
corresponding to predicted glycine residues assuming that the SI protein was 
initiated at CUG-373 and the initiator methionine was removed by the extract's 
amino peptidase activity (data not shown). However, the majority of the SI 
protein produced still could not be sequenced. This could indicate that the 
amino terminal blocking group is not an acetyl group. W ithout a positive 
control, however, such as a known acetylated protein, it is difficult to 
determine the effectiveness of the acetyl coenzyme A depletion system.
To prevent confusion of SI sequence data by peaks of contaminating S2,
I repeated SI sequencing experiments with SI labeled in the presence [3H] 
arginine. This amino acid was chosen because there are no arginine residues in 
S2 within the first 35 amino acids, whereas there are two adjacent arginine 
residues in the predicted sequence of CUG-373-initiated EIAV Tat located at 
amino acid positions three and four. In addition, the translation reaction was 
terminated after 45 minutes, when the rate of synthesis was still near maximal, 
by a 5 m inute 100°C incubation in the presence of 1% SDS. Such treatment may 
yield a fraction of EIAV Tat that is not amino terminally blocked. The 
effectiveness of this treatment should depend upon whether the blocking 
reaction was a co- or post-translational process. That is, this treatment would 
not have the desired effect if the blocking reaction is a highly efficient co- 
translational process. The EIAV Tat protein was immuno-precipitated from the 
pSP720 RNA directed in vitro translation products labeled with [3H]-arginine 
and subjected to amino terminal sequencing. Isolation by immunoprecipitation 
was necessary to purify EIAV Tat from a number of comigrating wheat germ
proteins, which become amino terminally modified with labeled arginine 
through the action of an arginine terminal transferase activity present in wheat 
germ extracts (Elias and Ciechanover, 1990). Amino-terminal sequencing of 5 x 
104 cpm of EIAV Tat protein prepared in this manner resulted in two clear, 
consecutive peaks of radioactivity, each of approximately 2 x 102 cpm, 
corresponding to the third and fourth residues of the polypeptide (Fig. 18). The 
position of these peaks are consistent with translational initiation at CUG-373, 
presuming amino peptidase processing of the initiator methionine residue. A 
considerable amount of radioactivity was detectable in the fraction 
corresponding to the fifth residue. It is common to have some carry over in 
sequence analyses of this type due to incomplete coupling efficiencies, 
particularly after consecutive labeled residues. However, the relative size of 
this peak is somewhat larger than would be expected from such carry over. 
Taken together with the fact that the second peak of radioactivity is slightly 
higher than the first peak, an unexpected finding, it was concluded that there 
were likely to actually be three populations of SI protein in this experiment.
The major population is the blocked protein that cannot be sequenced. This is 
evident by the low level of radioactivity recovered from the sequencer. The 
second population is the unblocked SI protein that lacks the initiator 
methionine, as evidenced by the peaks of radioactivity in the third and fourth 
fractions. A third population of SI protein appears to still bear the initiator 
methionine and would contribute to the radioactive peaks corresponding to 
residues four and five. This observation would appear to be logical, since the 
treatment used to prevent efficient blocking should also prevent efficient 
amino peptidase-mediated removal of the initiator methionine residue. In 
summary, it appears that EIAV Tat synthesized in vitro initiates at CUG-373 in 
the EIAV leader region and may be amino terminally blocked by an
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Figure 18. Microsequence analysis of the [3H]-arginine labeled SI (EIAV Tat) 
protein. Counts per minute (CPM) of tritium plotted against the predicted 
amino acid residue of the protein, assuming that translation initiates at CUG- 
373 and the amino-terminal methionine is removed by the amino peptidase 
activity of the wheat germ extract.
as yet undeterm ined functional group. Limited translation time followed by 
heat treatment may have allowed a fraction of the newly synthesized EIAV Tat 
protein to be captured in an unblocked form.
Comparison of Translation of the pSP720 RNA in Wheat Germ Extracts and 
Rabbit Reticulocyte Lysates
The pSP720 RNA was translated in wheat germ extracts or rabbit 
reticulocyte lysates in the presence of [^Hj-leucine rather than the more 
commonly used [35s]-methionine, since the SI protein is devoid of methionine. 
In wheat germ extracts, under conditions empirically determined to optimize 
amino acid incorporation (2.1 mM Mg++ and 114 mM K+), the SI, S2, and 
Agp90 proteins appeared as bands of different intensities on fluorographs of 
SDS-polyacrylamide gels (Fig. 19A). The SI protein appeared as the most 
intense band, the S2 band was the second most intense and the Agp90 band was 
the least intense. When accounting for the leucine content of each protein, SI 
and Agp90 each with nine and S2 with five leucine residues, it was determined 
that the S2 protein was actually the most abundant protein produced, 
accounting for approximately 42% of the total EIAV protein, while the SI 
protein accounted for 38% and Agp90 only 20% of the total (Fig. 19B). The CUG 
initiation codon of the SI protein and the sub-optimal AUG of the S2 protein 
appear to be efficiently recognized under these in vitro conditions.
In contrast to the relatively efficient translation of the pSP720 RNA 
transcript in wheat germ extracts, I was unable to obtain significant levels of 
amino acid incorporation in the rabbit reticulocyte lysate system. The levels of 
incorporation were consistently less than two-fold over the background 
incorporation of a control translation sample lacking exogenously added RNA. 
Nevertheless, I attempted to visualize EIAV-specific proteins on SDS-PAGE 
gels and were able to detect the SI and S2 proteins after exposure of the
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Figure 19. Quantitation of the SI, S2, and Agp90 proteins produced from the 
pSP720 RNA in wheat germ extracts. A. Flourograph of an SDS-PAGE gel of 
the pSP720 translation products synthesized under standard translation 
conditions that optimize amino acid incorporation. B. Graphical representation 
of the relative molar abundance of the SI, S2 and Agp90 proteins shown in A. 
These values were determined by densitometric scanning of the fluorograph in 
panel A.
fluorograph for three weeks (data not shown). It is not possible to load larger 
volumes of the lysate reaction mixture because of the high concentration of 
hemoglobin in the lysate that interferes with proper protein migration in the 
range below 15-kd. In this system the SI protein appeared as the predom inant 
product, and the S2 protein was barely detectable. I was unable to detect the 
Agp90 protein using the lysate system. These results were obtained using 
several different lots of reticulocyte lysate obtained from two different suppliers 
(Promega Corporation and Green Hectares). Thus, the tricistronic pSP720 RNA 
appeared to be translated inefficiently in reticulocyte lysates in contrast to its 
efficient translation in the wheat germ system.
The Effect of m 7GpppG Cap Analog on the Translation of the pSP720 RNA 
in  W heat Germ Extracts
The relative translational efficiency of the SI, S2, and env cistrons in the 
presence of the cap analog m 7GpppG was examined in order to determine 
whether the analog would affect the translation of the three cistrons equally as 
one w ould anticipate if leaky scanning accounts for the translation of each of 
the downstream cistrons. Alternatively, the internal cistrons could be initiated 
in a cap-independent manner through an internal initiation mechanism. In 
order to address these possibilities, I translated the pSP720 RNA in wheat germ 
extracts in the presence of increasing concentrations of m7GpppG. The results 
showed that addition of cap analog in the range of 0.5 to 2.0 mM led to a non­
linear decrease in the amounts of amino acid incorporation (Fig. 20A). At a 
m 7GpppG concentration of 0.5 mM, the level of translation decreased to 52% of 
the control translation containing no m 7GpppG. Increasing the level of 
m 7GpppG in the translation to 1.0 mM reduced translation to 44% of the 
control, while the maximum level tested, 2.0 mM, resulted in 39% of the control 
translation. These findings are consistent with cap-dependent translational
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Figure 20. Effect of m 7GpppG cap analog on the pSP720 RNA translation. 
pSP720 RNA was translated in wheat germ extracts in the presence of 
increasing concentrations of m 7GpppG cap analog. A. Plot of the incorporation 
of [3H]-leucine into acid insoluble protein versus the concentration of cap 
analog added to the translation mixture. The axis on the right hand side 
indicates the relative incorporation of radioactive amino acid as compared with 
a control translation that lacks cap analog. B. Fluorograph of an SDS-PAGE gel 
showing the relative abundance of SI, S2 and Agp90 at various cap analog 
concentrations. Lane 1, No cap analog; lane 2, 0.5 mM cap analog; lane 3,1 
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initiation of at least one of the three cistrons. In order to determine if the 
relative ratios of the proteins produced by the three cistrons were altered by the 
presence of the cap analog, equivalent amounts of acid insoluble radioactivity 
were examined on SDS polyacrylamide gels. The resulting fluorograph (Fig. 
20B) showed that the levels of the proteins corresponding to the internal 
cistrons, S2 and env, were not increased relative to the SI protein by the 
addition of cap analog. This result is consistent with cap-dependent leaky 
scanning (Kozak, 1989a), but an analysis of this type cannot rule out the 
possibility of a termination-reinitiation mechanism (Kozak, 1987; Peabody and 
Berg, 1986). However, taken together with compelling recent evidence 
supporting leaky scanning through the SI CUG for translation of the S3 protein 
in the bicistronic S1/S3 mRNA of EIAV (Carroll and Derse, 1993), it appears 
likely that leaky scanning by initiating ribosomes is responsible for the in vitro 
translation of the internal cistrons of the pSP720 tricistronic mRNA.
The Effect of the Potassium Ion Concentration on Translation of the pSP720 
RNA.
Based on the observation that many viruses produce structural proteins 
in greater abundance than the nonstructural regulatory proteins, one might 
expect that the gpl35 protein would be the predom inant product of the 3.5-kb 
tricistronic mRNA in vivo. Since the 3.5-kb RNA species, represented by the 
pSP720 RNA, is the only envelope length RNA thus far detected in EIAV- 
infected horses (Beisel, et al., 1993) and cultured equine cells (Rasty et ah, 1990), 
it would appear reasonable to assume that the EIAV envelope protein is 
predominantly, if not exclusively, synthesized from this RNA. Since in vitro 
translation conditions that optimize amino acid incorporation favored 
translation of the SI and S2 cistrons at the expense of the env cistron, I wanted 
to determine whether the relative ratios of the three proteins could be altered
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under different conditions. Since sub-optimal AUG and non-AUG initiation 
codons can be efficiently utilized for translational initiation under certain ionic 
conditions in cell-free systems (Kozak, 1989b; Peabody, 1989). The effects of 
varying the concentrations of mono- and di-valent cations on the translation of 
the three EIAV proteins produced by the pSP720 RNA were examined in the 
wheat germ system. The effect of K+ concentration on the translation of the 
pSP720 tricistronic message was examined by varying the level from 54 mM to 
154 mM while maintaining the Mg++ concentration at 2.1 mM. The wheat germ 
extract is supplied by the manufacturer as a buffered solution containing 107.5 
mM K+ and 4.2 mM Mg++, and the extract made up 50% of the final translation 
reaction volume. Therefore, the lowest attainable concentrations of K+ and 
Mg++ in this system were 54 mM and 2.1 mM, respectively. Additional 
potassium acetate (KAc) was added to separate translation reactions at 25 mM 
increments and the level of [3H]-leucine incorporation was determined. 
Maximum amino acid incorporation was obtained when the final K+ 
concentration was 114 mM, whereas further increases of the K+ concentration 
resulted in reduced incorporation.
An apparent effect of K+ on translation of the pSP720 RNA was a 
decrease in the level of the SI protein produced as the level of K+ was increased 
(Fig. 21 A). Concomitant w ith this decrease in SI expression was an increase in 
the levels of S2 and Agp90 expression. At 54 mM K+, the lowest concentration 
tested, the SI protein was the predominant translation product representing 
51% of the total protein produced, while the S2 and Agp90 proteins represented 
37% and 12%, respectively (Fig. 21B). As the amount of K+ added to the 
translation mixture was increased to 79 mM, the first and second cistrons 
appeared to be translated at nearly equivalent efficiencies, each contributing 
about 42% of the total translation product, while the Agp90 protein contributed
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Figure 21. Effect of potassium ion concentration on the translation of pSP720 
RNA in wheat germ extracts. A. Fluorograph of an SDS-PAGE gel of pSP720 
RNA translation products translated in the presence of increasing 
concentrations of potassium acetate. The amount of amino acid incorporated 
into protein was measured by a filter paper assay after translation, and 
equivalent amounts of acid insoluble radioactivity was loaded into each lane of 
the gel to facilitate direct comparison. The three EIAV proteins are indicated to 
the left of the figure. The final concentration of potassium acetate in each 
translation reaction is as follows: Lane 1,54 mM; lane 2,79 mM; lane 3,104 
mM; lane 4,129 mM; lane 5,154 mM. Lane M, [14C]-labeled low molecular 
weight protein standards (Life Technologies, Inc.). B. The fluorograph in A 
was scanned with Bio-Rad model 620 video densitometer and the optical 
density (OD) reading for each of the EIAV proteins was divided by the number 
of leucine residues in the protein to obtain a molar OD for each protein. The 
molar OD for each protein was divided by the total molar OD of the three 
EIAV proteins and multiplied by 100% to obtain the relative molar percentage 
of each EIAV protein is each lane. The percentage of each EIAV protein 
produced is plotted against the various potassium ion concentrations. SI, Solid 
columns; S2, hatched columns; Agp90, shaded columns.
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about 16%. At a K+ concentration of 104 mM, the S2 protein was the 
predominant product at about 47%, while the SI and Agp90 proteins 
represented 36% and 18% of the EIAV protein produced, respectively. Further 
increases in K+ resulted in only modest enhancement of S2 expression, but 
continued to decrease the level of SI and increase the level of Agp90 produced. 
At the highest K+ concentration tested, 154 mM, the S2 protein accounted for 
51% of the total protein produced, while the Agp90 protein surpassed the SI 
protein in efficiency representing 29% of the total, and the SI protein accounted 
for only 21% of the total EIAV protein synthesized from the tricistronic mRNA.
In summary, low K+ concentrations appear to favor that the three EIAV 
proteins be produced based primarily on their position in the message, that is 
the first cistron is translated more efficiently than the second and the second 
more efficiently than the third. With increasing levels of K+ the CUG codon of 
the first cistron becomes less efficiently translated, until finally at near 
physiological concentrations of K+ (Bernstein, 1954; Wickson-Ginzburg, 1963), 
it is the least efficiently translated of the three cistrons. Even at the highest 
levels of K+ tested, the Agp90 protein is still relatively poorly translated in the 
wheat germ system due to efficient recognition of the S2 sub-optimal AUG 
codon. However, its efficiency was improved about 2.5-fold from the lowest 
(54 mM) to the highest (154 mM) K+ concentrations examined here.
The Effect of M agnesium Ion Concentration on Translation of the pSP720 
RNA.
Non-AUG and sub-optimal AUG initiation codons are more efficiently 
recognized in wheat germ extracts at elevated magnesium concentrations 
(Kozak, 1989b). In order to assess the effect of magnesium ion (Mg++) 
concentration on the pSP720 RNA translation, I performed translation reactions 
at magnesium acetate (MgAc2) concentrations ranging from 2.1 to 4.1 mM and
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a constant KAc concentration of 114 mM. As mentioned above, the minimal 
Mg++ concentration that could be attained was fixed at 2.1 mM. This level was 
determined by the manufacturer to give the best amino acid incorporation for 
the BMV RNAs, their standard test RNAs. Additional MgAc2 was 
supplem ented to a series of translation reactions at 0.5 mM increments. Amino 
acid incorporation results showed that increased Mg++ levels resulted in 
significant reduction of translation (data not shown). The lowest tested Mg++ 
level of 2.1 mM was the best of the tested concentrations for the translation of 
the pSP720 RNA. The levels of incorporation at 3.6 and 4.1 mM Mg++ dropped 
to 45% and 34%, respectively, of that obtained at 2.1 mM Mg++.
U nder standard translation conditions, that is with 2.1 mM Mg++ and 114 
mM K+, the S2 protein was the predom inant product at 42% of the total EIAV 
protein translated, closely followed by the SI protein at 38%, while the Agp90 
protein accounted for 20% of the total EIAV protein synthesized (Figs. 19B and 
22). An increase in the M g++ level to 2.6 mM results in a significant rise in SI 
expression to 55% that is accompanied by sizable decreases in S2 and Agp90 
expression to 33% and 12%, respectively. An increase in Mg++ to 3.1 mM 
further favors the expression of SI to 60% , while S2 and Agp90 drop to 26% 
and 8%, respectively. Addition of Mg++ above 3.1 mM made accurate 
analysis of the protein ratios increasingly difficult due to the appearance of a 
num ber of unidentified low molecular weight products. In summary, the most 
equitable distribution of production of the three proteins was obtained at the 
lowest possible Mg++ concentration (2.1 mM) in this wheat germ translation 
system. As the level of Mg++ was increased, translation initiation from the first 
cistron, SI, was enhanced with concomitant reduced expression from the S2 
and env cistrons. In all cases the third cistron, the env cistron, was translated 
least efficiently.
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Figure 22. Effect of magnesium ion concentration on pSP720 RNA translation 
in wheat germ extracts. A. The pSP720 RNA was translated in wheat germ 
extracts in the presence of increasing concentrations of magnesium acetate. A. 
Fluorograph of an SDS-PAGE gel where equivalent amounts of acid insoluble 
radioactivity were analyzed in each lane. The three EIAV proteins are indicated 
to the left of the figure. The final concentration of magnesium acetate in the 
translation reaction loaded onto each lane of the gel is as follows: Lane 1,2.1 
mM; lane 2,2.6, mM; lane 3,3.1 mM; lane 4,3.6 mM; lane 5,4.1 mM. Lane M, 
[14C]-labeled low molecular weight protein standards (Life Technologies, Inc.). 
B. The relative molar percentage of each EIAV protein translated at each 
magnesium acetate concentration is shown (refer to legend to Fig. 21). SI, solid 








Co-translation of the pSP720 RNA w ith BMV RNA 4
In my early experiments I was intrigued with the relatively high 
translation efficiency of the EIAV tricistronic message as compared with BMV 
RNAs provided by the manufacturer as the test RNAs for the translation 
system (50-70% of BMV RNA incorporation). In order to obtain a more 
quantitative measure of the efficiency of the EIAV tricistronic mRNA in the 
w heat germ system, I performed co-translation experiments of this RNA with 
BMV RNA 4. The latter is a component of the BMV RNA mixture and is a 
highly efficiently translated message in the wheat germ system (Shih and 
Kaesberg, 1973). In addition, this RNA was a convenient choice since it results 
in the synthesis of a viral capsid protein of 20-kd that can be readily observed in 
the gel electrophoresis system used to resolve the pSP720 RNA proteins. The 
BMV RNA was added to the wheat germ translation mixtures at molar ratios of 
1:10,1:2, and 1:1 relative to the pSP720 RNA, which was added at the saturation 
concentration of 30 pg/m l.
To simplify the comparison, and also for the purpose of determining the 
efficiency of utilization of the SI CUG codon as compared with the BMV RNA 4 
AUG codon in the wheat germ cell-free system, the relative translational 
efficiency of only the SI cistron was compared to that of BMV RNA 4. The 
densitometer readings for the SI protein and the BMV coat protein were 
normalized for the num ber of leucine residues in each protein to allow direct 
comparison of the two proteins on a molar basis. At a one tenth molar ratio of 
BMV RNA 4 to the pSP720 RNA very little BMV coat protein was detected (Fig. 
23A, lane 2). Quantitation of these bands showed that there was more than 10- 
fold more SI produced than BMV coat protein (Fig. 23B). Increasing the level of 
BMV RNA 4 to one half molar equivalent resulted in a large increase in BMV 
coat protein expression (Fig. 23A, lane 3) to a point where it was expressed at a
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Figure 23. Co-translation of pSP720 RNA with BMV RNA 4 in wheat germ 
extracts. A. The pSP720 RNA was translated in wheat germ extracts in the 
presence of increasing amounts of BMV RNA 4. Equivalent volumes of 
translation mixture were analyzed on an SDS-PAGE gel. Lane 1, no BMV RNA 
added; lane 2, 0.1 molar equivalents of BMV RNA added; lane 3,0.5 molar 
equivalents of BMV RNA added; lane 4, equal molar amounts of pSP720 RNA 
and BMV RNA 4 added. Lane M, [14C]-labeled low molecular weight protein 
standards (Life Technologies, Inc.). The positions of the BMV RNA coat protein 
and the EIAV proteins are indicated to the left. B. Quantitation of the relative 
molar amounts of BMV coat protein and SI protein synthesized in each 
translation mixture. The fluorograph in panel A was scanned with a Bio-Rad 
model 620 video densitometer and the optical density readings for the BMV 
coat protein and the EIAV SI protein were normalized by dividing each by the 
num ber of leucine residues they contain. Each molar OD was divided by the 
sum of the molar OD readings of the two proteins to determine the relative 
percentage of these two proteins in a given translation experiment. SI, solid 
columns; BMV coat protein, hatched columns.
% of S1 or BMV Coat Produced
>
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level 1.7-fold greater than the SI protein. At an equimolar ratio of the two 
RNAs the BMV coat protein was produced at a level approximately 5-fold 
greater than that of the SI protein. Under the translation conditions employed 
in this experiment, translation of the SI cistron in the pSP720 RNA was 20% as 
efficient as the translation of the BMV coat protein from BMV RNA 4 when 
both viral RNAs were present at an equimolar amount in the same translation 
mixture.
EIAV Tat Synthesis Initiates at a CUG Codon and not an AUC Codon in 
Wheat Germ Extracts
The pSP720 in vitro transcription construct contains the entire ORF SI, 
while the pSP585 construct lacks sequences upstream of the Sma I site (nt 393) 
near the 5' border of ORF SI (nt 346). The data reported here demonstrate that 
SI sequences upstream of the Sma I site are required for EIAV Tat synthesis in 
wheat germ extracts. These sequences include CUG-373 and AUC-388, each of 
which has been independently reported to be responsible for initiation of Tat 
synthesis (Noiman et al., 1991; Carroll and Derse, 1993). In order to determine 
if AUC-388 can initiate Tat synthesis in the wheat germ system, the in vitro 
transcription construct pSP634 was generated. AUC-388 lies within a BamH I 
site that is immediately upstream of the Sma I site used to produce pSP585. 
Therefore by subcloning the 280 bp BamH I fragment of the pSR-1 cDNA clone 
into the BamH I site of the pSP65 polylinker, a construct was generated that 
contains the AUC codon of ORF SI, but lacks CUG-373. Since there is a second 
BamH I site in the cDNA clone within the overlapping region of ORF S2 and 
env, a 623-bp Sma I fragment of pSR-1 that includes sequences immediately 
downstream of the BamH I site near the 5' end of SI to the Sma I site of env that 
lies 36-bp downstream of the Msc I site used to produce pSP720 and pSP585. A 
comparison of the 5' end sequences of the pSP720, pSP585, and pSP634 RNAs is
shown in Figure 24A. As can be seen in this figure, the EIAV sequences (non­
italicized) of pSP634 RNA begin two nucleotides upstream of AUC-388. A 
consequence of this cloning scheme is that the adenine residue in the -3 position 
with respect to the putative AUC initiation codon has been replaced by a 
guanine residue. In general adenine residues are preferable in the -3 position of 
initiation codons, but either purine can result in efficient translation initiation 
(Kozak, 1986). Translation of pSP634 RNA in wheat germ extract resulted in 
the production of the S2 and Agp90 proteins, but not the Tat protein (Fig. 24B, 
lane 2). These data indicate that AUC-388 does not act as the Tat translation 
initiation codon in this in vitro system, and that sequences upstream of AUC- 
388 are required for Tat synthesis in vitro. These upstream  sequences include 
CUG-373, the codon demonstrated likely to initiate Tat synthesis based on the 
amino terminal sequence data presented in Figure 18 above.
The S3 Protein Synthesized In Vitro Initiates from an AUG Codon Provided 
by env  Sequences
The S3 open reading frame overlaps the env gene in an alternative frame 
near its 3' end and consists of 135 potential codons, none of which correspond 
to methionine. A multiply-spliced RNA has been described that contains ORF 
SI and ORF S3 (Stephens et al., 1990). This RNA contains four exons: 1, the 5' 
leader sequence and coding exon 1 of ORF SI; 2, coding exon 2 of ORF SI; 3, a 
101-nt exon that places 33 codons of gp90 in frame with ORF S3, the fourth of 
which is a methionine; 4, the major coding exon of ORF S3. The env sequences 
spliced to S3 contain two in-frame methionine codons corresponding to the 
third and fourth codon of the env-S3 fusion ORF, AUG-5447 and AUG-5480.
An epitope recognized by the monoclonal antibody used to identify the Agp90 
protein produced from the pSP720 transcript (refer to Fig. 12), lies between 
these two AUG codons (nt 5459-5485). Therefore, if the S3 protein is initiated at
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Figure 24. Translation of EIAV Tat is not initiated at AUC-388 in vitro. A . A  
comparison of the nucleotide and amino acid coding regions of the pSP720, 
pSP585 and pSP634 in vitro transcripts. Sequences in italics are derived from 
the pSP65 in vitro transcription vector poly-cloning site. The UGA stop codon 
in pSP720 that defines the 5'-end of the EIAV tat gene that encodes the SI 
protein is indicated with an asterisk. CUG-373 of pSP720 and AUC-388 of 
pSP720 and pSP634 are underlined along with their -3 and +4 context 
nucleotides. B. Fluorograph of an SDS-PAGE gel of the translation products of 
the pSP585 (lane 1), pSP634 (lane 2), and pSP720 (lane 3) in vitro translation 
products synthesized in w heat germ extracts. The EIAV proteins are indicated 
to the right of the figure.




UGA GAG...(21 ntl.-.AAC CUG GCU GAU CGU 
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GGG AUC CCC GGG ACA GCA GAG GAG AAC... 




the first of these two AUG codons, then it would contain this monoclonal 
epitope near its amino terminus. In order to address this possibility, a cDNA 
clone corresponding to the 1.5-kb cDNA S I/S3 was obtained and an 800-bp 
Pvu U/Stu  I restriction fragment was subcloned into the Sma I site of pSP65 to 
give pSPS3. The Pvu II site lies near the 5' end of the second exon and the Stu I 
site lies in the 3' redundant region. Therefore, this construct lacks sequences 
required for SI expression. The pSPS3 plasmid was linearized with Hind III 
within the vector polylinker region and used as a template for in vitro 
transcription. The transcripts were translated in wheat germ extracts in the 
presence of [35S]-methionine and analyzed on a SDS-polyacrylamide gel. The 
resulting autoradiograph showed that a protein of approximately 20 to 21-kd 
was synthesized (Fig. 25, lane 2). This apparent molecular weight is in 
accordance with the previously reported size of the S3 protein (Saman et al., 
1990). This protein can be immunoprecipitated with the gp90 monoclonal 
antibody (Fig. 25, lane 3) and a S3-specific peptide antisera directed against a 
carboxyl-terminal peptide of S3 (Fig. 25, lane 4). The monoclonal antibody also 
precipitated a large number of lower molecular weight products that were not 
recognized by the rabbit peptide antisera. These products are likely to be 
carboxyl terminal truncations of S3 resulting from proteolysis, premature 
translational termination, or synthesis from a partially degraded in vitro 
transcript. The data indicate that the S3 protein produced in wheat germ 
extracts is likely to be initiated at AUG 5459, the third AUG codon of the gp90 
cistron which results from a splicing event that juxtaposes 33 internal codons of 
the gp90 cistron (splice donor 5537) to the S3 cistron (splice acceptor 7235).
Discussion
The translational coding potential of the EIAV 3.5-kb transcript of FDD 
cells was examined using a cDNA clone and in vitro expression techniques. The
Figure 25. In vitro translation and immunoprecipitation of the S3 protein. A 
Pvu U/Stu  I restriction fragment of a cDNA clone, that was derived from a 
multiply-spliced RNA of EIAV that places a region of the env gene in-frame 
with the ORF S3 gene, was ligated into the pSP65 vector to produce pSPS3. In 
vitro transcripts were synthesized from this plasmid construct and translated in 
wheat germ extracts. The translation products were immunoprecipitated (IP) 
with either a monoclonal antibody (mab86) that recognizes an epitope of the 
gp90 envelope protein or a synthetic peptide antisera that was produced 
against a peptide corresponding to the predicted ORF S3-encoded protein, the 
ding to containing the coding region. Lane M, [14C]-labeled low molecular 
weight protein standards (Life Technologies, Inc.); lane 1, a translation reaction 
that lacked exogenously added RNA; lane 2, pSPS3 translation products; lane 
3, IP w ith mab86; lane 4, IP with ORF S3 synthetic peptide antisera.
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results clearly indicate that this transcript is tricistronic in vitro, since it directs 
the synthesis of EIAV Tat, S2, and a truncated envelope protein (Agp90) in the 
wheat germ cell-free translation system. The translational initiation site for the 
ORF S I -encoded EIAV Tat protein has been localized to sequences between the 
Stu I (nt 256) and Sma I (nt 393) sites of the viral leader sequence, since it is 
produced from the pSP720 RNA but not the pSP585 RNA. The observation that 
the Tat initiation codon lies upstream of the Sma I site has been confirmed by 
other researchers in studies of the bicistronic EIAV tat/rev (SI/S3) mRNA (Dorn 
et a l, 1990).
One research group (Noiman et a l, 1991) has reported that EIAV Tat 
synthesis is initiated from an AUC codon (AUC-388, nt 388-390) that lies 
immediately upstream  of the Sma I site (nt 393). This finding is somewhat 
surprising since AUC-388 lies in a less favorable context for translation 
initiation [AGG AUC C, where underlined nucleotides match the consensus 
sequence for translational initiation (Kozak, 1986)] than does an upstream CUG 
codon (AAC CUG G). Previous studies have shown that the presence of a 
purine residue in the -3 and a guanine residue in the +4 positions are critical for 
the recognition of non-AUG codons in vivo (Mehdi et a l,  1990). I was unable to 
detect Tat synthesis in vitro from AUC-388 using the pSP634 RNA, a synthetic 
transcript that contains AUC-388 but lacks sequences further upstream 
including CUG-373.
Sequence analysis of the amino terminus of in vitro synthesized EIAV Tat 
presented here is consistent with initiation at CUG-373, but not compelling due 
to an apparent amino terminal blocking group present on the majority of the 
Tat polypeptides produced under these conditions. I was, however, able to 
obtain the limited sequence data presented here by m anipulating the in vitro 
translation conditions in a manner that apparently allowed the synthesis of a
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small am ount of the Tat protein in an unblocked form. I also show here that the 
blocking group does not appear to be an acetyl group, since wheat germ 
extracts that were pre-treated to reduce the endogenous pool of acetyl- 
Coenzyme A did not produce Tat protein that was more readily sequenced.
The precise identity of this blocking group and the determination of whether 
this blocking reaction occurs in vivo, as well as in vitro, will require further 
investigation. The recently published data of Carroll and Derse (1993) appear 
to clearly confirm that CUG-373 is indeed responsible for initiation of the EIAV 
Tat protein. In this study, site-specific mutagenesis was used to alter CUG-373 
to a GUA valine codon resulting in the total loss of trans-activation of the EIAV 
LTR in transient transfection experiments. Furthermore, these researchers 
showed that mutagenesis of AUC-388 to a GUA codon did not result in reduced 
trans-activation. It is unclear why Noiman et al. (1991) were able to detect high 
levels of trans-activation in deletion mutants that lacked CUG-373, but 
contained AUC-388. The only significant differences between these two 
investigations is the use of different expression plasmids to produce the mutant 
Tat proteins in transfected cells, and the use of different cell lines to assay the 
trans-activation activity of the mutants. One possibility may be that the 
eucaryotic expression plasmid that was used may contain a cryptic splice donor 
that allows an alternative initiation codon to be placed in-frame with the second 
exon of the tat gene.
Translational initiation at non-AUG triplets has been shown to occur in 
both viral and cellular systems. One of the capsid proteins of adeno-associated 
virus (Becerra et al., 1985) and the C' protein of Sendai virus (Curran and 
Kolakofsky, 1988; Gupta and Patwardhan, 1988) initiate translation at ACG 
codons. Some cellular regulatory proteins involved in various stages of signal 
transduction pathways have been shown to initiate translation at CUG codons.
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In most of these cases, the CUG initiation codons lie upstream  of in-frame AUG 
codons that are responsible for the majority of translation of these proteins. The 
CUG codons result in the synthesis of amino-terminally extended proteins with 
as yet undefined functions. This was shown to be true for the hum an basic 
fibroblastic growth factor gene which directs the synthesis of at least three 
polypeptides in vivo. Two of these are produced from upstream CUG codons 
(Florkiewicz and Sommer, 1989; Prats et al., 1989). The c-myc nuclear 
transcription factor gene results in the synthesis of two proteins, one of which is 
initiated from an upstream CUG codon (Hann et al., 1988). While these 
extended proteins are presumed to perform unique functions in the cell, this 
remains to be proven experimentally. More recently, the murine Itk receptor 
tyrosine kinase has been shown to initiate translation exclusively at a CUG 
codon in vitro and in vivo (Bernards and de la Monte, 1990). The EIAV Tat 
protein is the first example of the utilization of a non-AUG codon in 
retroviruses, and like the murine Itk receptor, the synthesis of the Tat protein is 
initiated exclusively at the CUG codon. That is, there is no trans-activation of 
the EIAV LTR observed if CUG-373 is mutagenized to a non-initiator codon 
(Carroll and Derse, 1993).
Translation of the pSP720 RNA in wheat germ extracts under conditions 
that optimize amino acid incorporation results in synthesis of all three EIAV 
proteins, with both the EIAV Tat and S2 proteins being produced at a near two­
fold greater molar ratio than Agp90. The relatively efficient translation of the 
pSP720 RNA in the wheat germ system is contrasted by a dramatically reduced 
ability of the RNA to be translated in rabbit reticulocyte lysates. The reduced 
translational efficiency of the pSP720 RNA in the lysate system may be due to 
the presence of low amounts of double stranded RNA that often contaminate 
RNA synthesized in vitro using bacteriophage RNA polymerases (Gunnery et
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al., 1990). Such contamination previously led to the belief that the HIV-1 trans- 
activation response (TAR) RNA stem-loop structure, located at the 5' end of all 
HIV-1 RNAs, results in inhibition of translation in the reticulocyte lysate system 
due to activation of a double-stranded RNA-activated inhibitor (DAI) of 
translational initiation (Edery et al., 1989; SenGupta et al., 1989; SenGupta et al., 
1990). Upon rigorous purification of the in vitro transcripts, no such inhibition 
was detected. In fact, it now appears clear that elevated levels of highly 
purified TAR RNA can actually prevent activation of DAI (Gunnery et al., 1992), 
although others have claimed that an as yet undefined heat labile inhibitor is 
responsible for HIV-1 RNA translation inhibition in rabbit reticulocyte lysates 
(Geballe and Gray, 1992). It would be interesting to see if extensive 
purification of the pSP720 RNA to remove the putative contaminating dsRNAs 
improves its ability to be translated in reticulocyte lysates. The wheat germ 
system may be less sensitive to such contaminants, thereby allowing for 
efficient translation of the pSP720 RNA in this system.
The observation that addition of m 7GpppG cap analog to the translation 
reaction decreased expression of each of the three EIAV ORFs in the pSP720 
RNA nearly equivalently is consistent with a leaky scanning mechanism for 
translation of the downstream ORFs. Compelling evidence for leaky scanning 
through the EIAV Tat CUG of the bicistronic S1/S3 EIAV RNA has recently 
been published (Carroll and Derse, 1993). These researchers found that cell 
cultures transfected with S1/S3 expression vectors produced very low levels of 
SI protein as compared to the S3 protein. Site-specific mutagenesis of the SI 
initiator CUG to an AUG greatly increased the amount of SI produced and 
nearly completely prevented synthesis of the downstream S3 protein. By 
analogy, leaky scanning through the SI CUG of the pSP720 RNA is likely to
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result in S2 synthesis, and leaky scanning through both the SI CUG and the S2 
AUG to result in Agp90 synthesis.
Other known examples of functionally bicistronic RNAs in lentiviruses 
are the HIV-1 vpu/env and rev/nef BN  A s  (Schwartz, et a l, 1990b; Schwartz et a l, 
1992a). In both cases the evidence indicates that the downstream protein is 
efficiently translated in vivo due to leaky ribosome scanning through a sub- 
optimal AUG initiation codon for the upstream protein. Specifically, the Rev 
initiation sequence contains a cytidine in the -3 position (CU CCU AUG G) and 
that for Vpu contains a cytidine residue in the +4 position (AU GUA AUG C). 
The arrangement of the S2 and env genes of EIAV is very similar to that of the 
vpu and env genes of HIV-1 in that they are expressed from overlapping reading 
frames with the S2 or Vpu AUG initiation codon preceding that of the 
respective envelope polyprotein. The EIAV S2 AUG, like that of Vpu, lies in an 
unfavorable context for initiation due to the presence of a uridine residue in the 
-3 position. Furthermore, there is no evidence for the presence of any splice 
acceptor sites in the 23-nt span between the S2 and gpl35 initiation codons. 
Therefore, it is likely that efficient gpl35 expression in EIAV requires low level 
recognition of both the Tat CUG initiation codon as well as the sub-optimal S2 
AUG initiation codon by scanning ribosomes. More detailed analyses 
involving the characterization of site-specific mutants of the Tat and S2 initiator 
codons are necessary to clearly define the precise mechanisms involved in the 
translation of this tricistronic mRNA.
The EIAV 3.5-kb RNA bears a strong structural similarity to a singly- 
spliced message of HIV-1 (Tati) that contains the first exon of tat as its first 
cistron, vpu as the second cistron, and env as the third cistron. While this HIV-1 
mRNA is functionally tricistronic in vitro, it is monocistronic in vivo due to 
faithful translational initiation at the relatively strong Tat AUG initiation codon
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of the first cistron (Schwartz, et al., 1990b). Mutagenesis of bases at the -3 or +4 
position of the Tat AUG results in leaky ribosome scanning to the downstream 
Vpu and Env proteins (Schwartz et al., 1992a). In the case of HIV-1 a number of 
alternatively spliced envelope transcripts devoid of the Tat initiation codon are 
responsible for Env translation. However, to date the tricistronic 3.5-kb EIAV 
RNA studied here has been the only ewz;-containing RNA detected in infected 
animals (Beisel, et al., 1993). EIAV appears to have evolved a mechanism to 
express its envelope protein from a tricistronic message that involves the use of 
a non-AUG codon for the synthesis of the EIAV Tat and a sub-optimal AUG 
codon for that of S2, thereby enabling this virus to replicate with a relatively 
simple mRNA splicing scheme as compared to the primate lentiviruses.
Increases in the potassium ion concentration in the in vitro translation 
reaction to near physiological levels (Bernstein, 1954; Wickson-Ginzburg and 
Solomon, 1963) resulted in markedly reduced expression of the Tat and S2 
proteins w ith concomitant enhanced expression of the env cistron. Elevated 
levels of magnesium appeared to favor translation from the Tat CUG codon at 
the expense of the downstream ORFs. It has previously been determined that 
levels of Mg++ greater than 3 mM in wheat germ extracts resulted in enhanced 
initiation of translation from non-AUG and sub-optimal AUG codons placed 
upstream of the chloramphenicol acetyl transferase AUG codon (Kozak, 1989b). 
However, a Mg++ level of 1.9 mM resulted in infrequent initiation from these 
anomalous codons and thereby more accurately reflects the in vivo situation. In 
the present study, the Tat and S2 proteins were efficiently translated at 2.1 mM 
Mg++, the lowest level attainable in these extracts. The Tat and S2 proteins each 
comprised nearly 40% of the total EIAV protein synthesized, while the Agp90 
protein was only 20% of the total. Although this level of Mg++ was only slightly 
above the 1.9 mM previously determined by Kozak for near faithful initiation of
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the particular synthetic test RNAs, the levels of Tat and S2 synthesized were 
much greater than would normally be anticipated in vivo. It should be noted 
that 2.1 mM Mg++ was the optimal concentration tested here for amino acid 
incorporation for the pSP720 RNA and BMV RNAs. The previous studies 
noted a reduction in amino acid incorporation at 1.9 mM Mg++ as compared to 
3 mM Mg++. In the extracts employed in this study, increasing the Mg++ levels 
from 2.1 mM to 3.1 mM resulted in a considerable reduction in amino acid 
incorporation. These discrepancies may reflect differences in the preparation of 
the extracts, and may indicate that Mg++ levels lower than 2.1 mM may be 
required for obtaining a ratio of the three EIAV proteins similar to what might 
be expected in vivo. Nevertheless, I was clearly able to alter the relative levels of 
the three EIAV proteins by varying the concentrations of Mg++ and K+, 
suggesting that translation of each of the three cistrons may be affected or 
regulated by specific cellular ionic conditions. For the wheat germ extract 
system employed in the present studies the lowest attainable Mg++ level of 2.1 
mM and the highest tested K+ level of 154 mM yielded the highest proportion 
of the envelope protein and appeared to most closely approximate what one 
might anticipate to occur in vivo.
CHAPTER 3
IN VIVO EXPRESSION OF THE EIAV ORF PROTEINS
Introduction
When the research described in this dissertation was first begun, the 
sequence information leading to the discovery of the small open reading frames 
(ORFs) in EIAV had only recently been published (Kawakami et al., 1987; 
Rushlow et al., 1986). At that time no protein products had yet been shown to 
be encoded by these ORFs, and the roles of these putative proteins in EIAV 
infection were unknown. Shortly after this sequence information was 
published, Derse et al. (1987) demonstrated that the EIAV LTR could be 
specifically activated in EIAV-infected canine and feline fibroblast cell lines. 
These data indicated that EIAV, like other lentiviruses, encodes a trans-activator 
protein that is functionally homologous to the HIV-1 Tat protein. Thus, one of 
the ORF proteins was presumed to be this viral trans-activator.
Early experiments by Dorn and Derse (1988) using restriction fragments 
from proviral clones appeared to indicate that the S2 protein might be this 
trans-activator. However, it was not until the isolation of cDNA clones 
corresponding to the 1.5-kb S1/S3 mRNA, that the ORF SI-encoded protein was 
unambiguously identified as EIAV Tat (Dorn et al., 1990; Stephens et al., 1990; 
Noiman et al., 1991). Noiman et al. (1991) used a pool of antisera produced 
against three different synthetic peptides of the predicted Tat protein to detect a 
very low abundance 8-kd protein in EIAV-infected canine cells. The molecular 
weight of this protein correlates well with in vitro synthesized Tat protein 
(Schiltz et al., 1992). This is the only report to date of the direct detection of the 
tat gene product in vivo.
The putative S2 protein has yet to be detected in vivo or assigned a 
function in EIAV infection. Saman et al. (1990) have speculated that ORF S2
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may be the first exon of a putative EIAV Rev protein, and that ORF S3 would be 
the second exon of EIAV Rev. These researchers suggested that ORF S2 
contains a consensus splice donor signal at nt 5345 that could be spliced to a 
consensus splice acceptor near the 5'-end of ORF S3 (nt 7235). Such a splicing 
event would allow 17 codons of ORF S2 to be spliced to 135 codons in ORF S3. 
The ORF S2 sequences could provide a translational initiation codon for the 
synthesis of the putative Rev protein, since ORF S3 is devoid of methionine 
codons. To date, no cDNAs have been isolated from EIAV-infected cells that 
utilize this proposed splice donor site. Close inspection of this site shows that it 
is not a consensus splice site, since it lacks a critical uridine residue. The 
consensus sequence for a splice donor site is AGGU, where the splicing occurs 
between the two guanine residues, and the GU dinucleotide is absolutely 
conserved (Mount, 1982; Oshima and Gotoh, 1987). The sequence of the 
proposed splice donor within ORF S2 is AGGG and is therefore unlikely to be 
functional. Since there do not appear to be any other potential splice donor 
sites in ORF S2 it should produce a unique protein if it is expressed in vivo.
The 20-kd S3 protein was detected in EIAV-infected cells using both 
synthetic peptide antisera (Stephens et al., 1990) and antisera directed against a 
portion of the S3 protein expressed in E. coli. (Saman et al., 1990). Saman et al. 
also demonstrated that sera from EIAV-infected horses could specifically 
recognize the E. coli expressed S3 protein, indicating that the S3 protein is 
expressed during productive EIAV expression. The isolation of cDNAs 
corresponding to the multiply-spliced S I/S3 1.5-kb transcript of EIAV has 
shown that an AUG initiation codon of an internal region of the env cistron is 
spliced in-frame with the ORF S3 coding region (Rosin-Arbesfeld et a l, 1993; 
Stephens et al., 1990). Thus, a portion of the env gene consisting of 29 codons 
constitutes the first coding exon of rev (rev-1), and not ORF S2 as previously
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proposed (Saman et al., 1990). Stephens et al. (1990) showed that the predicted 
S3 protein contained sequence homology with the H3V-1 Rev protein, but it has 
only recently become apparent that the S3 protein is functionally homologous 
to the Rev proteins of other lentiviruses (Martarano et al., 1994; Fridell et al., 
1993).
Since I had an ongoing interest in comparing EIAV infection in primary 
cultures of equine fibroblasts that support either persistent or cytopathic 
infection, I examined the ability of these cells to trans-activate the EIAV LTR 
using a pLTR-CAT reporter plasmid. I examined the possibility that the 3.5-kb 
RNA might encode the Tat protein by determining the levels of trans-activation 
throughout the course of a cytopathic infection of FDD cells. In these cells, the
3.5-kb RNA is expressed at very high levels late in the infection cycle, while 
there is little change in the expression level of the multiply-spliced 1.5-kb RNA 
(Rasty et al., 1990). A significant increase in the Tat activity concomitant with 
increased expression of the 3.5-kb RNA would provide indirect evidence for the 
expression of the Tat protein from this RNA. I also expressed restriction 
fragments from a cDNA that corresponds to the 3.5-kb RNA in uninfected FDD 
cells along with the pLTR-CAT reporter plasmid to determine if the Tat protein 
is encoded by the 3.5-kb RNA. I used deletion mutants to examine which 
sequences in cDNA were required for Tat expression.
In the previous chap ter, I established that the EIAV 3.5-kb RNA is 
tricistronic in vitro. A desired goal of this research was to determine if this RNA 
is also tricistronic in vivo. In order to accomplish this goal, I first had to devise a 
method of detecting the various proteins encoded by the 3.5-kb RNA. In this 
chapter I will described my efforts to detect the three ORF proteins in vivo using 
immunological techniques.
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Materials and Methods 
Virus Strains and Cell Cultures
Canine (Cf2Th) and feline (FEA) fibroblast cultures that were either 
persistently infected with EIAV or uninfected were a gift from Larry Arthur 
(Program Resources, Inc., Frederick Cancer Research Facility, Frederick, MD). 
Primary cultures of fetal donkey dermal (FDD) cells and fetal equine kidney 
(FEK) cells were obtained from Dr. C. J. Issel (formerly of the Department of 
Veterinary Science, Louisiana State University, Baton Rouge, LA and currently 
with the Department of Veterinary Science, Gluck Equine Research Center, 
University of Kentucky, Lexington, KY). All cells were maintained in Eagle's 
minimal essential media supplemented with 10% fetal calf serum. Two related 
strains of EIAV, referred to here as the prototype strain and the FDD-adapted 
strain, were used during these studies. The prototype strain was generated by 
propagation of the Wyoming cell-adapted strain of EIAV (Malmquist et al.,
1973) in prim ary cultures of fetal equine kidney (FEK) cells, and the FDD- 
adapted strain was derived from the prototype strain by serial passage in FDD 
cells. Confluent monolayers of equine cells were infected with the indicated 
virus strain at a multiplicity of infection of one.
Chloramphenicol Acetyl Transferase Reporter Gene Plasmids
Plasmid vectors containing the bacterial chloramphenicol acetyl 
transferase (CAT) gene under the control of the SV40 immediate early promoter 
(pSV2CAT) or with no promoter (pSVOCAT) were purchased from the 
American Type Culture Collection, Rockville, MD. The plasmid pLTRCAT was 
constructed by subcloning the EIAV LTR from a lambda proviral genomic clone 
(A. 12) into the unique Hind III site of pSVOCAT located immediately upstream 
of the CAT gene. The proviral clone was digested with BsiN  I and Pvu II and a 
478-bp fragment was isolated containing the entire 321-bp EIAV 5-LTR flanked
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by 175-bp of cellular DNA 5' to the LTR and 1-bp of the EIAV leader region.
The BsfN I site was converted to a blunt-end using T4 DNA polymerase. 
Following the addition of H ind  HI linkers (New England Biolabs), the LTR- 
containing fragment was ligated to H ind  HI digested pSVOCAT.
Eucaryotic Expression Plasmid Constructs.
Eucaryotic expression plasmids were constructed by subcloning 
restriction fragments of the cDNA clone pSR-1 into an SV40 replacement vector, 
pSV2ACAT, derived from pSV2CAT (Gorman et ah, 1982). The pSV2ACAT 
vector provided by Keith Rushlow (formerly of the Department of Molecular 
Genetics and Biochemistry, University of Pittsburgh School of Medicine, 
Pittsburgh, PA) was produced by digestion of pSV2CAT with H ind  III and 
Hpa I to remove the CAT gene, followed by insertion of a synthetic linker that 
regenerates each of these sites and also provides a unique Xho I site. The 
eucaryotic expression plasmids described here are analogous to the in vitro 
transcription plasmids described in Chapter 2. The 720-bp Stu l/M sc  I and the 
585-bp Sma I/M sc  I of the pSR-1 cDNA were ligated to Stu I digested 
pSV2ACAT generating pSV720 and pSV585, respectively. The Stu I site of 
pSV2ACAT lies between the SV40 promoter and the unique H ind  HI site. The 
plasmid pSV634 was produced by digesting pSP634 (see Chapter 2: Materials 
and Methods) w ith EcoR I and Msc I and converting the EcoR I site to a blunt- 
end using the Klenow fragment of E. coli DNA polymerase I. The EcoR I site of 
pSP634 is located within the pSP65 multiple cloning site upstream of the EIAV 
sequence, and the Msc I site is the same site used to produce pSV720 and 585 
and is located within the EIAV env gene. The blunt-end fragment was ligated 
to Stu I digested pSV2ACAT to produce pSV634.
The plasmid pSV585met was constructed through multiple cloning 
steps, but the net result is the placement of a consensus translational initiation
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signal (GCC GCC ACC AUG G) into the Stu I/Sm a  I site of pSV585. This was 
accomplished by first subcloning a 280-bp BamH I restriction fragment of the 
pSR-1 cDNA into the unique Bgl II site of the vector pSV2met (provided by 
Keith Rushlow) to produce pSV2met280. pSV2met is a derivative of the 
aforementioned pSV2ACAT vector. A synthetic linker containing a consensus 
ATG initiation codon was placed into Stu I/H in d  HI digested pSV2ACAT to 
produce pSV2met. The nucleotide sequence of this synthetic linker is the 
following: CCT GCC GCC ACC ATG GAG ATC TCA. The ATG codon is 
im bedded in a Nco I site (CCATGG) and a Bgl II site (AGATCT) immediately 
follows this codon. There are two BamH I sites in the pSR-1 cDNA, one is 
located immediately upstream and overlaps the Sma I site in the leader region 
(GGATCCCCGGG) and the other is located in the region where ORF S2 and env 
overlap. In order to make a construct that contains the same ORF S2 and env 
sequences as the pSV585 and pSV720 clones, pSV2met280 was digested with 
Sma I and Xho I. The Sma I site lies immediately downstream and overlaps the 
Bgl n / BamH I hybrid site that lies immediately downstream of the consensus 
ATG codon, and the Xho I site lies downstream of the BamH I /B gl II site at the 
3'-end of the 280-bp insert from pSR-1. Thus, the net result is the removal of all 
of the pSR-1 cDNA sequences except for half a BamH I site and half a Sma I site 
that overlap each other (ACC AUG GAG ATC CCC, the sequences from pSR-1 
are underlined). A Sma I/Sa l I restriction fragment of pSP720 was then ligated 
to the large fragment of Sma I /Xho  I digested pSV2met280 to produce 
pSV585met. The Sma I site of pSP720 is the same Sma I site found in the leader 
sequence of the pSR-1 cDNA and the Sal I site of pSP720 lies immediately 
downstream of the Msc 1 /Sma I hybrid site. Therefore, the pSV585met plasmids 
contains the same EIAV sequences as pSV585 with the addition of two codons 
(ATC CCC) provided by the overlapping BamH I and Sma I sites of pSR-1. This
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plasmid is predicted to produce an amino-terminally truncated form of the 
EIAV Tat protein that is initiated from a consensus AUG methionine codon.
The cloning scheme introduces two non-native codons into the 5'-end of the tat 
gene, the AUG itself and a GAG codon which would encode a glutamate 
residue.
The plasmid pSVS3 was produced by ligating the Pvu 11/Stu I fragment 
of pSP-1 (S1/S3 cDNA) to Stu  I digested pSV2ACAT. The plasmid pSV3.5kb 
was constructed by digesting a complete proviral clone that was introduced 
into the pSV2ACAT vector (pSV2provirus, provided by Keith Rushlow) to 
completion with Sma I. Sma I cuts the proviral DNA in the leader region, in the 
pol gene, and in the 5'-end of the env gene. The fragment containing the pSV2 
sequences, the EIAV LTRs, and the truncated leader region and env genes was 
isolated and ligated to an 800-bp Sma I fragment from the pSR-1 cDNA clone to 
produce the pRLS plasmid. This construct is capable of producing authentic
3.5-kb RNA as a primary transcript that is initiated from the EIAV 5-LTR and 
polyadenyla ted from the EIAV 3'-LTR. For expression in COS-7 cells the pRLS 
plasmid was digested with Stu I which cuts in the R region of both LTRs. The 
resulting 3.5-kb fragment was subcloned into Stu I digested pSV2ACAT to 
produce pSV3.5kb. This construct produces the EIAV 3.5-kb RNA that is 
initiated from the SV40 immediately early promoter and polyadenylated by the 
SV40 poly A signal.
The S3 frame-shift plasmid, pSV3.5kbAS3, was derived from 
pSV3.5kb/LTR. The strategy for creating the frame-shift mutations was to 
digest the ORF S3 region w ith Apa I which cuts immediately downstream of the 
splice acceptor site at the 5'-end of ORF S3 (nt 7235). The 4-bp 3'-overhangs 
were removed with T4 DNA polymerase and the plasmid was religated to 
create the frame-shift. However, the SV40 polyadenylation signal of pSV3.5kb
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also contains an Apa I site, so the SV40 polyA signal was replaced with the 
EIAV 3-LTR prior to making the frame-shift mutation. This was accomplished 
by digesting pSV3.5kb with Spe I and EcoR I to release the SV40 polyA signal 
region. The Spe I site lies near the 3'-end of the env gene and the EcoR I site lies 
in the vector sequences downstream of the polyA site. This sequence was 
replaced with a Spe 1/EcoR I restriction fragment from the pRLS plasmid 
containing the 3' env gene sequences and the EIAV 3'-LTR. The resulting 
plasmid was referred to as pSV3.5kb/LTR and was used directly to create the 
ORF S3 frame-shift mutation as described above. All transfection plasmids 
were purified by two rounds of cesium chloride (CsCl) density centrifugation 
as previously described (Fordis and Howard, 1987).
Plasmid DNA Transfection and CAT Assays
CsCl density gradient purified DNA was used to transfect 60 mm  petri 
dishes of cells by the calcium phosphate coprecipitation method (Fordis and 
Howard, 1987). For transfection of EIAV-infected and control uninfected 
fibroblasts, ten micrograms of the indicated plasmid DNA was transfected. For 
co-transfection experiments of FDD cells, eleven micrograms of the following 
combination of plasmids was transfected: pLTRCAT (5 (ig); pSV(3-gal (1 (ig); 
pSV720, pSV585, pSV634, or pSV2ACAT(5|ig). The pSVp-gal plasmid (Promega 
Corporation), which contains the bacterial p-galactosidase gene under the 
control of the SV40 immediate early promoter, was added to each transfection 
to control for transfection efficiency. Cell lysates were prepared 48 hours post 
transfection as previously described (Fordis and Howard, 1987), and the p- 
galactosidase activity of the cell lysates from each transfection was measured 
according to the suppliers recommendations (Promega Corporation). The 
pSV2CAT (5pg) plasmid was used as a positive control DNA for CAT activity 
and was cotransfected with pSV2Acat (5 (ig) and pSVp-gal (1 |ig). Lysate
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volumes containing equivalent levels of (Lgalactosidase activity were assayed 
for CAT enzyme activity by the solvent partition method (Neumann et ah, 1987) 
using [14C]butyryl coenzyme A (New England Nuclear, Dupont) and 
chloramphenicol (Sigma Chemicals) as substrates.
Results and Discussion 
Expression of EIAV Tat in EIAV-infected Primary Equine Cells
When this project was initiated the roles of the three ORF proteins in 
EIAV infection were unknown, and viral trans-activation of the EIAV LTR had 
not yet been demonstrated for EIAV. During the course of the early 
experiments described here, it was reported the EIAV LTR could be trans- 
activated in canine and feline fibroblast cell lines that were persistently infected 
with EIAV (Derse et al., 1987). I examined the ability of persistently-infected 
FEK cells and cytopathically-infected FDD cells to exhibit viral trans-activation 
by transfecting these cells with a CAT reporter plasmid linked to the EIAV LTR. 
I was particularly interested in determining if indeed these equine cells 
expressed trans-acting factors, since low molecular weight multiply-spliced 
transcripts, that by analogy to HIV-1 and other lentiviruses would presumably 
encode these factors, were present at very low levels and often were un­
detectable (Rasty et a l, 1990). This is in contrast to other lentiviruses in which 
low molecular weight transcripts are found at levels similar to other viral 
transcripts (Arya et ah, 1985; Davis et ah, 1987).
An examination of trans-activation in a number of EIAV-infected 
fibroblast cell types was performed in order to show that EIAV-infected equine 
fibroblasts express a virally-encoded trans-acting factor. Persistently infected 
canine (Cf2Th), feline (FEA), and equine (FEK) cells or cytopathically infected 
FDD cells were transfected with the pLTRCAT plasmid or a positive control 
plasmid, pSV2CAT, that contains the CAT gene under the control of the SV40
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immediate early promoter. In order to determine the basal transcriptional 
activity of the EIAV LTR. in these various fibroblastic cells, uninfected cells of 
each cell type were transfected with the same plasmids. At 48 hours post­
transfection equivalent levels of total cellular protein were assayed for CAT 
activity. The data are presented as the CAT activity of each lysate versus time 
points taken at ten minute intervals during the assay (Fig. 26). The data 
indicate that the EIAV LTR is an exceedingly weak promoter in all uninfected 
cells tested, since transfection with pLTRCAT in these cells showed no 
detectable CAT activity under the conditions of this assay (Fig. 26, A-D open 
squares). Other assays performed using larger amounts of cell lysate an d /o r 
longer incubation time showed that the pLTRCAT plasmid does direct CAT 
gene expression at very low levels, but clearly above the background level of a 
promoterless CAT construct, pSVOCAT (data not shown). The basal level of 
CAT expression directed by pLTRCAT in FDD cells was calculated to be 2.2% 
of the level from the pSV2CAT plasmid. This is in agreement with previously 
reported results for the canine and feline cell lines, where the basal level of CAT 
expression from the EIAV LTR was measured at 2.0% and 2.7%, respectively, of 
the level of expression from the control pSV2CAT plasmid (Derse et al., 1987). 
Clearly, each of the infected cell types demonstrated distinctive fra«s-activation 
of the EIAV LTR (Fig. 26, closed squares), as demonstrated by CAT activity 
several fold higher than that of the positive control plasmid, pSV2CAT (Fig. 26, 
closed circles). The highest overall levels of CAT activity directed by the EIAV 
LTR were detected in FDD cells.
One of the original goals of this line of research, was to quantitatively 
compare the fra^s-activation levels of persistently and cytopathically infected 
equine cells. It is customary to use SV40 based plasmids, such as pSV2CAT, as 
a reference to compare relative CAT activities and to control for variation in
Figure 26. CAT assays of uninfected and EIAV-infected cells. A. Canine fetal 
thymus fibroblasts (Cf2Th); B. Feline embryonic fibroblasts (FEA); C. Fetal 
donkey dermal cells; D. Fetal equine kidney cells. Cells were transfected with 
CAT expression plasmids under control of the EIAV LTR (pLTRCAT) or the 
SV40 immediate early promoter (pSV2CAT) and cell lysates were assayed for 
CAT activity by the solvent partition method at 48 hours post-transfection. □, 
pLTRCAT in uninfected cells; ■ , pLTRCAT in EIAV-infected cells; O, 
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transfection efficiency. This is believed to be a valid means of quantitating CAT 
activity and trans-activation levels from a single cell line, but it may not be valid 
for comparisons made between cell lines, since the pSV2CAT plasmid contains 
the SV40 enhancer element that is known to exhibit differential activity in 
various cell types (Davidson et ah, 1986; Ondek et ah, 1987). Furthermore, it is 
difficult to accurately determine the precise trans-activation levels of the EIAV 
LTR in infected cells due to the barely detectable basal activity of the EIAV LTR 
in uninfected cells. The level of CAT activity of the persistently infected FEK 
cells was more than 10-fold lower, than that in FDD cells (Fig 26 D., closed 
squares). However, the low levels of CAT activity in FEK cells are due in large 
part to a resistance of these cells to be transfected by foreign DNA, as evidenced 
by the absence of CAT activity directed by the positive control plasmid 
pSV2CAT (Fig. 26D., circles). A great deal of time and effort was spent 
attempting to improve the transfection efficiency of FEK cells. Included in 
these attempts were the following: variation in the length of time the cells were 
exposed to the calcium phosphate precipitate; variation in the length of time of 
the glycerol shock performed after removal of the precipitate; pre-treatment of 
the cells with DEAE-dextran at various concentrations; DEAE-dextran- 
mediated transfection under a number of conditions; and cationic liposome- 
m ediated transfection. Another member of our research group has attempted 
to use electroporation to introduce DNA into FEK cells w ithout success. The 
CAT assay data presented here represent the best transfection results obtained 
and were the result of prolonged exposure of the cells to a calcium 
phosphate/D N A  precipitate (12-18 hours). Due to this resistance of FEK cells 
to take up  foreign DNA by any of the methods and conditions tested, I decided 
not to pursue quantitative comparisons of trans-activation levels in FEK and 
FDD cells.
138
Infection of FDD cells with an FDD-adapted strain of EIAV results in 
severe cytopathology and subsequent cell death within about 14 days post­
infection. Previous experiments showed that viral RNA could be detected at 4 
days post-infection and appeared to reach maximal levels at 6 days post­
infection. This high level expression of viral RNA was maintained at 8,10, and 
12 days post-infection (Rasty et al., 1990). In order to determine the levels of 
trans-activation through the course of cytopathic infection, a time course 
experiment was performed in which EIAV-infected FDD cells were transfected 
with the pLTRCAT reporter plasmid at 3 to 12 days post-infection, and cell 
lysates were harvested for assay of CAT activity 48 hours post-transfection. For 
the purpose of this experiment, equal amounts of total protein from each lysate 
was subjected to a one hour CAT assay, and the level of CAT activity measured 
at the end of this hour are represented graphically (Fig. 27). The results of this 
experiment indicate that the level of CAT activity expressed from the EIAV LTR 
increases as the infection progresses. The highest level of CAT activity was 
attained at 14 days post-infection at a time when most cell were exhibiting 
severe cytopathology.
The data presented here were the first demonstration of EIAV trans- 
activation in cells of equine origin and demonstrate that equine fibroblast cells 
produce EIAV Tat despite a low abundance of low molecular weight 
transcripts. The isolation of the pSR-1 cDNA clone corresponding to the 3.5-kb 
RNA that is the predominant transcript in EIAV-infected FDD cells, and the 
finding that this transcript was capable of encoding the EIAV Tat protein in 
vitro, led to the proposal that EIAV may express Tat from this envelope-length 
message in vivo. The experiments described below involve the utilization of 
SV40 replacement vectors to express the pSR-1 cDNA in uninfected FDD in
Days Post-infection
Figure 27. Time course of EIAV Tat trans-activation in cytopathically-infected 
FDD cells. EIAV-infected FDD cells were transfected with the pLTRCAT 
plasmid at various time points after infection. 48 hrs post-transfection the cells 
were harvested and the CAT activity of the lysates was determined. In this 
figure, the final amount of chloramphenicol converted to [14C]-butyryl 
chloramphenicol after a one hour assay is plotted against days post-infection, 
which is the num ber of days from infection of the cells with EIAV to the time 
that they were harvested for CAT analysis.
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order to determine if the 3.5-kb transcript may encode the EIAV Tat protein in 
vivo.
Expression of EIAV Tat from the Tricistronic pSR-1 cDNA In Vivo
As previously stated, the pSR-1 cDNA clone that I have characterized, 
corresponds to the singly-spliced 3.5-kb EIAV mRNA and contains the ORF SI, 
ORF S2, and env genes. Other research groups have cloned cDNAs 
corresponding to the major multiply-spliced EIAV transcript and have shown 
that this transcript is capable of encoding the ORF SI and ORF S3 proteins 
(Dorn et a l, 1990; Noiman et ah, 1991). The first splicing event in this SI I S3 
transcript joins the viral leader to the ORF SI coding sequences and is identical 
to the single splicing event identified in the 3.5-kb RNA (Schiltz et al., 1992). 
Thus, the 1.5-kb transcript can be derived directly from the 3.5-kb RNA by 
additional splicing events involving splice donors and acceptors located 
downstream of ORF SI. Since it is now clear that the EIAV ORF SI protein is 
the viral trans-activator, EIAV Tat (Dorn et al., 1990), and that the 3.5-kb and 1.5- 
kb RNA are identical through the SI gene, I was interested to ascertain if the 
pSR-1 cDNA clone could direct the synthesis of the Tat protein in cultured FDD 
cells. Towards this end, restriction fragments of the pSR-1 cDNA sequence 
were subcloned into a eucaryotic expression plasmid, pSV2ACAT. The 
construct pSV720 is analogous to the pSP720 transcript described earlier and 
contains the 720-bp Stu 1/Msc I restriction fragment of pSR-1 subcloned into the 
unique Stu I site of pSV2ACAT located between the SV40 immediate early 
promoter and polyadenylation signal. Two additional subclones were 
constructed, pSV585 and pSV634, which are essentially 5'-deletions of the 
pSV720 construct (Fig. 28A). These constructs were made to determine which 
sequences are required for EIAV Tat expression in vivo. The pSV585 construct 
lacks cDNA sequences between the Stu I (nt 256) restriction site located in the
Figure 28. RNAs corresponding to Tat cDNA expression plasmids and CAT 
assays. A. The 5'-ends of the RNAs expected to be produced in vivo from the 
cDNA expression constructs. The first 45 nt of each construct (bold, italics) are 
derived from the SV40 immediate early leader region. This sequence contains 
no AUG codons that might serve to initiate EIAV Tat synthesis. The sequence 
following the leader region in pSV720 and pSV585 is derived directly from the 
pSR-1 cDNA by ligation of the Stu I and Sma I restriction sites, respectively, of 
this cDNA to the Stu I site of pSV2CAT. The pSV634 vector contains some 
sequences derived from the polylinker of pSP65 (italicized, not bold) that lie 
between the SV40 leader and the cDNA sequences. The UGA termination 
codon that marks the 5'-end of the Tat open reading frame is indicated by an 
asterisk and is only present in pSV720. The single letter amino acid codes are 
presented beneath the tat codons. pSV634 encodes some additional amino 
acids (italicized) not found in pSV720 due to the presence of the pSP65 
sequences. The positions of the proposed CUG and AUC translational 
initiation codons are underlined along with the context nt in the -3 and +4 
positions. B. CAT assays of lysates from transfected FDD cells. The cDNA 
constructs described above were transfected into FDD cells along with 
pLTRCAT and an SV40 directed beta-galactosidase expression plasmid. Cell 
lysates were assayed for beta-galactosidase expression and volumes of lysate 
corresponding to equivalent units of beta-galactosidase activity were assayed 
for CAT enzyme activity by the solvent partition method of Neum ann et al., 
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terminal redundant region (R) and Sma I (nt 393) restriction site located in the 
leader region. The CUG codon (nt 373-375) and the AUC codon (nt 388-390), 
that have independently been proposed to initiate EIAV Tat synthesis (Carroll 
and Derse, 1993; Noiman et al., 1991), lie between these two restriction 
endonuclease cleavage sites, so the pSV585 construct lacks both of these codons. 
The pSV634 construct contains the AUC codon but lacks the upstream CUG 
codon (Fig. 28A). All three constructs are 3'-coterminal extending to the MscI 
(nt 5655) restriction site within the env gene. If EIAV Tat synthesis is initiated at 
the suggested CUG codon, then pSV720 would contain all the necessary genetic 
information for EIAV Tat expression while pSV585 and pSV634 would lack the 
translational initiation codon for this protein. If EIAV Tat synthesis is initiated 
from the AUC codon, then both pSV720 and pSV634 should be able to direct the 
synthesis of the Tat protein.
Monolayers of FDD cells were cotransfected with either pSV720, pSV634 
or pSV585 and the pLTRCAT reporter plasmid. Cotransfection of pSV720 with 
pLTRCAT clearly results in frans-activation of the EIAV LTR as evidenced by 
an increase in CAT enzyme activity of more than 60-fold as compared to 
transfection with the pLTRCAT plasmid alone (Fig. 28B). Cotransfection of 
pSV585 resulted in no significant trans-activation of the LTR, suggesting that 
sequences residing between the Stu I  site within the EIAV R region of the LTR 
and the Sma I site within the leader, which include the CUG and AUC codons, 
are absolutely required for expression of EIAV Tat from this cDNA clone in 
cultured FDD cells. Cotransfection of pSV634 with pLTRCAT resulted in CAT 
activity similar to that of the pSV585 cotransfection experiment, indicating that 
the AUC codon is incapable of directing the synthesis of the EIAV Tat protein 
in FDD cells. These data are consistent with initiation of the EIAV Tat protein 
at the CUG codon located within the EIAV leader region.
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I have demonstrated EIAV Tat synthesis in vivo by cotransfection of the 
cDNA corresponding to the 3.5 kb transcript into FDD cells with a plasmid 
directing CAT gene expression promoted by the EIAV LTR. The resulting 
trans-activation of the LTR, as evidenced by a 60-fold increase in CAT 
expression, demonstrates that functional EIAV Tat protein encoded by ORF SI 
is produced. The relatively low levels of trans-activation observed for EIAV as 
compared to those reported for HIV may reflect differences in the amount of 
trans-activator protein produced as a result of initiation at the sub-optimal CUG 
codon in the EIAV case.
Horses Infected w ith EIAV Produce Antibodies against the ORF S2 Protein
The predicted protein product of ORF S2 bears no significant sequence 
homology to any known lentiviral protein, and to date no protein product has 
been shown to be encoded by ORF S2 in vivo. In an effort to establish whether 
an ORF S2 encoded polypeptide is produced during productive EIAV infection, 
I examined sera from EIAV infected horses for the presence of antibodies to the 
putative ORF S2 gene product. I accomplished this goal by examining the 
ability of these sera to recognize the in vitro translated product in an 
immunoprecipitation reaction.
The ORF S2 polypeptide and a portion of the gp90 envelope protein 
were synthesized in wheat germ extract from a synthetic RNA similar to that 
produced by the pSP585 plasmid described above. The transcription template 
employed in this experiment, pSPS2env, differs from pSP585 in that it includes 
sequences from the MscI (5655) to the first Hind III (5775) restriction 
endonuclease digestion site in the env gene. This additional envelope sequence 
results in the synthesis of a truncated gp90 protein with an apparent molecular 
weight of approximately 20-kd on SDS-polyacrylamide gels, as opposed to the 
15-kd truncated gp90 protein of pSP585. The [^Si-labeled in vitro translation
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products were immunoprecipitated with sera obtained from an EIAV-infected 
horse followed by SDS-PAGE analysis. Analysis of the in vitro translation 
products showed the synthesis of the 20-kd truncated envelope protein and the 
7-kd ORF S2 polypeptide (Fig. 29, lane 1). These labeled products were 
immunoprecipitated with increasing concentrations of partially purified IgG 
obtained from the serum of an EIAV-infected horse (see Chapter 2 Materials 
and Methods). As anticipated, the truncated gp90 envelope protein reacts 
strongly with the EIAV-infected horse IgG (IH IgG) fraction at all 
concentrations tested (Fig. 29, lanes 2-5). The ORF S2 protein was only faintly 
immunoprecipitated by 8 pg of EIAV-infected horse IgG (Fig. 29, lane 2), but 
was clearly immunoprecipitated with 40 pg of the IgG (Fig, 29, lane 3). 
Interestingly, further increases in the amount of IgG resulted in dramatically 
reduced precipitation of the 7-kd S2 protein with the concomitant appearance 
of a slightly larger (approximately 9-10 kd) protein (Fig. 29, lanes 4 and 5). At 
the highest concentration of IgG (400 pg), there was no detectable precipitation 
of the 7-kd S2 protein, but a relatively large amount of the higher molecular 
weight protein. Although I cannot be certain that this higher molecular weight 
protein is related to the S2 protein, the concomitant disappearance of the 7-kd 
S2 protein gives indirect support to the notion that the EIAV-infected horse 
anti-sera may contain an activity that results in covalent modification of this 
protein. Preliminary experiments using the non-binding supernatants from IH 
IgG immunoprecipitations to react with anti-S2 peptide antisera, demonstrate 
that this protein can be precipitated with S2-specific antisera and therefore is 
S2-related (data not shown). Further experiments will be required to clearly 
determine if this product is indeed related to the S2 protein and the precise 
nature of the putative modification. Neither the truncated gp90 nor the
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Figure 29. Immunoprecipitation of in vitro translated ORF S2 protein with 
EIAV-infected horse IgG. M, [14C]-labeled molecular weight standards; lane 1, 
[35S]-labeled in vitro translation products from wheat germ extract programmed 
with pSPS2env RNA; lane 2, immunoprecipitation (IP) with 8 jig  of infected 
horse (IH) IgG; lane 3, IP w ith 40 |ig of IH IgG; lane 4, IP with 80 |ig of IH IgG; 
lane 5, IP with 400 jig IgG.
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S2 protein demonstrated any reactivity with control sera from normal 
uninfected horses (data not shown).
It has been presented here that the in vitro synthesized S2 protein can be 
specifically immunoprecipitated by EIAV-infected horse sera. Other 
researchers in our laboratory have shown that sera from both naturally infected 
and experimentally infected horses react with synthetic peptides corresponding 
to regions of the S2 protein (J. Ball, unpublished results). Characterization of 
viral envelope variants propagated from horse macrophage cultures infected 
with horse virulent EIAV, has shown that although a num ber of mutations arise 
throughout the gp90 coding sequence and in the major coding exon of the S3 
protein, no mutations were found in the region where ORF S2 and env overlap 
(Alexandersen and Carpenter, 1991). Taken together these data strongly 
indicate a role for the ORF S2 gene product during EIAV infection, although no 
function has as of yet been defined for this protein.
Attem pts to Detect the ORF SI, S2 and S3 Proteins In Vivo
Many attempts were m ade to identify the ORF proteins in vivo both in 
EIAV-infected equine cells and in various type of transfected cells. The most 
extensive trials involved immunoprecipitation of cell lysates with ORF-specific 
peptide antisera followed by fractionation on SDS-polyacrylamide gels and 
transfer to nitrocellulose membranes for Western blot detection of the 
immunoprecipitated proteins with the same peptide antisera used for 
immunoprecipitation. Early experiments of this type were performed using 
[125I]-protein A, and later experiments used the more sensitive chemi- 
luminescent detection systems. In short, none of these experiments resulted in 
detection of the ORF proteins. There may be a number of potential reasons for 
the inability to detect each of these proteins. In infected cells, these proteins 
may be temporally regulated and expressed at high levels at only specific times
148
during infection. These proteins are also either known to be or presumed to be 
regulatory proteins, and such proteins often have short half-lives to aid in the 
regulation of their activities.
It was hoped that high level expression of the ORF proteins from SV40- 
based transfection plasmids expressed in COS-7 cells might help to overcome 
some of these problems. This expression system typically affords high-level 
expression of protein because the plasmids contain the SV40 origin of 
replication, and the COS-7 cells constituitively express the SV40 large T antigen 
that is required for replication of the plasmid DNA. Unlike other transient 
expression systems, this system allows the plasmid DNA to replicate after 
entering the cell, thereby increasing the copy number of the transfecting 
plasmid in the cell. The ORF proteins expressed from SV40-based plasmids 
were not detected by any of the following methods using the synthetic peptide 
antisera: (1) combined immuno-precipitation/W estern blotting as described 
above; (2) in vivo metabolic cell labeling with [35S]-methionine and [35S]- 
cysteine followed by immuno-precipitation; (3) immunofluorescence assay 
(IFA).
One problem with transient expression of proteins by DNA transfection 
is that at best about 10% of the cell population will take up and express the 
transfecting DNA. It is also cumbersome to transfected large numbers of cells 
by this method. Most of the transfections described here were performed in 
small petri dishes of 60 mm in diameter. In order to produce larger quantities 
of EIAV Tat (SI), canine fibroblast cells were cotransfected with the pSV720 Tat 
expression plasmid and a neomycin resistance gene expression plasmid pJNL-1 
(kindly provided by Gus Kousoulas, Department of Veterinary Microbiology 
and Parasitology, Louisiana State University School of Veterinary Medicine, 
Baton Rouge, LA). By propagating the transfected cells over an extended
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period of time in media supplemented with the neomycin analog G418, cells 
that had integrated copies of the neomycin resistance gene into their genomes 
were selected. Single cell clones of the neomycin resistant cells were isolated 
and allowed to divide into a clonal population of neomycin resistant cells.
These clonal populations were then transfected with the pLTRCAT plasmid to 
determine if they had also inserted the EIAV tat gene into their genomes. CAT 
assay results from a number of clones showed that they did indeed express the 
EIAV tat gene (data not shown). These cells, that constituitively express the tat 
gene, should provide a means to isolate a large amount of the EIAV Tat protein, 
since every cell expresses the protein. Large quantities of cell extract were 
immunoprecipitated with the SI peptide rabbit IgG followed by Western 
blotting with the same antibody preparation. Unfortunately, these attempts 
also failed to detect the Tat protein.
The expression of EIAV Tat from a non-AUG codon is likely to result in 
very low intracellular protein levels. Although some proteins are known to be 
expressed efficiently in vitro from non-AUG codons, they are not expressed at 
high levels in vivo (Bernards and de la Monte, 1990; Florkiewicz and Sommer, 
1989). Thus, I turned my attention to improving the translational initiation 
sequence of Tat in an attem pt to elevate its synthesis to more readily detectable 
levels. Towards this end, I produced a plasmid construct, pSV585met, that 
places the tat gene in-frame with a consensus AUG methionine codon. The net 
result of the cloning manipulations employed to generate this construct (see 
Materials and Methods) is a 24-bp insertion into the Stu 1 /Sma I hybrid 
restriction site of pSV585 (Fig. 30A). Included in this 24-bp sequence is a 
Kozak's consensus methionine AUG initiation codon (GCC GCC ACC AUG G). 
This manipulation resulted in replacement of the first five codons of EIAV tat 
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Figure 30. Expression of EIAV Tat from a consensus methionine codon. A. A 
schematic diagram of the structure of the pSV585 plasmid is shown at top with 
the nucleotide sequence containing the consensus methionine codon that was 
inserted into the Stu I /Sm a  I site shown below. The isoleucine (I) and proline 
(P) are part of the native Tat structure. The methionine (M) and glutamate (E) 
residues are added to the amino terminus of Tat as a result of the cloning.
B. CAT assay of pSV585met transfected into FDD cells. ■, pLTRCAT 
cotransfected with pSV2ACAT; a , pLTRCAT cotransfected with pSV720; • , 
pLTRCAT cotransfected with pSV585met.
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ability of the pSV585met construct to express Tat was examined by 
cotransfection of this plasmid with pLTRCAT into FDD cells. The pSV585met 
plasm id resulted in trans-activation levels of the EIAV LTR that were on 
average 5 to 6-fold greater than those of the pSV720 plasmid (Fig. 30B) 
However, attempts to detect the Tat protein produced by pSV585met directly 
by immunoprecipitation and Western blotting of transiently transfected FDD 
cells, yielded no detectable EIAV Tat protein.
All of these efforts were dependent upon detection of the Tat protein 
using rabbit antisera produced against a synthetic peptide corresponding to a 
region of the Tat protein. Although this peptide antisera was reactive with the 
in vitro synthesized Tat protein (see Chapter 2, Fig. 12), a relatively large 
am ount of in vitro translation product was required to precipitate this protein.
A fairly low percentage (approximately 5-10 %) of the in vitro synthesized Tat 
protein was precipitated even when using 100 pg of partially purified IgG. 
These findings indicated that although the antibody was highly specific for the 
Tat protein, either its affinity for the protein an d /o r its titer in the overall pool 
of rabbit IgG was not very high. In an attem pt to circumvent potential 
problems with antibody affinity, the Tat protein was expressed as a fusion to 5 
repeated copies of a 13 amino acid sequence of the c-Myc oncoprotein that 
contains an epitope recognized by a monoclonal antibody. The resulting fusion 
protein contains 65 amino acids placed amino-terminal to the Tat protein 
coding region. This work was performed in collaboration with Pat DiMario, 
who routinely uses Myc-tagged proteins for detecting proteins expressed in 
Xenopus oocytes. This expression system involves the microinjection of in vitro 
transcripts into oocytes followed by detection of the tagged protein by 
immunofluorescence. In vitro transcripts containing the Myc-tagged Tat protein 
and provided to Pat DiMario for analysis. However, no Tat protein could be
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detected in this system. I am currently confirming the integrity of the in vitro 
transcription plasmid by DNA sequencing. The in vitro transcripts could also 
be tested by in vitro translation followed by immunoprecipitation with either SI 
peptide antisera or c-Myc monoclonal antibody. In summary, a wide variety of 
techniques have been employed in order to detect the Tat protein in vivo, but 
none of these were successful.
Early experiments for the detection of the S2 protein in transfected cells 
were performed using the pSV585 expression construct. This construct was 
preferred over the pSV720 construct, since it is not capable of Tat synthesis and 
the ORF S2 cistron would be the first cistron in an S2/env bicistronic RNA. The 
subsequent cloning and characterization of Tat cDNAs (Stephens et al., 1990; 
Noiman et al., 1991) showed the presence of a functional splice donor 
immediately downstream of the Tat UAA termination codon. There is also a 
functional splice acceptor located in the region where the ORF S2 and env genes 
overlap. The presence of these splicing signals indicates that the primary 
transcript encoded by the pSV585 construct could be spliced in a manner that 
results in the removal of the ORF S2 and env translational initiation codons. 
Depending upon the efficiency of this splicing event, it may not be possible to 
express sufficient S2 protein from this construct to detect by the immunological 
methods employed here.
By analogy to HIV-1, the expression of proteins from partially-spliced 
envelope-length RNAs could be achieved through the action of a Rev-like 
protein. Although the S3 protein had not been directly shown to have Rev-like 
function in EIAV at the time that these experiments were performed, there was 
some indirect evidence for Rev function from S3 defective proviruses and from 
limited sequence homology with the HIV-1 Rev protein (Stephens et al., 1990).
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A plasmid was constructed that was analogous to pSV720, but contained 
the entire envelope coding region. This construct, pSV3.5kb, was expected to 
produce a prim ary transcript of approximately 4.0-kb that could be spliced to 
produce 1.8-kb EIAV S1/S3 mRNA. If the EIAV S3 protein does indeed harbor 
Rev-like activity, then its synthesis from the spliced transcript should allow the 
expression of unspliced 4.0-kb RNA. COS-7 cells were transfected with the 
pSV3.5kb plasm id DNA and total cellular RNA was isolated 48 hours post­
transfection for analysis by Northern blot hybridization. The hybridization 
probe used was a 400-bp random  prime-labeled Nco I/S sp  I restriction fragment 
from pSV720. The Nco I site of pSV720 lies about 45-bp upstream of the SV40 
early transcription initiation site and the Ssp I site lies near the end of ORF SI 
about 10-bp upstream  of the splice donor used to produce the S1/S3 RNA. The 
choice of a probe that hybridizes to sequences in the 5'-end of the transcripts 
upstream  of all splicing signal allows for equivalent hybridization of the probe 
to either spliced or unspliced transcripts. The results clearly indicate the 
presence of three EIAV-specific transcripts (Fig. 31). The predominant 
transcript was the 4.0-kb full-length unspliced RNA and the small 1.8-kb 
multiply-spliced transcript was present, but at levels that were several fold 
lower than the unspliced RNA. An additional transcript of intermediate size 
(2.2-kb) was also observed and is likely to represent a partially-spliced 
transcript, that is only one of the two introns are removed.
These data indicate that the pSV3.5kb plasmid directs the synthesis of 
high levels of unspliced RNA in COS-7 cells. However, I was not able to detect 
synthesis of the S2 protein from transfected COS-7 cells by either Western 
blotting of immunofluorescence assays. It is likely that the level of expression 
of the S2 protein is adversely affected by the presence of uridine residue in the 
-3 position relative to the AUG initiation codon. Expression strategies designed
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Figure 31. Northern blot analysis of pSV3.5kb RNAs in transfected COS-7 cells. 
Lane 1, RNA isolated from control untransfected COS-7 cells; Lane 2, RNA 
isolated from COS-7 cells transfected with pSV3.5kb; M, RNA molecular weight 
standards in kilobase pairs (Life Technologies, Inc.).
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to improve the context of the S2 initiation codon may aide in detection of this 
protein.
The S3 protein was not detected in EIAV infected equine cells or COS-7 
cells transfected with the pSVS3 plasmid using rabbit antisera produced against 
a synthetic peptide. The pSVS3 plasmid contains the S3 sequences taken from a 
cDNA clone corresponding to the S I/S3 transcript. This transcript results from 
the splicing of four exons: (1) the EIAV leader exon; (2) the ORF SI exon; (3) an 
exon derived from the gp90 coding region of the env gene; (4) the ORF S3 exon. 
The envelope sequences from exon 3 are spliced in-frame with the ORF S3 
coding sequences and could provide a translational initiation codon for 
expression of the S3 protein. I available a panel of monoclonal antibodies that 
were produced to m ap epitopes on the EIAV gp90 envelope glycoprotein (Ball, 
1990). One of these, mab86, recognizes an epitope, gp90A, located within the 
region of gp90 that is spliced to ORF S3. Therefore, this antibody may not only 
react the gp90 protein, but may also recognize the S3 protein. This monoclonal 
antibody was used in an attempt to detect the S3 protein in EIAV-infected 
equine cells. EIAV-infected FDD cells harvested at 6 days post-infection and 
persitently-infected FEK cells were lysed in a detergent buffer and equivalent 
amounts of protein from each lysate were immunoprecipitated with the mab86 
monoclonal antibody. The immune-precipitates were fractionated on a 15% 
polyacrylamide gel and transferred to a nitrocellulose membrane for Western 
blot detection of the immunoprecipitated protein. The blot was probed with 
the mab86 monoclonal antibody followed by a rabbit anti-mouse IgG antibody 
and finally with a goat anti-rabbit peroxidase conjugated antibody. The blot 
was visualized by incubating with a peroxidase-activated chemiluminescent 
detection reagent. A protein of approximately 20-kd was detected in both 
EIAV-infected FDD cells (Fig. 32, lane 2) and FEK cells (Fig. 32, lane 4) but not
156





Figure 32. Western blot analysis of the S3 protein in EIAV-infected equine cells. 
Lane 1, uninfected control FDD cells; lane 2, EIAV-infected FDD cells 6 days 
post-infection; lane 3, control FEK cells; lane 4, EIAV-infected FEK cells.
157
in uninfected control cells (Fig. 32, lanes 1 and 3). The molecular weight of this 
protein is similar to that previously reported for the S3 protein (Saman et al., 
1990). Since I was unable to detect this protein with S3 peptide antisera, I 
cannot definitively rule out the possibility that this protein may be a 
degradation product of the gp90 envelope protein. Interestingly, the gp90 
protein was unable to be detected in this experiment. The interaction of gp90 
with the gp45 transmembrane protein is known to be easily disrupted. It may 
be that the extensive washing of the cells prior to lysis may have removed the 
majority of the gp90 protein. Alternatively, the gp90 protein may have been 
unable to efficiently enter the 15% gel used in this experiment or may have not 
been efficiently transferred to the nitrocellulose membrane. The intense band 
near the top of the autoradiograph, that is found in all lanes, represents the 
heavy chain of the monoclonal antibody used to immunoprecipitate the S3 
protein. This protein is recognized by the rabbit anti-mouse IgG used in the 
detection process. The appearance of this band at near equivalent intensity in 
each lane indicates that near equivalent amounts of antibody were used to 
immunoprecipitate each sample and that the recovery of the immune 
complexes, their application to the gel, and the transfer of the fractionated 
proteins to the membrane were similar for each of the four samples. The 20-kd 
detected in this experiment actually appears as a doublet with the upper band 
being the major protein. This lower band may represent an unphosphorylated 
form of the EIAV Rev (S3) protein. The HIV-1 Rev protein is known to be 
phosphorylated on serine residues, and the phosphorylation can be augmented 
by phorbol esters suggesting phosphorylation by protein kinase C (Hauber et 
al., 1988). I have analyzed the amino acid sequences of both the HIV-1 Rev 
protein and the EIAV S3 protein for the presence of consensus phosphorylation 
sites. Both proteins contain three potential phosphorylation sites for casein
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kinase H (S, T X X D, E; where X may be any amino acid), and the HIV-1 Rev 
protein contains two potential protein kinase C phosphorylation sites (S, T X R, 
K) while S3 contains three. Thus, it appears that the S3 protein has the potential 
to be phosphorylated, but no such modification has yet been reported for the 
EIAV S3 protein.
By analogy to HTV-1 and other lentiviruses, the EIAV Rev (S3) protein is 
expressed from a multiply-spliced transcript and is expected to be present early 
in the infection cycle. The FDD cells used above were harvested at 6 days post- 
infection at a time when all of the viral RNAs are expressed at high levels 
(Rasty et ah, 1990). In order to examine the temporal expression of the 20-kd 
protein detected above, lysates of FDD cells harvested at various times after 
infection were subjected to Western blot analysis with the mab86. Each time 
point corresponded to cells from a single 75 cm2 flask of cells, and all cell 
lysates were normalized to contain equivalent levels of protein. The 20-kd 
protein was clearly evident at 20 hours post-infection (Fig. 33, lane 4) and was 
unable to be detected at the previous time point of 8 hours post-infection (Fig. 
33, lane 3). The level of the protein continues to increase throughout the early 
phase of the infection cycle and appears to reach a maximum somewhere 
between 2 and 5 days post-infection (Fig. 33, lane 6-7). The appearance of this 
protein within 8-20 hours post-infection, at a time when the 3.5-kb env RNA can 
not be detected (Rasty et ah, 1990), is consistent w ith what one w ould expect for 
the expression of the S3 protein from an early viral mRNA and strongly argues 
against this protein being a gp90 degradation product.
As a means to obtain more compelling evidence that the 20-kd protein 
detected in equine cells is indeed the S3 protein, COS-7 cells were transfected 
with a S3 cDNA expression plasmid, and the S3 protein produced was 
compared to that produced in equine cells. Although the cDNA employed in
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Figure 33. Time course of S3 expression in EIAV-infected FDD cells.
Individual 75 cm2 flasks of FDD cells were infected with an FDD-adapted strain 
of EIAV at a multiplicity of infection of 1. Cells were harvested at the indicated 
times after infection and lysed in a detergent buffer. Equivalent amounts of 
protein from each time point was subjected to immunoprecipitation w ith the 
M86 monoclonal antibody, fractionated on a 15% polyacryalmide gel, 
transferred to a nitrocellulose membrane, and the membrane probed with the 
M86 antibody. Lane 1, uninfected control FDD cells; lane 2 ,4  hours post­
infection; lane 3,8 hours post-infection; lane 4,20 hours post-infection; lane 5, 
24 hours post-infection; lane 6,48 hours post-infection; lane 7,5 days post­
infection; lane 8 ,7  days post-infection; M, prestained rainbow molecular 
weight standards (Amersham Corporation).
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this experiment is derived from the S1/S3 multiply-spliced RNA, the pSVS3 
plasmid was designed to lack sequences required for expression of the Tat 
protein. The SI I S3 cDNA was digested with Pvu II in the SI coding region and 
Stu I in the redundant region of the 3-LTR. The resulting S3-containing 
fragment was subcloned into the Stu I site of pSV2ACAT to generate pSVS3.
This plasmid was transfected into COS-7 cells, and cell lysates were subjected to 
immunoprecipitation/W estern blot detection with mab86 48 hours post­
transfection. The Western blot result indicates that transfected COS-7 cells 
specifically express a protein of approximately 20-kd that reacts with mab86 
(Fig. 34A, lane 4). This protein does, however, appear to migrate slightly faster 
than the 20-kd protein detected in EIAV-infected FDD cells (Fig. 34A, lane 2). It 
is difficult to precisely compare the mobilities of the proteins detected into these 
two samples because of the large amount of the protein precipitated by mab86 
antibody from both cell types.
In a separate experiment using less cellular lysate, it was more obvious 
that the two proteins do not have the same mobility (Fig. 34B). In this gel 
system, the two forms of the 20-kd protein produced in EIAV-infected FDD 
cells were also more clearly resolved, although there is very little of the lower 
molecular weight form in this particular sample (Fig. 34B, lane 1). The S3 
protein produced in the transfected COS-7 cells does appear to co-migrate with 
the low molecular weight form of the 20-kd protein produced in FDD cells, and 
there is a very small amount of protein in the pSVS3-transfected COS-7 that 
does co-migrate with the high molecular form detected in FDD cells.
From these data, it is tempting to speculate that the mab86-reactive 20-kd 
proteins of EIAV-infected FDD cells and pSVS3-transfected COS-7 cells may 
indeed be S3-related proteins that differ in their phosphorylation state. It is 
possible that some virally-encoded factor, that w ould be lacking in the
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Figure 34. Comparison of the S3 proteins expressed in EIAV-infected FDD cells 
and COS-7 cells transfected with a S3 cDNA expression plasmid. A. Lane 1, 
Uninfected FDD cells; lane 2, EIAV-infected FDD cells; lane 3, untransfected 
COS-7 cells; lane 4, COS-7 cells transfected with the pSVS3 cDNA expression 
construct. B. Lane 1, EIAV-infected FDD cells; lane 2, pSVS3 transfected COS- 
7 cells.
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transfected COS-7 cells, may be required for efficient post-translational 
modification of the S3 protein. Alternatively, there may be inherent differences 
between FDD and COS-7 cells that result in differential post-translational 
modification of the S3 protein.
Earlier in this section, the plasmid construct pSV3.5kb was described 
which primarily expresses an unspliced 4.0-kb envelope-length RNA in 
transfected COS-7 cells. I speculated that the synthesis of the S3 protein from a 
fully-spliced RNA early after transfection might allow the accumulation of the 
unspliced RNA, if S3 functions in a manner analogous to HIV-1 Rev. The 
ability of the pSV3.5kb construct to direct the expression of S3 protein in 
transfected COS-7 cells was examined. This construct produces an S3 protein 
w ith similar mobility to that produced in EIAV-infected FDD cells (Fig. 35, lane 
3). Thus, there do not appear to be cell-specific differences between FDD and 
COS-7 cells that allow for proper modification of the S3 protein in FDD cells. If 
indeed there are virally-encoded factors that aide in post-translational modi­
fication of the S3 protein, then those factors m ust also be encoded by the 
pSV3.5kb construct. It is tempting to speculate the S2 protein may play such a 
role, since it has yet to be assigned a function in viral infection. Further 
experimentation will be required to explore this possibility.
Further support for the identification of the 20-kd protein as the S3 
protein was obtained from mutational analysis of the pSV3.5kb construct. The 
unique Apa I restriction site in this construct found immediately downstream of 
the splice acceptor site within ORF S3 was used to create a frameshift mutation. 
The pSV3.5kb vector was digested with Apa I and the 4-base cohesive ends 
were removed with T4 DNA polymerase. The plasmid was religated and 
resulted in a 4 bp deletion near the 5'-end of the major ORF S3 coding exon.
This deletion also results in frameshift mutation of the gp45 protein but does
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Figure 35. Expression of the S3 protein in transfected COS-7 cells. The S3 
protein was detected in transfected COS-7 cells with mab86 by Western 
blotting. Lane 1, control COS-7 cells; lane 2, pSVS3-transfected cells; lane 3,
pSV3.5kb-transfected cells; lane 4, pSV3.5kbAS3-transfected cells.
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not affect the gp90 coding region. This plasmid (pSV3.5kbAS3) was transfected 
into COS-7 cells that were subsequently analyzed for expression of the 20-kd 
protein. The results showed that no 20-kd protein was produced by this 
construct (Fig. 35, lane 4). This plasmid was, however, able to efficiently 
produce the Tat protein as evidenced by trans-activation of the EIAV LTR upon 
co-transfection of the plasmid w ith a pLTRCAT construct (data not shown). 
This indicates that this plasmid is capable of expressing EIAV-specific 
transcripts and proteins. The lack of detection of the 20-kd protein when 
disrupting the S3 reading frame without affecting the gp90 coding region, 
argues that this protein is indeed S3 and not a degradation product of gp90. 
There are at least three possibilities that might explain the differential mobility 
of the S3 proteins produced in COS-7 cells from the pSVS3 and pSV3.5kb 
constructs. The first is that there could be some sequence aberration in the 
pSVS3 construct that produces an altered protein. It seems unlikely that a 
m utant protein would produce co-migrating species that differed in relative 
abundance in FDD and COS-7 cells (Fig. 34). A second possibility is that the 
splice sites utilized in the RNA from which the S3 cDNA was cloned may be 
different from those actually utilized in these cells. This also seems an unlikely 
possibility, since cDNAs identical to this one have been independently cloned 
by a number of other laboratories (Stephens et a l, 1990; Noiman et al. 1991; 
Biesel et a l, 1993) and no alternatives have yet been identified. Furthermore, 
the higher molecular weight product is not likely to be produced by cell-type- 
specific alternative splicing since it can be detected in all three different cell 
types examined: FDD, FEK and COS-7. The third possibility is that there may 
be a virally-encoded protein that regulates the post-translational modification 
of the S3 protein. Since the pSVS3 construct is only capable of encoding the S3 
protein, the putative protein that modifies S3 would not be present in cells
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transfected with pSVS3 alone. This putative factor would have to be produced 
by the pSV3.5kb construct, since this construct does produce the higher 
molecular weight form of the S3 protein. This construct contains the env gene 
and three small ORFs SI, S2 and S3, it is tempting to speculate that the S2 
protein may be this putative regulator since the role of the others are well 
defined.
The results presented here confirm that the S3 protein uses a small 
region of the enu-coding region to provide a translational initiation signal, and 
that the S3 protein can be detected with a monoclonal antibody that recognizes 
an epitope of gp90 that lies near its amino terminus. The monoclonal antibody 
recognizes two forms of the 20-kd S3 protein that are similar in molecular 
weight. The relative distribution of these two forms can be altered by 
expression of other EIAV proteins either by viral infection or transfection of 
cDNA expression vectors. The low molecular weight form predominates in the 
absence of other EIAV proteins, while the high molecular form is favored when 
the Tat, S2, and envelope proteins are co-expressed with the S3 protein.
CHAPTER 4
SUMMARY, CONCLUSIONS, AND FUTURE STUDIES
Summary and Conclusions 
In this dissertation, the coding potential of the singly-spliced EIAV 3.5- 
kb RNA was examined in vitro. Restriction fragments of a cDNA 
corresponding to the 3.5-kb RNA were subcloned into the pSP65 in vitro 
transcription vector. The pSP720 transcription plasmid contains the entire SI 
and S2 open reading frames (ORFs) and a 5' portion of the env gene. Synthetic 
transcripts produced from this plasmid were translated in wheat germ extracts 
and shown to encode three distinct proteins. These were identified by 
immunoprecipitation as the ORF SI-encoded EIAV Tat (SI) p ro te in , the ORF 
S2-encoded polypeptide (S2), and a truncated gp90 envelope protein (Agp90).
Interestingly, the Tat protein was efficiently produced in the wheat germ 
in vitro translation system even though the tat ORF lacks an ATG initiation 
codon. The pSP585 transcription plasmid, which lacks the first 1.6 codons of the 
tat ORF, was unable to produce the Tat protein in vitro. These first 16 codons 
include a CUG (CUG-373) codon and an AUC (AUC-388) codon each of which 
has independently been claimed to initiate Tat synthesis. The in vitro 
transcription plasmid pSP634 was constructed to address whether AUC-388 
could initiate Tat synthesis in the wheat germ in vitro translation system. This 
construct is similar to the pSP585 construct, but it only lacks the first 14 codons 
of the tat ORF. AUC-388 is the 15th codon in the tat ORF, so the pSP634 
construct retains AUC-388 while the pSP585 construct lacks it. In vitro 
translation of pSP634 RN A resulted in the synthesis of the S2 and Agp90 
proteins only. The inability of this construct to direct the synthesis of the Tat 
protein suggests that the presence of AUC-388 is insufficient for the initiation of 
Tat translation in the wheat germ system.
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The in vitro analysis of the sequences required for the expression of the 
Tat protein were also confirmed in vivo. The same cDNA restriction fragments, 
that were used to create the in vitro transcription plasmids described above, 
were subcloned into a eucaryotic expression vector and transfected into FDD 
cells w ith a pLTRCAT reporter plasmid. Cell lysates were assayed for CAT 
activity to determine the fraws-activation capabilities of these constructs. These 
experiments showed that only the pSV720 plasmid, which contains the entire 
tat ORF was capable of trans-activating the EIAV LTR. The pSV585 plasmid 
which lacks CUG-373 and AUC-388 and the pSV634 plasmid that contains 
AUC-388 but lacks CUG-373 were incapable of trans-activating the EIAV LTR. 
These findings indicate that AUC-388 is insufficient to direct Tat synthesis in 
vivo as well as in vitro and suggest that CUG-373 may be the Tat initiation 
codon.
The amino-terminal sequence of the in vitro synthesized Tat and S2 
proteins were analyzed in order to determine their respective initiation codons. 
The S2 protein was readily sequenced, and was found to initiate from the first 
AUG in ORF S2. This AUG codon lies in an unfavorable sequence context for 
translation initiation (UAU AUG G) due to the presence of a uridine residue in 
the -3 position, however the S2 protein was readily detectable in wheat germ 
extract translations programmed with the pSP720, pSP634 and pSP585 RNAs. 
The Tat protein was initially unable to be sequenced, most likely due to the 
presence of an unknown blocking group on the amino terminal residue. The 
possibility that this blocking group might be an acetyl group was examined by 
translating pSP720 RNA in wheat germ extracts that had been depleted of the 
acetyl group donor acetyl coenzyme A. However, this treatment did not result 
in the production of Tat protein that was more amenable to sequence analysis, 
suggesting that the putative blocking group is not an acetyl moiety. Limited
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amino-terminal sequence analysis of the Tat protein was obtained by stopping 
the translation reaction after 30 minutes of incubation, while the rate of 
synthesis was still near maximal. It was hoped that the rate of translation at 
this time may be greater than the rate of the reaction that results in the addition 
of the blocking group. This could allow some Tat protein to be trapped in an as 
yet unblocked form. Sequence analysis of [3H]-arginine labeled Tat protein 
prepared in this manner, clearly demonstrated two consecutive peaks of 
radioactivity corresponding to the second and third amino acid residues of the 
protein. This arrangement of arginine residues is precisely what would be 
expected if the Tat protein initiates from CUG-373 and the initiator methionine 
is removed by the amino peptidase activity of the wheat germ extract. From 
these data we conclude the EIAV Tat protein initiates from CUG-373 and that 
the amino terminus is blocked by an undetermined functional group.
One of the original goals of this research was to compare the efficiency of 
translation of the various cistrons of the pSP720 RNA in the wheat germ and 
rabbit reticulocyte in vitro translation systems. This synthetic transcript was 
translated efficiently in wheat germ extracts as evidenced by amino acid 
incorporation levels that were on average 20 to 30% of those of BMV control 
RNAs. The CUG initiation codon of the tat cistron and the sub-optimal AUG 
codon of the ORF S2 cistron were apparently efficiently recognized by the 
wheat germ ribosomes, since these two proteins accounted for about 80% of the 
total protein synthesized, while the Agp90 protein accounted for only 20%. 
Translation of this RNA in reticulocyte lysates resulted in very low levels of 
amino acid incorporation. Limitations on the am ount of lysate that can be 
loaded onto polyacrylamide gels without appreciable distortion from unlabeled 
hemoglobin in the lysate, made analysis of the reticulocyte translation products 
difficult. Some data was obtained by exposing autoradiographs for extended
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periods of time, however the lack of complete resolution of the Tat and S2 
bands m ade quantitation of these proteins impractical. The limited data that 
was obtained did  appear to be similar to that obtained in the wheat germ 
system. Specifically, the CUG-initiated Tat protein appeared as the most 
prominent band, while significantly less S2 protein was synthesized, and no 
detectable Agp90 protein was produced.
The mechanism of translation of the three dstrons in wheat germ 
extracts was examined by translating the pSP720 RNA in the presence of 
m 7GpppG cap analog. In nearly all cases, eucaryotic translation initiation is 
believed to occur by binding of the 40S ribosomal subunit to the 5' cap structure 
of the mRNA followed by its scanning to the first AUG codon in a favorable 
context for translational initiation (Kozak, 1992). More recently, cap- 
independent internal initiation models have been proposed for a num ber of 
viral and cellular RNAs (reviewed by Oh and Samow, 1993). Addition of cap 
analog to the translation mixture should severely reduce cap-dependent 
translation initiation, but have little effect on internally initiated cistrons. In the 
case of the pSP720 RNA, the overall translation level was severely reduced by 
the addition of cap analog and gel analysis indicated that each of the three 
cistrons were proportionately affected. These results argue against an internal 
initiation mechanism for the translation of either the ORF S2 or env cistrons, 
and support a leaky ribosome scanning mechanism for translation of these 
cistrons. The EIAV Tat protein and the ORF S3-encoded Rev-like protein have 
been shown by other researchers to be encoded by a small bicistronic RNA of 
about 1.5-kb in length (Carroll and Derse, 1993). These researchers have used 
site-specific mutagenesis to change the Tat CUG codon to an AUG and have 
concluded that the synthesis of the Rev protein is dependent upon a weak 
translation initiation codon for the Tat protein. Similar mutational studies on
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the Tat and S2 initiation codons in the tricistronic 3.5-kb RNA should be 
performed to more precisely delineate the mechanism of translation of the 
cistrons in this RNA.
In vitro translation systems are known to utilize non-AUG codons and 
AUG codons in sub-optimal sequence contexts much more readily than they are 
utilized in vivo (Kozak, 1989b). However, the ionic conditions of the wheat 
germ translation system may be altered to more accurately reflect in vivo 
translational initiation from these codons (Kozak, 1989b). The effect of changes 
in magnesium and potassium ions in the translation reaction on the relative 
initiation efficiency of each of the three cistrons of pSP720 RNA was examined. 
Low levels of potassium ion were found to favor translational initiation at the 
CUG codon of the SI Tat protein. Increases in potassium ion concentration 
resulted in decreased translation from the CUG codon associated with a 
concomitant increase in the levels of the S2 and the Agp90 proteins. Increases in 
the magnesium ion concentration favored synthesis of the CUG-initiated Tat 
protein. Thus, the CUG codon was least efficiently recognized at the lowest 
concentration of magnesium ion tested and the highest level of potassium ion 
tested. The efficiency of translational initiation from the Tat CUG codon in the 
pSP720 RNA was analyzed by performing co-translation experiments of this 
RNA with brome mosaic virus (BMV) RNA 4. When the two RNAs were 
present in equimolar amounts, the Tat protein was found to be produced at a 
level of approximately 20% of that of the BMV coat protein that was encoded 
from BMV RNA 4. These data quantitatively confirmed that the CUG initiation 
codon of the pSP720 RNA is recognized with high efficiency in the wheat germ 
in vitro system under conditions that optimize amino acid incorporation.
The first demonstration of EIAV Tat activity in equine cells is presented 
here. The Tat activity in cytopathically-infected equine cells was shown to
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increase throughout the infection cycle. These increases in Tat activity parallel 
increases in the level of the 3.5-kb, which is unusually high in FDD cells. The 
levels of the multiply-spliced tat/rev RNA do not change appreciably during 
this same time span. These data provide indirect evidence that the 3.5-kb RNA 
may indeed produce the Tat protein in vivo. The in vitro synthesized S2 protein 
was shown to react with sera obtained from ELAV-infected horses. Although 
there has been no direct identification of the S2 protein in EIAV-infected cells, 
the fact that EIAV-infected horses produce antibody to this protein provided 
evidence that this protein is produced during infection.
The expression of the EIAV S3 (Rev) protein from an AUG codon 
provided by the env gene through an RNA splicing event was examined in vitro 
and in vivo using a monoclonal antibody directed against the gnu-encoded gp90 
protein. Wheat germ extracts programmed with an in vitro transcript derived 
from a Rev cDNA resulted in the translation of a 20-kd protein. This protein 
could be immunoprecipitated with peptide antisera directed against sequences 
encoded by ORF S3, the second coding exon of Rev (rev-2), and a monoclonal 
antibody directed against an amino-terminal epitope of the gp90 envelope 
protein. These results indicate that env gene sequences provide the first coding 
exon of the EIAV rev gene. The 20-kd Rev protein could also be detected in 
cells transfected with a Rev cDNA expression vector and in EIAV-infected cells. 
The Rev protein detected in infected cells occurs in two forms with similar 
sizes, the larger form being the most abundant. The Rev cDNA expression 
vector (pSVS3) was only capable of producing the lower molecular weight 
form. An expression vector that produces the 3.5-kb RNA, which can be spliced 
in vivo to the 1.5-kb tat/rev RNA, was able to produce the higher molecular 
weight for of Rev. These data may indicate that the Rev protein is specifically
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modified in EIAV-infected cells by a protein encoded by the 3.5-kb RNA or its 
spliced derivatives.
In conclusion, the EIAV 3.5-kb has been shown to be tricistronic in vitro, 
since it is capable of encoding the Tat (SI), S2 and envelope proteins. The Tat 
protein does not appear to be initiated from AUC-388 in vitro or in vivo, and 
amino-terminal sequence analysis is consistent with initiation at CUG-373. The 
Tat protein produced in vitro appears to be blocked by an undetermined 
functional group. Under standard translation conditions that optimize amino 
acid incorporation, the Tat, S2, and Agp90 proteins were synthesized at a molar 
ratio of approximately 2:2:1. Alterations in the levels of potassium and 
magnesium ions of the translation system could reduce the translational 
efficiency of the CUG-initiated cistron w ith a concomitant increase in the 
efficiency of expression of the downstream cistrons. The S2 protein produced 
in vitro could be specifically immunoprecipitated with sera obtained from 
EIAV-infected horses indicating that this protein is produced during infection. 
The ORF S3-encoded Rev protein could be detected both in vitro and in vivo 
with a monoclonal antibody directed to an epitope located near the amino 
terminus of the gp90 protein. Thus, the Rev protein is produced from an AUG 
initiation codon provided by sequences within the env gene of EIAV through an 
RNA splicing event.
Future Studies
A goal of this research, that was not able to be attained, was to determine 
whether EIAV 3.5-kb RNA was tricistronic in vivo. A number of obstacles must 
be overcome before this question can be addressed. One of these obstacles is 
the lack of high titer antisera that will allow the detection of the SI Tat protein 
and the S2 protein. The one research group that has been able to detect the Tat
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protein in vivo used a combination of antisera produced against a number of 
synthetic peptides (Noiman et al., 1991). This could be a possible future 
strategy, but such combinations of antisera typically result in high backgrounds 
due to cross-reactivity to other cellular proteins. Perhaps the synthetic peptide 
antisera, that we now have in hand, may be more useful if we affinity purify the 
antibody using the synthetic peptide immobilized to a column resin. Another 
option would be to express these ORF proteins in E. coli and use the purified 
expressed protein to produce high titer polyclonal antisera. The preferred 
option would be to produce monoclonal antibodies that recognize specific 
epitopes on these proteins. There is also the possibility of using an epitope 
tagging strategy to detect these proteins. This strategy may be open to some 
criticism since the natural proteins would not be used. It would, however, 
have the advantage of allowing for the possibility of detecting all three ORF 
proteins using a single antibody. This would be particularly im portant if an 
analysis of the relative expression of the three EIAV proteins from the 
tricistronic RNA was an experimental goal. The use of different antibodies with 
different affinities to the target proteins could never yield quantitative data of 
this type. One would need to be cautious to insure that the monoclonal epitope 
is equivalently recognized in the different environments of the various 
peptides. Most immunological detection strategies employ a denaturation step 
before or during antibody detection. For example, in Western blotting the 
protein sample is first run on a denaturing polyacrylamide prior to transfer to a 
membrane and probing with antibody. Antibody incubations of 
immunoprecipitation reactions are normally performed in buffered solutions 
containing a number of detergents. Denaturation of proteins for the detection 
of linear epitopes should minimize the concerns of the epitope's "intra-protein" 
environment. Another concern that is of particular importance in the case of
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the strategy of multicistronic RNAs, is that such exogenously introduced 
epitopes m ust not contain AUG codons or other potential, non-AUG initiation 
codons.
A second obstacle, that must be overcome in the determination of the 
tricistronic nature of the 3.5-kb RNA in vivo, is the ability of the 3.5-kb RNA to 
be spliced to one of the three small EIAV Tat expressing transcripts. Although I 
have shown here that the pSV3.5kb vector produces primarily the 3.5-kb 
transcript, there are significant levels of other ELAV-specific RNAs that 
presumably arise from splicing. This problem could be overcome by site- 
specific mutagenesis of the two splice donor sites in the 3.5-kb RNA. The first 
of these sites lies between the Tat termination codon and the S2 initiation 
codon. Thus, splicing events that utilize this splice donor site result in the 
removal of the S2 and gpl35 initiation codons. The second splice sites lies in 
the env cistron downstream of the S2 termination codon. RNA analysis of the 
mutants would have to be performed, so that one could assure that cryptic 
splice sites would not be activated by mutating the natural sites. If no cryptic 
sites are activated, then a vector similar to pSV3.5kb that lacks these splice 
donor sites, should allow the expression of high levels of 3.5-kb RNA only.
Such constructs will be required for the definitive examination of the coding 
capabilities of the 3.5-kb in vivo.
The third obstacle that m ust be overcome in determining the tricistronic 
nature of the 3.5-kb RNA in vivo, is the inability to stably maintain and 
propagate plasmid vectors that contain EIAV env sequences in E. coli. Typical 
high copy number cloning vectors the contain EIAV env sequences accumulate 
mutations when grown in bacterial cultures. In this dissertation, I have 
described how I tried to minimize the frequency of these mutations by 
propagating enu-containing plasmids in standard LB media, rather than
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enriched media such as "super broth" or "terrific broth", and growing the 
cultures at 30°C rather than the standard 37°C. While this approach is 
sometimes successful, it cannot be relied upon. Recently, Cunningham et al. 
(1993) have described the stable maintenance of EIAV env sequences in low 
copy num ber plasmids. All future experiments that involve the expression and 
detection of the EIAV envelope glycoproteins should employ these vectors. I 
have already constructed low copy number vectors that are analogous to 
pSP720 and pSV720 but contain the entire EIAV env gene. These vectors should 
prove useful in future research.
In addition to the need for in vivo data on the EIAV 3.5-kb RNA, there 
are a num ber of interesting experiments that should be performed in the in vitro 
system. Perhaps the most interesting of these would be the further 
investigation of the mechanism of translation of the three cistrons. The data 
presented here that demonstrates the cap-dependence of the three cistrons of 
the 3.5-kb RNA is merely consistent with a leaky ribosome scanning 
mechanism for translation and does not provide any direct evidence to support 
this hypothesis. Site-specific mutagenesis of the Tat CUG initiation codon and 
the S2 sub-optimal AUG codon to stronger initiation sequences, would be 
expected to reduce translation of the downstream cistrons in vitro and possibly 
completely prevent their expression in vivo. Such experiments would provide 
strong direct evidence for the involvement of a leaky ribosome scanning 
mechanism in the translation of the three cistrons of this RNA.
The putative post-translational modification of the in vivo synthesized S3 
protein and the potential involvement of the EIAV-encoded proteins in 
mediating this modifications is certainly worthy of further investigation. 
Although other researchers have reported the detection of the EIAV Rev 
protein in vivo (Saman et al., 1990; Stephens et al., 1990), they have not observed
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that the protein exists in two forms. It is possible that the combination of a 
highly-specific monoclonal antibody and the sensitive chemiluminescent 
detection techniques used here, may have allowed the detection of this low 
abundance form of the protein. Based upon similarities of EIAV Rev with the 
HIV-1 Rev protein, which is known to be a phosphoprotein, it appears likely 
that this modification could be phosphorylation. This hypothesis is readily 
tested by performing in vivo labeling experiments of either EIAV-infected cells 
or pSV3.5kb-transfected cells in the presence of [32P]. A similar experiment was 
performed during the course of my work, but I used the pSVS3 vector 
transfected into COS-7 cells. As presented here, the Rev protein produced from 
this vector is very inefficiently modified. I was, however, able to detect a faint 
[32P]-labeled band that co-migrated with an [^S]-labeled protein of 20-kd and 
was immunoprecipitated with the mab86 monoclonal antibody. This result was 
less than convincing and did not lend itself well to presentation, so I decided 
not to include it in the text.
The question of whether other EIAV proteins may be involved in the 
putative modification of the Rev protein is a particularly intriguing one. This 
hypothesis is based primarily upon the observation that the pSVS3 vector that 
produces only Rev cannot be efficiently modified, while the pSV3.5-kb vector 
produces large amounts of the modified protein. One way to test whether the 
other EIAV proteins are involved would be to co-transfect the pSVS3 vector 
with the pSV3.5kbAS3 vector described in Chapter 3. The latter vector contains 
a frame-shift mutation in the ORF S3 exon of the rev gene and does not produce 
the Rev protein in vivo. If indeed, the pSV3.5kb plasmid encodes a factor that 
facilitates Rev phosphorylation, then this factor may also be encoded by 
pSV3.5kbAS3. If the latter plasmid vector is capable of directing the 
modification of the Rev protein encoded by the pSVS3 vector, then this would
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provide strong evidence for this hypothesis. Deletion mutants of the 
pSV3.5kbAS3 construct then could be generated to localize the sequences 
required to mediate this modification.
Another topic of interest that requires further study is the role of the S2 
protein in EIAV infection. One approach taken by researchers on HIV-1 and 
other lentiviruses to investigate the roles of predicted proteins with unknown 
functions, is to mutate the region of the genome that encode the protein in an 
infectious proviral clone and determine the effect of the mutation on viral 
infection. Researchers that work on EIAV have not had the luxury of the 
availability of infectious proviral clones until recently. The instability of clones 
containing the viral envelope sequences has made the construction of proviral 
clones very difficult. The use of low copy num ber plasmids has recently 
allowed the generation of infectious proviral clones. We now have these clones 
in-hand and could begin analysis of ORF S2 mutants. Since ORF S2 overlaps 
with the env gene in an alternative reading frame, site-specific mutagenesis 
would be required to specifically interrupt the S2 coding region.
The observation that the SI Tat protein synthesized in vitro is amino 
terminally blocked also warrants further study. Also the observation that the 
S2 protein synthesized in vitro is apparently modified by sera from EIAV- 
infected animals is also worthy of further study. Perhaps the first investigation 
that should be performed, is to try and determine whether these observations 
apply to the in vivo produced proteins. Since we presently do not have a means 
of detecting these proteins in vivo, these studies may need to await the 
development of improved detection techniques.
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